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ABSTRACT 
 
Abushanab Dina H, Masters: 
June: 2017, Pharmacy 
Title: Cost-Effectiveness Analysis of Sedatives in the Management of Neonates 
Undergoing Mechanical Ventilation in the Intensive Care Setting in Qatar 
Supervisor of Thesis: Dr. Daoud Al-Badriyeh, PhD 
Background. Neonates with respiratory distress syndrome (RDS), admitted to the 
neonatal intensive care unit (NICU) at the Women’s Hospital (WH) in Qatar, often 
require mechanical ventilation (MV) to maintain ventilator synchrony. No economic 
evaluations of morphine or fentanyl as stands alone or in combination with midazolam 
for sedation in NICU exist in the literature. The objective of this study was to evaluate 
the clinical and economic impact of sedatives in mechanically ventilated neonates with 
RDS in the Qatari NICU. 
Methods. A comparative retrospective cost-effectiveness study sought to evaluate 126 
critically ill neonates receiving morphine versus fentanyl, 64 patients receiving morphine 
monotherapy versus morphine plus midazolam, and 268 patients receiving fentanyl 
monotherapy versus fentanyl plus midazolam at WH in Hamad Medical Corporation 
(HMC), Qatar. Available medical records in the duration from October 2014 to January 
2016 were utilized. Decision analytic models from the hospital perspective were 
designed to measure all the possible consequences of all comparisons. The primary 
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endpoints were the successful drug sedation rate, based on the Premature Infant Pain 
Profile (PIPP) scoring scale, and the overall direct medical cost of therapy. Sample size 
calculations were to achieve results with 80% power and a significance level of 0.05. 
Sensitivity analyses were conducted to enhance the robustness and generalizability of 
the results.  
Results. Morphine monotherapy achieved sedation success in 68% of patients with an 
incremental cost-effectiveness ratio (ICER) of QAR 490.36 per additional sedation 
success compared to 43% with fentanyl. Morphine also produced better sedation in 
neonates with an ICER of QAR 21, 206.85 compared to its combination with midazolam 
(66% versus 34%). The fentanyl monotherapy dominated the combination of fentanyl 
and midazolam, with a net cost saving of QAR 43,811.83 per patient and a 51% 
successful sedation rate, compared to 33%. Here, the study group of fentanyl plus 
midazolam combination did not achieve the calculated sample size and, hence, the 
evaluation of this group is piloting in nature. Sensitivity analyses demonstrated 
robustness of all study conclusions. 
Conclusion. The current study is the first clinical and economic analysis of morphine, 
fentanyl, and midazolam in the NICU in literature, including in Qatar. Morphine 
monotherapy produced higher sedation levels over fentanyl monotherapy and the 
morphine plus midazolam combination but with higher costs. Fentanyl monotherapy 
had cost savings over its combination with midazolam, while its reported higher clinical 
effectiveness over the combination cannot be interpreted due to the limited sample 
size.  
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Chapter 1: Introduction 
1.1 Respiratory distress syndrome (RDS) 
The standard definition of RDS was originally described by Bernard et al in the 
American/European Consensus Conference in 1994 as patients who have bilateral 
pulmonary infiltrates along with arterial hypoxemia. To make a diagnosis of RDS, the 
ratio of a patient’s concentration of arterial oxygen in the blood over the inspired 
fraction of oxygen (PaO2/FiO2) should be less than 200 millimeter of mercury (mmHg), 
and the incidence of left atrial hypertension should be excluded (1, 2). Later in 2012, 
Ranieri et al updated the definition of RDS and classified it into three categories based 
on the range of hypoxemia: mild (200< PaO2/FiO2 ≤300 mmHg), moderate (100< 
PaO2/FiO2 ≤200 mmHg), and severe (PaO2/FIO2 ≤100 mmHg) (3). As a result, the arterial 
hypoxemia occurs due to the accumulation of edema fluid in the distal air spaces of the 
lung, disturbing the blood gas exchange. The excretion of the carbon dioxide is also 
affected, which leads to increasing the respiratory rate and the effort of inhalation (4-6). 
Several clinical disorders have been associated with the RDS development, including in 
patients with established respiratory or non-respiratory infections. Here, pneumonia, 
whether bacterial, viral, or fungal, has been found to be the main cause of RDS 
development. This is followed by severe sepsis, which is often associated with the 
pneumonia or other extra-respiratory source of infection, such as peritonitis (7-9). 
Aspiration of gastric contents, hemorrhage, shock after major trauma, severe acute 
pancreatitis, pulmonary injury associated with transfusion, and drug reactions are other 
common causes of RDS (9).  
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Notably, many patients who are diagnosed with acute respiratory failure (ARF) following 
RDS can also develop non-respiratory organ failure, such as hematologic anomalies, 
including anemia and thrombocytopenia (10), cardiac failure that needs vasopressor 
support, and renal failure that needs dialysis. In the majority of cases, the non-
respiratory organ failures are due to severe sepsis, and in other cases they may be 
related to shock (11).  
1.2 Pathology of RDS 
In 1977, Bachofen et al and colleagues first described the pathological characteristics 
of the lung in patients with RDS. They identified several ultrastructural details that were 
observed during different phases of the disease, with these being the acute, subacute, 
and chronic phases (8), (Figure 1.1):  
a. During the acute phase, defined as the first six days, the interstitial and alveolar 
edema with accumulation of neutrophils, macrophages, and red blood cells in the 
alveoli is found (Figures 1.1.a and 1.1.b). This is added to injury in the endothelium 
and epithelium (Figure 1.1.c) and the hyaline membranes in the alveoli (Figure 
1.1.b).  
b. During the subacute phase, defined as the next 7–14 days, reabsorption happens 
in an effort to repair the edema, and alveolar epithelial type II cells proliferation 
results. Further, fibroblasts are infiltrated and deposition of collagen is noticed.  
c. During the last phase, i.e. chronic phase, that happens after 14 days, the 
infiltration of the acute neutrophilic is resolved except in cases of superimposed 
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nosocomial pneumonia. More mononuclear cells and alveolar macrophages, and 
more fibrosis and alveolar epithelial repair are also seen.  
 
 
 
Figure 1.1 Phases of the lung during RDS (8) 
 
Abbreviations in section c: A: alveolar space; BM: exposed basement membrane; C: capillary; EC: 
erythrocyte; EN: endothelium; LC: leukocyte 
 
 
1.3 RDS in newborn  
RDS has multiple synonyms in neonates including:  
• Hyaline membrane disease 
• Neonatal respiratory distress syndrome 
• Infant respiratory distress syndrome 
• Surfactant deficiency 
Some premature infants born before 28 weeks of gestation in the first 24 hours (hrs) 
after birth develop RDS due to deficiency in surfactants, resulting in low lungs 
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compliance, alveolar surface tension, declined gas exchange and the need for high 
ventilatory pressures. RDS rarely happens in full term neonates and sometimes 
proceeds to bronchopulmonary dysplasia (BPD) which is a chronic lung disorder that 
occurs due to prolong use of mechanical ventilation (MV). Risk factors of RDS include 
prematurity, stress during delivery, especially in case of blood deficiency, infection, 
gestational diabetes, and when an emergency cesarean delivery is required (12). RDS in 
newborn is diagnosed through the clinical signs and symptoms of the infants along with 
the chest radiograph features that include, low lung volume and ground glass 
appearance called reticulogranular with air bronchograms (Figure 1.2). In order to 
discuss the pathophysiological features of neonate’s RDS, understanding the 
development of normal fetal alveolar is essential. The fetal alveolar development 
undergoes four stages (13): 
• Embryonic stage: The first appearance of the fetal lung as foregut protrusion starts 
during this phase at around 26 days gestation. Then the lung begins to extend 
forming the main bronchi at around 33 days gestation, which later extends to 
developing mesenchyme and segmental bronchi. 
• Pseudoglandular stage: During this phase, which occurs at 16th to 25th weeks of 
gestation, approximately 15 to 20 airway branches are developed from the 
segmental bronchi forming the terminal bronchioles. Then the blood vessels and 
epithelial cells develop.  
•  Canalicular stage: This stage occurs at 16th to 25th weeks of gestation, where the 
bronchioles and alveolar ducts of the gas exchange area are created and the 
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mesenchyme cells are more vascular. Later, the differentiation of cuboidal 
epithelial cells into type II of alveolar cells as well as the cytoplasmic lamellar body 
formation occurs, which indicate the presence of surfactant.  
• Saccular stage: This phase happens at around 24 weeks of gestation where the 
formation of alveoli (responsible for air exchange) occurs.  
 
 
 
Figure 1.2 Chest radiograph of neonatal RDS. (A) shows the severe RDS which indicates the low 
lung volume compare to (B), moderate RDS which indicates high lung volume (14) 
 
1.3.1 Pathophysiology of RDS in neonates 
• Surfactant deficiency 
Deficiency of surfactant, which is a complex of 90% lipids and 10% protein (13, 
15) is the main cause of RDS that has effect on reducing the alveolar surface tension and 
collapse atelectasis, increasing the lung volume, enhancing the alveolar expansion and 
lung compliance, and maintaining the blood oxygenation. The production of surfactant 
is developmentally regulated, therefore the deficiency of surfactant is most commonly 
seen among preterm infants (16).  
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In addition to the deficiency, inactivation of surfactant may play a role in respiratory 
distress development due to different factors such as aspiration of meconium and blood 
in the alveoli, proteinaceous edema and inflammatory cells in addition to congenital 
pneumonia (17, 18).  
• Inflammation and lung injury 
Animal experiments suggested that surfactant deficiency is associated with 
accumulation of neutrophils in the lung that leads to increasing the permeability of 
protein, pulmonary edema, and drainage of liquid and protein. The study was done in 
ten preterm lambs with gestation age of 127 ± 1 days undergoing MV for eight hrs (19). 
Pulmonary edema occurs due to the deficiency in the fluid pulmonary absorption in the 
fetus lung which is mediated by the sodium channels found on epithelial cells (ENaC). 
The expression of these channels increases with the gestational age and, thus, the 
preterm babies born with insufficient numbers of ENaC, leading to the development of 
fluid retention. Another study was conducted in human preterm showed that decreased 
polymorphonuclear leukocytes (PMNs) and platelets, and increased release of elastase 
and thromboxane release, were associated with RDS (20) 
1.4 Epidemiology of RDS in neonates 
Internationally, the mortality in the infant population due to RDS has obviously 
declined in the United States (US), for example, from 268 deaths per 100,000 live births 
in 1971 to 15 per 100,000 live births in 2008 (21). Around 30% to 40% of neonates 
admitted to hospital due to RDS and about 7% to 50% of neonates are diagnosed with 
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RDS (22). Approximately 92% of premature infants born at 24 to 25 weeks of gestation 
are diagnosed with RDS, 88% in 26 to 27 weeks, 76% in 28 to 29 weeks, and 57% at 30 to 
31 weeks. Prematurity has been shown to be a serious and wide problem that results in 
neonatal mortality, with many of the mortality and morbidity cases attributed to RDS. 
Globally, around fifteen million babies are born preterm annually and the complications 
of preterm birth are the primary cause of mortality among pediatrics under five years of 
age with an estimation of one million deaths in 2013. Among 184 countries, the rate of 
preterm birth of babies born ranges between 5% and 18%. There are variations in the 
countries in relation to the survival rates. In low-income countries for example, half of 
the neonates born at or below 32 weeks and die because of the dearth in the cost-
effective care, including warmth, breastfeeding provision, and essential infections care. 
However, the majority of the babies survive in high-income settings (23).  
On the other hand, in the adult population around 200,000 were annually diagnosed 
with RDS in the US, for example, where 40% died due to the same reason. The African 
American and Hispanic patients have also a greater incidence of mortality due to RDS 
compared with Caucasian patients. RDS has been shown to be an essential cause for 
ARF in pediatric patients as well (24).  
The signs and symptoms of RDS arise either at birth or afterwards and they include:  
• Respiratory signs and symptoms: tachypnea, grunting sounds, apnea, cyanosis, 
inspiratory stridor. 
• Retractions in the intercostals, subcostal, or suprasternal spaces. 
• Poor feeding. 
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• Sharp pulling in of the chest below and between the ribs with each breath. 
• Flaring of the nostrils. 
Complications of RDS include (12): 
• Pulmonary complications include: 
➢ Atelectasis. 
➢ Pneumothorax. 
➢ Hemorrhage. 
• Blood and blood vessel complications include: 
➢ Sepsis. 
➢ Patent ductus arteriosus (PDA). 
The management of RDS includes (12): 
• Surfactant replacement therapy. 
• Oxygen therapy. 
• Invasive or non-invasive MV. 
Oxygen therapy was the only strategy of management of neonates with RDS before 
1960. Later in 1970s, continuous positive airway pressure therapy (CPAP) and antenatal 
corticosteroids were proposed. After that in 1990, surfactant replacement therapy was 
introduced. Although no complications of surfactant administration were reported, 
infants treated with an early surfactant therapy tended to have a higher prevalence of 
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PDA. After that, ventilators were introduced to greatly enhance the outcomes of 
patients with RDS (22). 
1.5 Noninvasive ventilation (NIV)  
The NIV is the ventilatory support or positive pressure into the lungs through a 
mask without any use of invasive endotracheal airway (25, 26). It is used to prevent the 
problems associated with endotracheal intubation (EI) and conventional MV, mainly the 
ventilator-associated pneumonia (27, 28). Noninvasive pressure support ventilation 
(NIPSV) is the main modality of the NIV. CPAP has also been used in many cases of ARF 
(29, 30).  
Modes of NIV: 
• CPAP: this mode is a substitute for invasive ventilation that does not need an 
endotracheal tube (ETT) and allows spontaneous breathing during continuous 
pressure that is applied in the patient’s nares. It enhances the gas exchange and 
surfactant production, improves the chest wall stabilization, and reduces the 
breathing effort, intubation and surfactants (31).  
• NIPSV: This type involves a ventilator with two levels of pressure; expiratory 
pressure [expiratory positive airway pressure (EPAP) or Positive end-expiratory 
pressure (PEEP), like CPAP and inspiratory positive airway pressure (IPAP)]. Once 
the patient begins the inspiration, the ventilator delivers the inspiratory and 
pressure support via a decelerated flow, resulting in constant IPAP. After finishing 
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the inspiratory process, the pressure support is stopped and the pressure 
decreased to the preset EPAP (31).   
1.6 Invasive MV 
Noninvasive MV does not always deliver effective oxygenation and stable 
pulmonary procedure. Therefore, invasive MV is an important and life-saving method to 
save patients, including the preterm neonates, with RDS in particular, when the non-
invasive technique fails. Invasive MV has been shown to prevent lung damage 
development and BPD, and reduce the mortality rate in preterm newborns. MV is based 
on volume-cycled and pressure-cycled ventilations and are supplied at various rates, 
volumes, and pressures (21). 
Modes of MV: 
• Volume-cycled mode: A constant inspiratory flow is used to deliver the gas leading 
to peak pressure applied to the airways that is greater than that needed for lung 
distension (plateau pressure). The applied airway pressures vary according to 
changes in the pulmonary compliance (plateau pressure) and airway resistance 
(peak pressure) (21). This mode of ventilation is widely used as a first choice in the 
emergency department (ED). However, the main drawback of this mode is that 
high airway pressures may need to be applied, which cause barotrauma. Hence, 
close monitoring of patient’s lung status is required to avoid cases such as RDS 
deterioration, pneumothorax, chest-wall rigidity, increased intra-abdominal 
pressure and psychomotor agitation and, thus, increased peak pressure.  
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• Pressure-cycled mode: The delivery of volume depends on the compliance of 
patient’s pulmonary status. Peak inspiratory pressure (PIP) is used and the 
difference in the pressure between the MV and the lungs increases until the peak 
pressure is achieved. As the lung inflates, the inspiratory flow decreases, resulting 
in an equal distribution of gas all over the lungs. Close monitoring is very 
important to avoid changing in the tidal volumes (21).  
• High-frequency oscillatory support: Ultra-high respiratory rates (180-900 breaths 
per minute), low tidal volumes (1-4 milliliter/kilograms (mL/kg)), and high airway 
pressures (25-30 mmH2O) are used in this mode. The mode is used in intensive 
care units (ICUs) especially for preterm neonates with RDS to improve oxygenation 
and restore lung functions (21).  
Examples of modes of ventilatory support (32):   
• Continuous Mandatory Ventilation (CMV): Regardless of the patient’s pulmonary 
effort, the delivery of breath is supplied at preset periods. It is commonly used in 
paralyzed patient.  
• Assist-Control Ventilation (ACV): The ventilator supplies the breaths in 
synchronization with the patient’s respiratory drive, and with each inspiratory 
effort, a complete tidal volume is delivered by the ventilator. This mode allows 
spontaneous breathing between ventilator and the breaths, and it is the mode of 
choice for patients with intact respiratory effort. 
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• Intermittent Mandatory Ventilation (IMV): In this mode, preset breaths are 
delivered and unlike ACV, spontaneous breathing is not accepted.  
• Synchronous Intermittent Mandatory Ventilation (SIMV): The ventilator supplies 
the breaths in synchronization with the patient’s respiratory effort, which limits 
the barotrauma that may happen with IMV in patients who are forcefully exhaling. 
It also allows the spontaneous breathing. A major disadvantage of this ventilator is 
that the breathing efforts of the patients are increased. 
• Pressure Support Ventilation (PSV): This ventilator is used for spontaneously 
breathing patients to reduce the incidence of barotrauma and breathing effort. In 
this type of ventilation, a support pressure is set to help each spontaneous breath. 
It is used in patients with mild to moderate respiratory failure and patients with 
sufficient respiratory effort.  
1.7 Neonatal Intensive Care Unit (NICU)  
NICU is a specialist hospital ward  that provides intensive care treatment and 
monitoring for critically ill neonates, such as preterm neonates with low birth weight 
babies [less than 2494.756 grams (g)], or with medical conditions that need special care 
(33). 
Factors that increase the risk of babies to be admitted to the NICU (33): 
• Maternal factors: 
➢ Age younger than 16 or older than 40 years. 
➢ Drug or alcohol exposure. 
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➢ Diabetes and hypertension.  
➢ Bleeding. 
➢ Sexually transmitted diseases (STD). 
➢ Multiple pregnancy. 
➢ Too little or too much amniotic fluid. 
➢ Premature rupture of membranes. 
• Delivery factors: 
➢ Fetal distress/birth asphyxia. 
➢ Breech delivery presentation.  
➢ Meconium. 
➢ Nuchal cord.  
➢ Forceps or cesarean delivery. 
• Baby factors: 
➢ Birth at gestational age less than 37 weeks or more than 42 weeks. 
➢ Birth weight less than 2,500 g or more than 4,000 g. 
➢ Resuscitation in the delivery room. 
➢ Birth defects. 
➢ Respiratory distress including rapid breathing, grunting, or apnea. 
➢ Infections, seizures, hypoglycemia. 
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➢ Need for extra oxygen, special treatment or procedures such as a blood 
transfusion. 
1.8 Opioids 
Opioids are considered the most effective and best choice of drugs for fighting 
moderate to severe pain. Examples of opioids are: morphine, fentanyl, codeine, 
hydrocodone, methadone, oxycodone, hydromorphone, and meperidine. Opioid 
receptors are generally presented in the central nervous system (CNS) but are also 
found in the peripheral tissues. The stimulation of these receptors is produced by the 
endogenous peptides (34). Opioids are classified into four groups (34): 
• Opioids that are produced by the human body, known as endogenous opioid 
peptides, such as enkephalins and endorphins. 
• Opioids that are generated from the nature, which are called alkaloids like 
morphine and codeine. 
• Semisynthetic opioids made by synthesis from a natural substance, with 
hydrocodone and oxycodone as examples. 
• Synthetic opioids made by chemical synthesis, including methadone and fentanyl. 
The main types of opioid receptors (34) are: 
• Mu receptors. These are mostly located in the brainstem to produce different 
types of effects such as supraspinal analgesia, respiratory depression, urinary 
retention, sedation, euphoria, constipation, and physical dependence. 
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Enkephalins, morphine, fentanyl and codeine are known as weak agonists of Mu 
receptors, and others like naloxone and naltrexone are antagonists of these 
receptors.  
• Kappa receptors. These are found in the spinal cord in addition to the brainstem 
and they are responsible for the effects of spinal analgesia, dysphoria, sedation, 
and respiratory depression. Dynorphin is an agonist, whereas naloxone and 
naltrexone are antagonists of kappa receptors. 
• Delta receptors. The brain is the only location of these receptors, which are in 
charge for supraspinal and spinal analgesia, respiratory depression, urinary 
retention, and physical dependence. Examples of agonists of these receptors are 
enkephalins and meperidine. 
The use of opioids as sedatives is necessary for patients undergoing MV with RDS to 
facilitate the stressful procedure of MV, enhance the ventilator-patient synchrony, 
eliminate pain, and maintain the neuro-endocrine system, pain, and biomedical and 
physiologic responses (35). Sedative medications are used extensively for pain relief in 
critically ill neonates and have been shown to improve the ventilator synchrony and 
pulmonary function and reduce the neuro-endocrine responses (36). Here, morphine, 
fentanyl, and midazolam are the main sedation of focus of research in the current 
thesis. These as well as other sedatives that are used commonly in the NICU settings are 
discussed below: 
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1.8.1 Morphine  
Morphine, a phenanthrene derivative is the main alkaloid of opium. It is the 
prototype opiate analgesic and narcotic, and acts mainly in the CNS and the smooth 
muscle through the opioid Mu receptor. It is used for the relief of moderate to severe 
pain in addition to its sedative effect. Morphine sulfate injection is a sterile, non-
pyrogenic isobaric solution free of antioxidants, preservatives or added neurotoxic 
substances administered as intravenous (IV), epidural or intrathecal (37). According to 
the formulary of Hamad Medical Corporation (HMC, the main health care provider in 
Qatar, comprising eight major hospitals), each mL injection contains 15 milligram (mg) 
of morphine sulfate which allows for single use only. It has been reported that, in 2013, 
523,000 Kg of morphine were produced, 45,000 kg was utilized for pain relief in the 
developed countries, and around 70% of morphine was used to produce other opioids 
such as hydromorphone, oxycodone and heroin (34).  
1.8.2 Fentanyl 
Similar to morphine, fentanyl is a Mu opioid agonist used to relieve moderate to 
severe pain in addition to its sedative effect, and is about 80 times more potent narcotic 
analgesic compared to morphine. It is a sterile, non-pyrogenic, preservative free 
aqueous solution for IV or intramuscular (IM) injection. After that, many analogues of 
fentanyl were developed, including:  
1. Alfentanil (Alfenta®), an ultra-short [5-10 minutes (min)] acting analgesic. 
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2. Sufentanil (Sufenta®), an exceptionally potent analgesic (5 to 10 times more potent 
than fentanyl) for use in cardiac surgery (41).  
In 2012, fentanyl was the most commonly utilized synthetic opioid in clinical practice. In 
2013, 1700 kg were used worldwide (42).  
Each mL of solution contains fentanyl citrate equivalent to 50 microgram (mcg) of 
fentanyl base, adjusted to pH 4.0 to 7.5 with sodium hydroxide according to HMC 
formulary. 
1.8.3 Diamorphine 
Diamorphine hydrochloride is a prodrug, derivative of morphine, acts on the Mu 
opioid receptor, and is more potent compared with morphine. It is recommended to 
relieve severe pain, particularly in terminally ill patients who need palliative care. 
Diamorphine is metabolized into morphine through acetylation once it reaches the brain 
by injection. But, if taken orally, it is metabolized into morphine before passing the 
blood brain barrier. The main excretion occurs through the kidney as glucuronides 
mostly, in addition to as morphine as well. Approximately, 7 to 10% of the drug is 
eliminated into the feces by the biliary system (43).  
1.8.4 Midazolam 
Midazolam hydrochloride is available as a sterile, pyrogenic-free and intended 
for the IV or IM injection dosage form (44). Midazolam is a hypnotic-sedative with 
anxiolytic and amnestic properties. Each mL is comprised of midazolam hydrochloride 
that is equivalent to five mg of midazolam compounded with 0.8% sodium chloride and 
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0.01% disodium edetate, and 1% preservative of benzyl alcohol, based on HMC 
formulary. In 1970s until 1990s, the anticonvulsant characteristics of midazolam were 
studied and, in 2010, midazolam was considered the most widely used benzodiazepine 
as an anesthetic (39).  
1.8.5 Pancuronium  
Pancuronium is a synthetic, long-acting steroid neuromuscular blocking drug, 
and it competitively binds to the nicotinic receptor at the neuromuscular junction, 
inhibiting the binding of acetylcholine and leading to skeletal muscle relaxation and 
paralysis effects. As a neuromuscular inhibiting medication, it can seriously affect the 
respiratory function resulting in respiratory paralysis, thereby it should be given to 
patients who are maintaining an adequate airway and respiratory support (45). At HMC, 
each mL contains two mg of pancuronium. 
1.9 Pharmacoeconomics 
1.9.1 What is pharmacoeconomics? 
Pharmacoeconomics is the field of study that evaluates the costs and 
consequences of pharmaceutical products and services. Pharmacoeconomics has been 
defined as “the description and analysis of the costs of drug therapy to the health care 
system and society”. It combines the descriptive and analytic methods to evaluate the 
pharmaceutical interventions and deal with three types of outcomes: economic, clinical 
and humanistic, referred to as ECHO model, to prevent, treat, diagnose, or manage 
diseases (Figure 1.3) (44). 
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Figure 1.3. ECHO model (49) 
 
What are the features that characterize the economic evaluations? (49)  
• Pharmacoeconomics deals with both the costs and outcomes, better guiding the 
decision making to take the best decision. 
• The pharmacoeconomics analysis deals with choices. Because of resource scarcity 
and the inability of humans to produce all the required consequences, it is 
necessary that choices must be taken considering all areas of human activity.  
The above two features of pharmacoeconomics analysis led the scientists to describe 
the pharmacoeconomics evaluation as the comparative analysis of alternative actions in 
relation to their costs and outcomes. As a result, the pharmacoeconomics evaluation is 
used to identify, measure, value, and compare the costs and outcomes of different 
pharmaceutical alternatives (Figure 1.4). It helps clinical decision makers to prioritize 
different and competing health care services in relation to the use of interventions, drug 
formularies and achieving the efficient utilization of resources (49).  
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Figure 1.4 Economic evaluation as the comparative analysis of alternatives (49) 
 
1.9.2 Classification of cost (48) 
• Direct cost. It is the exchange of money for the consumption of the resources, 
which can be further classified into:   
➢ Direct medical cost, which involves costs of medical services such as clinical 
services, diagnostic and laboratory tests, hospitalizations, interventions, 
intervention’s monitoring, home medical services, and nursing services.  
➢ Direct nonmedical cost, which involves costs that are not associated with 
medical services such as travel cost to receive health care, hotel stays, and 
children care. 
• Indirect or productivity cost. It is the unpaid resource commitment such as lost 
patient’s time or productivity from work due to the illness.  
Costs can be also classified into (48): 
• Fixed cost. It is the cost that does not vary when the output is increased or 
decreased, such as building cost and employee salary. 
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• Variable cost. This is the cost that does change with an increase or decrease in the 
output, such as choosing between different medication products for the same 
indication.  
• Average cost. This is the resources consumed per unit of output. 
• Marginal cost. It is the change in the total cost of generating one more or one less 
unit of output. 
• Opportunity cost. It is the amount that a resource could earn in its greatest value 
of the alternative use.  
• Intangible cost. This is the unphysical cost, such as cost used to treat pain or 
fatigue.  
1.9.3 Four types of pharmacoeconomics evaluations to assess the costs and 
consequences of different alternative therapies (44, 48, 50) 
• Cost-Effectiveness Analysis (CEA) 
CEA is a technique designed to compare programs or interventions with different levels 
of efficacy or safety outcomes. Costs are measured in monetary unit whereas outcomes 
are measured and expressed in natural units depending on a specific therapeutic 
outcome. Examples of natural units are: lives saved, cases succeed, life expectancy, or 
drop in blood glucose. 
Costs and effects of interventions can be combined into an average cost-effectiveness 
ratio (ACER/CER) or an incremental cost-effectiveness ratio (ICER): 
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➢ An ACER is the total cost of a program or intervention divided by 
its therapeutic outcome. While ACER can help clinical decision makers 
recognize cheaper alternatives, ACER does not enable calculating the 
additional cost associated with an intervention as compared to a cheaper one. 
ACER can be described as follows: 
 
Figure 1.5 ACER equation (44) 
 
➢ ICER is the ratio of the difference in the costs divided by the difference in the 
effectiveness which represents the incremental cost associated with one 
intervention over another. The ICER can be summarized as follows: 
 
      Figure 1.6 ICER equation (44)  
 
There are three advantages of CEA: 
➢ It is easy to perform as the practitioners are generally very familiar with the 
national unit as a measure of effect.  
➢ Unlike cost-benefit analysis, the clinical outcomes are not expressed in the 
difficult-to-measure monetary unit. 
➢  Unlike cost minimization analysis, different treatment options with different 
levels of an outcome can be compared. 
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Disadvantages of CEA are: 
➢ Different treatment options can only be compared at a time against the same 
type of outcome.  
➢ Multiple CEAs in a single comparison may be needed, to compare alternatives 
against multiple types of outcomes.  
➢ It cannot combine the humanistic type of outcome with the natural unit 
outcome into a single unit of measurement. It does not consider the multi-
dimensional nature of outcomes. 
• Cost-Minimization Analysis (CMA) 
This type of analysis is used when two or more interventions are evaluated and 
compared in which the outcome is therapeutically equivalent, but with the costs, 
including the acquisition, preparation and administration costs, being considerably 
different. An example of this is comparing two generics for the same consequence.     
The disadvantage of CMA is that it assumes both treatment options have the same 
effectiveness and, thus, its application to interventions is limited.  
• Cost-Benefit Analysis (CBA) 
CBA is a tool that allows the clinical decision makers to identify, measure, and compare 
the benefits accrued from a program or intervention with the costs of providing it. The 
program or the treatment should measure and convert the costs and the benefits of the 
program or intervention into equivalent monetary units. The decision makers express 
the costs and benefits as benefit to cost ratio (B:C) or a net benefit, to then favor the 
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intervention that has the highest net benefit or B:C ratio, or the lower net cost or C:B 
ratio (44).  
The advantage of CBA is that it can be used to compare interventions with different 
outcome measures, because all types of outcomes are unified by being valued in 
monetary units. A disadvantage however is that no universal agreement on using one 
standard method for evaluating the monetary values of outcomes exist. 
• Cost-Utility Analysis (CUA) 
CUA is a tool used for comparing treatment options when taking in consideration the 
quality of life (QOL) of patients. CUA considers the cost, and the quality and quantity of 
patient-years. Cost is expressed in monetary units, and the outcome is measured in the 
quality-adjusted life year (QALY), which is based on patient-weighted life utility. Utility is 
a scale measure of patient satisfaction in health, with ‘0’ represents death, a utility score 
of ‘1’ represents full health, and the scores between > 0 to <1 representing morbidity. 
The incremental cost-utility ratio (ICUR) is used to express the incremental cost to the 
additional QALY gained by the patient. QALY indicates the number of life years 
throughout which adjustment (enhancement) in QoL takes place out of the total 
numbers of life years.  
Advantages of CUA include: 
➢ Alternatives that have different type of outcomes can still be compared. 
➢ Integrates mortality and morbidity into a single common unit. 
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➢ Utility adjustment over the years can be conducted to consider the long term 
varying status of disease morbidity.  
Disadvantages of CUA include: 
Lack of consensus on the best methods for measuring accurate utilities. There are three 
methods to measure the utilities: rating scale, standard gamble, and time tradeoff. 
There is no consensus to use a standard method due to subjectivity in measuring patient 
preference. Summary of the four studies is shown in Table 1.1. 
 
Table 1.1. Summary of the four different pharmacoeconomics methodologies (48) 
Method Cost Outcome Goal 
CMA Monetary value Assumed equal To determine the lowest cost of treatment 
CBA Monetary value Monetary value To yield the greatest net benefit or B:C ratio 
CEA Monetary value Natural unit To determine the additional cost per a unit of 
effectiveness gained when one treatment 
option is compared to another 
CUA Monetary value QALY To determine the additional cost per a unit of 
quality gained when one treatment option is 
compared to another 
 
 
Other types of economics evaluations (48): 
• Cost of Illness (COI) 
This type of economic evaluation is often referred to as burden of illness, which is to 
measure the direct and indirect costs associated with a particular illness. This method is 
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not used to compare between treatment options but to give an estimation of the 
financial burden of an illness.  
• Cost-Consequence Analysis (CCA) 
CCA is a technique in which the clinical outcomes and costs of programs or interventions 
are calculated and reported separately in studies.  
1.9.4 Decision Analysis 
Decision analysis is a systematic quantitative tool for evaluating and comparing 
the relative value of different decision options. It was developed as an approach to 
assist the health care providers in making decisions in relation to managing patient’s 
diseases by providing data about which program or intervention has the greatest value 
or outcome. This model is usually used for CEA and CUA, especially when the clinical 
decision is complex, with uncertainty in outcomes generated (51).  
Steps for conducting the decision analysis (44, 50): 
• Identifying and framing the research question: 
The researcher should clearly describe the problem or the research question in an 
appropriate level of detail. This includes the determining of the perspective, objective, 
and duration of follow up of the analysis.  
• Specifying the treatment alternatives: 
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The researcher ideally studies the alternative under assessment against the best of 
standard treatments. Where appropriate, a treatment alternative or drug therapy is also 
compared to no therapy (placebo). 
• Constructing the decision tree: 
Lines are drawn to link the branching points that are called “nodes”. Nodes are places 
where different patient management pathways generate.  
The decision tree consists of nodes, branches, and outcomes.  
➢ Nodes can be decision or chance nodes: 
(i) Decision nodes indicate points where different management pathways 
generate based on a decision, and these are represented by square boxes. 
(ii) Chance nodes indicate points where different consequence pathways 
generate by chance, and these are represented by circles.  
➢ Lines are drawn out of the nodes, and they connect between the different 
nodes from right to left, to form branches. Branches are made of consequent 
outcomes of interest to be followed up until final outcomes. Outcomes can be, 
for example, death, disability or health, with the end of follow up in a branch 
represented by triangles in the tree.  
• Estimating the probabilities: 
Different sources of data can be used to find and estimate the unbiased probabilities for 
the different outcomes in a tree. For example, parameters in relation to the 
effectiveness of an intervention can best be retrieved from randomized controlled trials 
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(RCTs), meta-analysis (MA) studies, or observational studies. Due to the different levels 
of evidence provided by different sources of data, sensitivity analysis is used to enhance 
confidence.  
• Analyzing the decision tree:  
After estimating the probabilities and outcomes, the researcher needs to analyze the 
data by a process called “folding back and averaging out”, where the researcher has to 
calculate the overall probability of a whole pathway by multiplying all the probabilities 
of different outcomes considered in this pathway.  
If the cost of the intervention is of interest, the calculated probability of the whole 
pathway is then multiplied of the overall cost of the pathway to generate the 
proportional cost of the pathway. Then, the sum of the proportional costs of all 
pathways is the total cost of the intervention, which as an example can be utilized into a 
cost-effectiveness equation.  
• Conducting a sensitivity analysis to test the uncertainty: 
Once the modeler has finished the baseline analysis, sensitivity analysis, known as 
“uncertainty analysis” should be carried out to enhance the robustness and increase the 
generalizability of the results. Sensitivity tests, which can be deterministic or 
probabilistic depending on the type of variable, are produced by modifications to the 
base case values of several key variables, such as costs and probabilities, to evaluate the 
robustness of the study economic outcome. Base case values are substituted by the 
highest and lowest values within a reasonable uncertainty range of the baseline values. 
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Where a substitution changes the study economic conclusion, more values within the 
range replace the base case value. This is repeated until the exact variable value, at 
which the study outcome changes, is identified. Reporting this as part of the study 
results does not only better indicate the robustness of results, but also boosts the 
generalizability of them when being interpreted by decision makers in other settings, 
with different model inputs, e.g. different drug prices. 
Main different types of sensitivity analysis (50, 51) are:  
➢ One-way sensitivity analysis is the simplest type of sensitivity analyses, used 
when the changes in the outcomes are assessed against adjustments in one 
variable at a time, while the values of all other inputs are remaining constant 
at baseline. Adjusting one variable at a time can be also via what is called 
‘scenario sensitivity analysis’, where a whole methodological scenario of 
interest is introduced into the baseline model for assessing the influence on 
the outcomes. 
➢ Multivariate sensitivity analysis: when the changes in the outcomes are 
evaluated as the value of two or more variables are changed, while the values 
of all other inputs are remaining constant at baseline. 
➢ Threshold analysis or break-even point. This is an extension of a sensitivity 
analysis in which the baseline input value is changed to the exact point where 
the study's conclusion changes.  
 
30 
 
There are important issues for consideration in the conduction of decision tree (44, 50): 
• Perspective: 
The perspective, which is whose point of view the clinical or policy decision is being 
made from, is important in the pharmacoeconomics analysis as it determines the type 
of cost and outcome to include in an analysis. There are three main types of 
perspectives: 
➢ Payer perspective. The cost of obtaining a service is included in the analysis. 
Examples of this perspective include insurance companies, Medicare, and 
Health Maintenance Organization (HMOs).  
➢ Provider perspective. The cost of providing a specific service is included in the 
analysis, such as hospitals, health system, and provider group. 
➢ Society perspective. The broadest and most comprehensive type of 
perspectives, which includes all costs and effects regardless of who bears 
them. 
• Setting: 
The population of the study must be clearly defined by stating the inclusion and 
exclusion criteria to which the results will apply. 
• Granularity: 
 The researcher must determine the best amount of detail to include in the decision 
analysis of a particular clinical decision and its outcomes. It is the one of the most 
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difficult decisions the researcher might face. For example, a researcher decides to look 
at the adverse reactions of a medicine, the researcher can engage and collaborate with 
experts or clinicians to help him obtain the sufficient level of detail to present the 
problem.  
• Time horizon: 
It indicates the time period of interest, during which the relative outcomes will occur 
and decision options, including costs and effects, are considered.  
1.9.5 Time adjustment for costs (48, 50): 
Same monetary units from different time points have different values for them, 
hence for the purpose of calculation, these need to be adjusted.  
Transformation accounts for:  
• Inflation. Accounts for changes in purchasing power of monetary value over time 
in the past. Common measures of inflation include: 
➢ Consumer price index (CPI). It measures the variation in the price level based 
on a stable market basket of services or goods.  
➢ Gross domestic product price index. This is the total monetary value of goods 
and services generated in a country in a certain time period. Unlike CPI, it is not 
based on a stable market basket of services or goods.  
➢ Personal consumption expenditures (PCE) Index. It involves the actual and 
imputed expenditures of households. 
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• Time preference (social discount factor). Future costs and outcomes are adjusted 
to their current values through the discounting, whereby these are valued 
differently depending on how far in the future they occur.  
1.10 Opioids and cost 
The worldwide market of opioids was estimated to be more than US$50 billion in 
2009. There has been a 10-fold rise in the use of opioid medications since the 1990s, 
which has attributed to a critical economic burden on the health care system. Florence 
et al and colleagues found that the health care accounts for approximately one third of 
costs attributable to the prevalence of opioids’ prescriptions, which indicates a huge 
economic burden on the health care system. Globally, between 2004 and 2008, out of 
all opioids, the consumption of morphine and fentanyl were increased by 19.8% and 
31.1%, respectively. In 2008, the consumption of morphine was 54.6% in US, 26.4% in 
Europe, 6.4% in Canada, 3.3% in Australia and New Zealand, 0.9% in Japan, and 8% in 
other regions, whereas, the fentanyl consumption was 48.1%, 40.8%, 3.2%, 1.2%, 1.3%, 
and 5.4%, respectively, in the same countries. In relation to the Middle East region 
within the period 2004-2008, the growth in the morphine consumption was moderate 
as observed in Israel, Jordan, Saudi Arabia, and Egypt, while a higher rate of increase in 
the consumption was reported for fentanyl in Israel, Cyprus, Turkey, Egypt, and Jordan, 
during the same period (52).  
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1.11 Qatar country profile 
Qatar is independent state located in the Middle East, Asia with an area of 
11,586 square kilometers. In 2016, the population reached 2,258,283 living in Qatar. The 
population growth rate was 2.64% in 2016 and ranked 16 compared to the world. Arabic 
is the official language, whereas English is considered the second language of the 
country. Also, Qatari Riyal (QAR) is the main currency used in the country (53, 54).  The 
total public health expenditure on health was 1.875% of gross domestic product (GDP) 
per capita in 2014 (55). As long as the investment continues to increase with increasing 
demand for excellent health care providers, the growth of the population will continue 
in the years ahead. The national growth in the health care and hospital activity provision 
and the demand for professionals in Qatar can be illustrated in Figure 1.7 (56).  
Under the umbrella of the Ministry of Health in Qatar, the services of health are 
provided via (i) the primary health care centers, constituting the basic care provided at 
21 medical centers, (ii) specialized clinics, and (iii) hospitals, and (iv) the private sector 
that plays an adjunct role in providing health services, mostly via 3 general hospitals, 
131 dental clinics, and 128 clinics for medical services. In the past, Qatar provided free 
health care services to all people until 1999, when Qatar faced an increased pressure on 
budgets. This forced the country to shift toward health insurance (57).  
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Figure 1.7. The Nation’s growth in Qatar (56) 
 
 
1.11.1 Statistics from Qatari NICU setting  
With regards to the local Qatari setting, the total number of admissions in 2015 
to the NICU at Women’s Hospital (WH) in HMC, a tertiary referral unit and the major 
and busiest NICU in Qatar, was 2,094 cases. Twenty-one neonates were admitted with 
gestational age of less than 24 weeks, 77 with gestational age of 24-26, 121 with 
gestational age of 27-29 weeks, 268 with gestational age of 30-32 weeks, 620 with 
gestational age of 33-36 weeks, 988 with gestational age of 37-41 weeks, and 8 with 
gestational age greater than 41 weeks. Of admissions, 101 patients (4.8%) died because 
of a variety of reasons. (Unpublished data, extracted from the local statistical Vermont 
Oxford database, NICU, WH at HMC). 
Similar to the international data, prematurity was the major reason for the NICU 
admission in Qatar (n= 1101, 53%), followed by RDS (n= 629, 30%), and major congenital 
anomalies (n= 174, 8.3%). Up to 183 patients (8.7%) were admitted due to other 
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reasons. 1,204 (57.5%) were admitted after cesarean delivery, while 890 (42.5%) were 
normally delivered. Around 1297 (62%) of admitted neonates received oxygen therapy. 
Noninvasive nasal CPAP ventilation was used among the admitted neonates (n= 877, 
41.9%), and 137, (6.5 %) used other types. For those who received MV, 375 (17.9%) 
underwent the conventional type of ventilation, 108 (5.2%) received high frequency 
ventilation, and 378 (18.1%) received any other ventilations. Out of the total number of 
admissions, 1940 patients (92.6%) have been successfully discharged to home from the 
NICU, whereas 54 (2.6%) neonates were transferred to other hospitals. (Unpublished 
data, extracted from the local statistical Vermont Oxford Database, NICU, WH at HMC). 
1.11.2 Status of sedation use in the Qatari setting 
The current drug sedation use in the NICU of HMC is not based on a local 
comparative evidence. There is no universal protocol for the use of sedatives in the 
NICU settings of HMC. In relation to the NICU population of HMC, different hospitals in 
within the corporation use morphine and fentanyl as sedatives for the pain associated 
with MV to different levels, including the extent to which the economic outcomes are 
considered. Al-Wakra Hospital of HMC, for example, is using fentanyl as a first-line of 
therapy to manage the neonates pain with MV, and it has been doing so for years. This 
is when, for more than a year now, since 2015, the WH of HMC, who used to also rely 
on fentanyl, changed practices to use morphine for the same population. Different NICU 
settings, therefore, are using different treatment strategies in within HMC. There is even 
no agreement on the strategy of using a medication as a first line. While some clinicians 
use morphine as monotherapy, a combination of morphine with midazolam is 
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commonly used by others in the same population. A similar adjunct therapy also exists 
when fentanyl is used. All this is associated with confusion by decision makers 
throughout HMC in relation to what constitutes the best approach to management in 
the NICU populations.  
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Chapter 2: Review of literature  
Sedative medications are commonly used to relieve the pain associated with the 
invasive MV among critically ill patients in general. In the neonatal population, the 
comparative evaluations of morphine and fentanyl, whether as head-to-head or against 
other sedatives, are relatively very limited in the literature. Only eight studies have been 
conducted in this population, which focus on the efficacy and safety type of outcomes in 
which the economic evaluations were not considered.  
• Direct comparison between morphine and fentanyl 
The only study that directly compared between fentanyl and morphine in 
neonates undergoing MV was conducted by Saarenmaa et al, in Finland in 1998. A total 
of 163 infants with gestational age of 24 weeks or more and with different underlying 
diseases, including RDS, were randomized to receive a continues infusion of either 
fentanyl (10.50 mcg/kg/hr, followed by 1.50 mg/kg/hr) or morphine (140 mcg/kg/hr 
followed by 20 mg/kg/hr) for at least one day. Saarenmaa et al assessed the severity of 
pain by measuring physiological parameters, hormonal response, and behavioral pain 
scale. The study illustrated that a statistically significant difference in relation to b-
Endorphin in favor of fentanyl. During the opioid infusion, the mean arterial blood 
pressure constantly persisted in both therapy groups without any difference in the need 
for vasoactive agents. After two hrs of infusion, there was no statistical difference in the 
heart rate (HR). After 24 hrs however, the HR decreased by –8 and –3 beats/min (bpm) 
in the fentanyl and morphine groups, respectively. Noradrenaline and adrenaline 
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plasma concentration reductions were similar in all patients. With respect to the safety 
parameters, neonates receiving morphine developed significantly lower gastrointestinal 
motility (47%), as compared with the fentanyl group (23%) (P< 0.01). Necrotizing 
enterocolitis (NEC) and urinary retention were more frequently associated with patients 
sedated by fentanyl (12% and 56%), respectively compared with morphine (10% and 
55%) (58). 
• Direct comparison between morphine and midazolam 
Anand et al conducted, in 1999, a pilot RCT in nine centers of 67 mechanically 
ventilated preterm neonates, with gestational age of 24 and 32 weeks, who received 
loading and maintenance doses of morphine, midazolam, or placebo for 14 days. This 
study was to investigate the incidence of poor neurologic outcomes in patients, at 0 to 
28 days of age, receiving either morphine or midazolam, compared to placebo. The 
severity of illness was measured via the Clinical Risk Index, the level of sedation by the 
COMFORT score, and the level of pain by the Premature Infant Pain Profile (PIPP) scale. 
The findings of this trial demonstrated poor neurological outcomes in 32%, 24%, and 4% 
in neonates given midazolam, placebo, and morphine, respectively (P= 0.03). There was 
no statistically significant difference in the severity of illness during birth among all 
patients. At the time of hospital discharge, the Neonatal Medical Index Risk was 
significantly different among the three groups (P= 0.01) in which Grades I, II, and IV 
were higher in the midazolam group, Grade III was higher in the morphine group, and 
Grade V was higher in the placebo group. With respect to the level of sedation, at 12 hrs 
after finishing the therapy infusion, this decreased as COMFORT scores were 
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significantly increased in neonates given morphine (P= 0.005). Other groups did not 
show any difference after the treatment. The pain level was significantly reduced in 
morphine (P< 0.001) and midazolam groups (P= 0.002) but not in patients receiving 
placebo. In relation to the secondary outcomes, the duration of MV, NICU stay, hospital 
stay, and oral enteral feeding did not significantly change among sedation groups. Two 
cases of mortality occurred in the placebo group, one case in the midazolam group, and 
none in patients given morphine (59).  
• Comparison between two different durations of morphine 
While the neurodevelopment outcomes were evaluated in the short term follow 
up by Anand et al, Grunau et al (2009) assessed the neurological outcomes in the longer 
term, at 8 and 18 months, by using the Bayley Mental Development Index (MDI) and 
Bayley Psychomotor Development Index (PDI) questionnaire. Here, morphine was 
administered to 137 preterm (≤ 32 weeks) and 74 full-term mechanically ventilated 
babies. High administration of morphine was significantly correlated with low PDI at 8 
months (r= -0.43) only. Spending more days on MV and the lower gestational age 
however, were significantly associated with low MDI and PDI at 8 months (r= −.33; r= 
−.43) and (r= .21; r= .26), respectively (60).   
• Direct comparison between morphine and diamorphine 
In another study conducted in the United Kingdom, in 1998, by Wood et al, 88 
mechanically ventilated preterm neonates of less than 35 gestational age, greater than 
two hrs but less than 48 hrs old, who needed intermittent positive pressure ventilation 
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(IPPV) and had respiratory diseases, were randomized to receive either morphine (bolus 
dose: 200 mcg/kg over two hrs, followed by continuous infusion of 25 mcg/kg/hr) or 
diamorphine (bolus dose: 120 mcg/kg over two hrs, followed by continuous infusion of 
15 mcg/kg/hr). Three different steps were performed to assess the level of sedation. 
Initially, the authors assessed the beat to beat variability of the arterial blood pressure 
(ABP), then the nurses completed a sedation score for the neonates, and finally plasma 
concentrations of adrenaline and noradrenaline were measured. Both groups did not 
show a statistically significant increase in the mean ABP after 24 hrs of continuous 
infusion. The sedation score was also similar between the two groups after 24 hrs of 
sedation. While the adrenaline level decreased significantly in neonates treated with 
both medications after 24 hrs of infusion, the noradrenaline concentration was reduced 
statistically significantly in the neonates given morphine only (61).  
• Direct comparison among morphine, pancuronium and morphine plus 
pancuronium combination  
Another RCT evaluating the use of morphine, but against pancuronium and the 
morphine plus pancuronium combination, in 95 preterm infants (≤ 34 weeks) with RDS 
that underwent MV, was conducted by Quinn et al in Ireland in 1992. Neonates who 
received morphine were started on a dose of 50 mcg/kg/hr and then increased to 100 
mcg/kg/hr if the neonate was still anxious after two hrs of the previous dose. Neonates 
on pancuronium received doses of 100 mg/kg/hr, and those on combination therapy 
received 50 mcg /kg/hr of morphine and 100 mcg/kg/hr of pancuronium. The authors 
assessed the blood pressure, HR, peak inspiratory pressure, oxygen concentration, 
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adrenaline and noradrenaline levels, Intraventricular hemorrhage (IVH), pneumothorax, 
pulmonary interstitial emphysema, PDA, duration of MV, and mortality. The blood 
pressure increased significantly in the combination group, the three groups showed 
significant changes in the peak inspiratory pressure and none demonstrated significant 
change in the HR and oxygen concentration. The level of adrenaline did not change 
significantly in any of the groups, however, the noradrenaline level decreased 
significantly in the morphine group only (P< 0.02). There was no significant difference 
among all groups in relation to the clinical outcomes (62).  
• Direct comparison between morphine and placebo 
In a 2003 study, by Simons et al in Netherlands, the routine use of morphine 
infusion was reported in 150 newborns (younger than 3 days after delivery) with 
different medical disorders, including RDS undergoing MV, who included neonates with 
postnatal age younger than three days and required MV for less than eight hrs. 
Neonates were randomized to receive either morphine with a loading dose of 100 
mcg/kg, followed by continuous infusion of 10 mcg/kg/hr or placebo for less than seven 
days. The clinical outcome was based on the analgesic and the sedation effect using 
three scales: PIPP, Neonatal Infant Pain Scale (NIPS), and Visual Analogue Scale (VAS). 
Simons and colleagues reported that there was no statistically significant difference in 
any of these scales between the two study groups. This is added to that the stay at the 
NICU was similar in both groups. Morphine however, significantly reduced the incidence 
of IVH as compared to the placebo (P= 0.04).  
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• Direct comparisons between fentanyl and placebo 
Orsini et al evaluated the use of fentanyl in twenty premature infants received 
MV due to RDS in the USA in 1995. The patients were randomized to receive either 
fentanyl (5 mcg/kg bolus over 20 mins followed by maintenance dose of 2 mcg/kg/hr for 
72 hrs, which was then reduced to 1 mcg/kg/hr for the following 24 hrs and 0.50 
mcg/kg/hr for the last 24 hrs, after which, the infusion was discontinued) or placebo. 
Orsini et al utilized a behavioral state score to assess the behaviors of the neonates 
through measuring the incidence of IVH, PDA, BPD, sepsis, NICU stay, and the duration 
of MV. The study showed that fentanyl decreased the behavioral states statistically 
significantly as compared to the placebo at 16 hrs, 24 hrs and 48 hrs, (P= 0.04, P= 0.01, 
and P< 0.001, respectively). Fentanyl did not have a statistically significant effect on the 
duration of NICU stay (63).  
Guinsburg et al also compared between fentanyl and placebo in Brazil in 1998, in which 
the premature infants who underwent MV were randomized to receive either fentanyl 
(3 mcg/kg) or placebo (0.20 ml of normal saline). Similar to Orsini et al, Guinsburg et al 
assessed the behavioral outcome of patients but using different criteria; Neonatal Facial 
Coding System (NFCS) and postoperative comfort score (PCS). The study reported that 
fentanyl significantly increased the level of PCS score (P< 0.00001). Also reported, is a 
significant reduction in the HR as compared to placebo (P= 0.003), (P= 0.011), 
respectively (64).  
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The eight different studies utilized different primary endpoints to assess the sedation 
status of the neonates. The sedatives also performed differently using these different 
outcome measures, and performed differently in studies in different settings, providing 
a very limited aggregate evidence to guide decision makers in other settings in relation 
to which sedative is better over the other.     
2.1 Study rationale  
Based on the literature review conducted (above), particularly in relation to the 
Qatari status as discussed in the introduction of the thesis, under section “1.11.2”, there 
are no pharmacoeconomics studies in literature, including in Qatar, that have evaluated 
the economics of fentanyl and morphine in neonate population whether as a standalone 
or relative to others, as a monotherapy or in combination with midazolam, and for 
whatever underlying medical condition. Also, a systematic review is needed to answer 
questions in relation to characteristics and quality of research, including the strength 
and limitation of methodological aspects used, of fentanyl and morphine in patients 
with respiratory disorders in the ICU. With the lack of research method standardization 
and a typical lack of compliance with established standards, answers to the study 
questions in relation to literature characteristics and trends will be of practical value as 
recommendations for consideration by researchers, in settings like the Qatari ICU, in 
planning and organizing their research, especially in relation to the important 
pharmacoeconomics research as approximately 20% of the total hospitals budgets go to 
ICU expenses (65). This is added to enabling a better understanding of the quality of 
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evidence by decision makers as they contrast this against current strengths and 
weaknesses of methods in literature. 
2.2 Significance of the research 
The findings from the proposed study will be of immediate and major 
significance to the management of neonate agitation in the ICU setting, internationally, 
regionally, as well as at the Qatari level.  
At the international level, the fact that the current investigation focuses ‘in particular’ 
on evaluating fentanyl versus morphine is of at most significance. While fentanyl and 
morphine are the most widely used opiates in the NICU, to the best of our knowledge, 
there is only one literature study that compared directly between fentanyl and 
morphine in neonates. The significance of the study also extends to the incorporation of 
an evaluation of the monotherapy versus combination sedation of neonates. The study 
evaluates fentanyl versus its use with adjunct midazolam, and also morphine versus its 
use with adjunct midazolam. To date, there are no any reports in literature that have 
explored the benefit of sedative combinations in the neonatal ICU settings. Also, the 
economic analysis component in this study is of a unique significance. To our 
knowledge, there are no pharmacoeconomics evaluations that have assessed the 
economics of fentanyl and morphine in neonates alone or in comparison in literature. 
The economic analysis is essential as in settings where resources are scarce and/or ICUs 
are busy, such as in the NICUs at the HMC, the longer is a duration of action for a 
sedative, the fewer occasions for doctors to be called in, which results in a reduced need 
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for additional drugs over hours. Within this context, the performance of the different 
sedatives in practice and, hence, their economic impact should be evaluated.  
At the regional level, the project’s aims are also novel, and at all levels of the ICU 
population. While the morphine and fentanyl were internationally evaluated in adult 
populations of the ICU for different underlying conditions, no research project has been 
undertaken with the same aims in the region, whether in neonates, pediatrics or adults. 
Furthermore, no other academic unit or health institution in Qatar (or the region) has 
attempted to evaluate the sedation management of acute agitation in the ICU through a 
comparative evaluation that is based on economic modeling.  
2.3 Objectives  
The overall goal of this research is to generate information to facilitate the 
delivery of safe, efficacious and cost-effective management of morphine, fentanyl and 
midazolam in patients undergoing MV due to RDS in the local Qatari NICU and global 
settings as well. To achieve this, the research needed to go through two phases:  
Phase 1: 
A comprehensive systematic review was conducted to summarize the quality of the 
methodological aspects, including strength and weaknesses, of the comparative 
evaluations, especially the economic evaluations, on the use of fentanyl, morphine, and 
midazolam in neonates with respiratory disorders undergoing MV in the ICU. This is not 
to review the evidence and the use of sedatives, but to guide future research in relation 
to the evaluation of the study sedatives. 
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Phase 2: 
To comparatively evaluate the use of the sedative agents in the management of acute 
agitation in the mechanically ventilated patients in the Qatari NICU, three objectives 
were developed; 
1. Perform a clinical and economic analysis of morphine monotherapy versus 
fentanyl monotherapy. 
2. Perform a clinical and economic analysis of morphine monotherapy versus 
morphine and midazolam combination. 
3. Perform a clinical and economic analysis of fentanyl monotherapy versus fentanyl 
and midazolam combination. 
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Chapter 3: Materials and Methods 
3.1 Phase 1: Systematic review of literature methods  
3.1.1 Literature review 
The electronic databases MEDLINE, EMBASE, OVID, Science Direct, Springer Link, 
and EconLit were utilized to identify studies. The following keywords were used to 
capture a broad sample of studies: “morphine”, “fentanyl”, “hypnotics”, “sedatives”, 
“sedation”, “respiration”, “respiratory”, “artificial, respiration”, “mechanical ventilator”, 
“mechanical ventilation”. The search strategy in Appendix 1 was used for PubMed, 
including operators and MeSH, and this was adapted for other databases. The search 
included gray literature, such as books, dissertations, conferences, working papers, 
government publications, and was supplemented with a general internet search using 
Google and Google Scholar, where free text searching used the same search terms as in 
the main search. Manual screening of reference lists in found articles was also carried 
out.  
3.1.2 Inclusion and exclusion criteria 
Inclusion criteria: 
• Literature publications were included until December 2016. No considerations 
were made of whether articles are freely available. 
• Therapy based comparative study. No considerations were made of whether 
studies are retrospective or prospective. 
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• Study of either fentanyl or morphine, or both. 
• Mechanically ventilated subjects with respiratory disorders in the ICU. 
Exclusion criteria: 
• Non-English language. 
• Non-human studies. 
• Non-comparative research, e.g. letters, general reviews, editorials. 
• Non-respiratory underlying indications. 
3.1.3 Data collection and handling  
Articles identified as eligible for inclusion were categorized based on whether a 
study is of a clinical or an economic evaluation. Eligible articles were reviewed 
independently by two investigators, where key information was extracted. These 
included author, year of paper, country, ICU setting, interventions, comparators, 
medical conditions of the subjects, inclusion and exclusion criteria, sample size, study 
design, stratification, primary and secondary outcome measures, type of 
pharmacoeconomics evaluation, modelling, perspective, types of cost, time adjustment, 
sensitivity analyses, and sources of data. All investigators have training in 
pharmacoeconomics research. For validation purposes, the third investigator reviewed 
the extraction (and database population) of the relevant data from each included 
article. Disagreements, including in relation to miscoding, were further discussed until 
agreement is achieved. 
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Numerical and percentage measures were used to describe the distribution of variables, 
and cross tabulation was used to provide information about comparison of frequency 
data. The PRISMA checklist has been followed in completing the systematic review, as 
shown in Appendix 2.  
3.1.4 Quality assessment 
A quality assessment was independently conducted by investigators, as already 
discussed above. The Consolidated Standards of Reporting Trials (CONSORT) (66) was 
used to assess the quality of RCTs, Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) (67) was used for cohort studies, and the 
pharmacoeconomics studies were assessed via the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) (68). 
3.2 Phase 2 
Corresponding to the study objectives, methods of the study relate to three 
different evaluations: 
• Evaluation 1: morphine monotherapy versus fentanyl monotherapy  
• Evaluation 2: morphine monotherapy versus morphine plus midazolam 
combination 
• Evaluation 3: fentanyl monotherapy versus fentanyl plus midazolam combination 
In overall, the research is of comparative retrospective observational cohort studies. In 
cohort studies, a free-outcome population that is under exposures of interest is 
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followed up retrospectively or prospectively throughout time to examine the 
development of specific outcome measures of interest. In this study, morphine and 
fentanyl were retrospectively evaluated due to that (as discussed above, under sedation 
in Qatari setting) fentanyl is not a currently available option for sedation in the NICU of 
WH in HMC, which is the setting of the current study. Here, the medical records of the 
neonates in the WH of HMC were utilized. In all evaluations, study groups were 
comparatively examined via CEAs.  
3.2.1 Ethics approval  
The observational research received the required ethics approval from the ethics 
committee of the Medical Research Center (MRC) at HMC on March 13th, 2016. (See 
Appendix 3).  
No informed consent was required as the study was a retrospective cohort study.  
3.2.2 Setting  
HMC is the main non-profit public health care provider in Qatar, with 23,500 
staff and 2100 beds in 2015. It is the only public institution in Qatar to provide a wide 
range of the safest and most effective health care services, covering the needs of about 
90% of the population in Qatar. HMC leads multiple health areas, for example diabetes, 
cancer, women’s health, pediatrics’ health, organ transplantation, dialysis, and mental 
health. The eight hospitals that HMC comprises are classified into three categories: 
tertiary hospitals, continuing care and general hospitals. WH is a tertiary hospital and 
the largest delivering center with 300 beds, providing different services, such as 
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women’s care, obstetrics, high risk births, gynecological, and neonatal care services. 
HMC has the Joint Commission International accreditation, USA, and was the first health 
care organization in the region that receives the Institutional Accreditation Council for 
Graduate Medical Education (56).  
 
 
 
Figure 3.1. Sheer scale of HMC services, including as compared to Supreme Council of Health  
and Primary Health Care Corporation (56) 
 
The NICU in WH is a specialized, advanced tertiary ward, and the largest NICU in the 
region that offers the greatest kind of care for newborns who are critically ill, including 
premature babies, babies with RDS, cardiac disorders, congenital anomalies, multiple 
organ failure, and many other medical conditions. The unit has recently been extended 
to deliver a total of 107 beds in both the intensive and intermediate care units. The 
WH’s NICU provides rooms for breastfeeding, and counselling (69).  
 
 
52 
 
3.2.3 Population 
All agitated neonate patients, including preterm and full term, who underwent MV in 
NICU due to RDS were eligible for inclusion. Included neonates in addition, received 
initial therapy of any of the study therapy groups. 
The study groups, including medications and standard doses, were: 
Evaluation 1: morphine monotherapy versus fentanyl monotherapy 
• Fentanyl monotherapy 
➢ (0.5-3 mcg/kg loading dose, followed by 1-5 mcg/kg/hr continuous infusion). 
• Morphine monotherapy 
➢ (100-200 mcg/kg loading dose, followed by 15-30 mcg/kg/hr continuous 
infusion). 
Evaluation 2: morphine monotherapy versus morphine plus midazolam combination 
• Morphine monotherapy 
➢ (100-200 mcg/kg loading dose, followed by 15-30 mcg/kg/hr continuous 
infusion). 
• Morphine + midazolam combination  
➢ Morphine (100-200 mcg/kg loading dose, followed by 15-30 mcg/kg/hr 
continuous infusion). 
➢ Midazolam (0.1-0.2 mg/kg, followed by 0.01-0.06 mg/kg/hr continuous 
infusion). 
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Evaluation 3: fentanyl monotherapy versus fentanyl plus midazolam combination 
• Fentanyl monotherapy:  
➢ (0.5-3 mcg/kg loading dose, followed by 1-5 mcg/kg/hr continuous infusion). 
• Fentanyl + midazolam combination: 
➢ Fentanyl (0.5-3 mcg/kg loading dose, followed by 1-5 mcg/kg/hr continuous 
infusion). 
➢ Midazolam (0.1-0.2 mg/kg loading dose, followed by 0.01-0.06 mg/kg/hr 
continuous infusion). 
Exclusion criteria: 
• Neonates who received surgeries, major procedures (such as intercostal drains, 
chest-drain removal, intubation), and retinal examinations for retinopathy of 
prematurity. 
• Neonates with congenital anomalies, birth defects, and hypoxic ischemic 
encephalopathy (HIE). 
• Not ventilated or not sedated neonates. 
• Neonates with pulmonary hypertension or pulmonary hemorrhage.  
• Neonates received sedation for other indications, such as neonate with burn or 
cardiac problems. 
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3.2.4 Outcome measures 
• Primary measures: 
➢ The groups were compared according to the rate of successful sedation, based 
on a PIPP scale as documented by the nurses in Cerner. PIPP scale is one of the 
most valid and reliable measures used in literature to reflect the clinical and 
agitation status of the patient and neonate’s need of sedation (70). The 
agitation is measured by the nurses at the NICU to monitor on drug sedation. 
The PIPP scale consists of questions regarding seven criteria, each question has 
score range from 0-3 to give a total score range of 0-21 (Table 3.1). 
➢ Resource utilization, including an estimation of the overall direct medical costs 
of managing acute agitation in the neonate study population. 
• Secondary measures: 
➢ Need for alternate sedation with initial sedation failure. 
➢ Adverse drug reactions (ADRs). 
➢ Need for increased medication doses. 
➢ Length of NICU stay. 
➢ Duration of MV in the NICU. 
➢ Duration of sedation in the NICU. 
➢ Withdrawal symptoms. 
➢ Mortality. 
➢ Persistent agitation. 
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PIPP procedure  
• A PIPP total score range between 0 and 6 indicates no or mild pain, thus no action 
is required.  
• A PIPP total score range from 7-12 reflects a moderate pain and, therefore, the 
clinicians start implementing non-pharmacological measures, such as heat or cold 
therapy, sucrose solution, blanket application, pacifier, swaddling, nesting, breast 
feed, quite environment (reducing light, noise and activity around the neonate), 
and soothing voice.  
• A PIPP total score greater than 12 indicates that the baby is feeling severe pain, 
hence pharmacological intervention is initiated.  
 
Table 3.1. PIPP assessment tool for neonates 
Indicators 0 1 2 3 Score 
Gestational age ≥ 36 weeks 32- 35 weeks 28-31 weeks < 28 weeks  # 
Behavioral state Active, awake, 
eyes open, 
facial 
movements 
Quiet, awake, 
eyes open, no 
facial 
movements 
Active, awake, 
eyes closed, 
facial 
movements 
Quiet, asleep, 
eyes closed, 
no facial 
movements 
 # 
HR maximum 
(bpm) 
0-4/min 
increase 
5-14/min 
increase 
15-24/min 
increase 
≥25/min 
increase 
# 
Oxygen saturation  92-100% 89-91% 85-88% 84% or less # 
Brow bulge None Minimum Moderate Maximum # 
Eye squeeze None Minimum Moderate Maximum # 
Nasolabial furrow None Minimum Moderate Maximum # 
#: total score  
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Definition of the outcome measures: 
• Successful sedation 
Successful sedation was defined as an agitated neonate’s final PIPP score that is reduced 
to less than seven or maintained less than seven following receiving any of the initial 
study sedation when the initial PIPP score was greater than seven.  
• Sedation failure 
This is defined as the agitated neonate’s final PIPP score remaining above seven 
following receiving any of the initial study sedation when the initial PIPP score was 
greater than seven. Here, the consequences were: 
➢ Receiving increased dose. 
➢ Switching to an alternative. 
➢ Developing withdrawal symptoms: including known related symptoms; seizure, 
agitation, irritability, and tachycardia that appeared after the fifth days of 
receiving sedation (71), and the final PIPP score of the baby increasing to more 
than seven after the initial score was below seven following initiating sedation.  
➢ Death: defined as any death case that arose during receiving sedation during 
the first 28 days of life defined by World Health Organization (WHO) (72) and 
the United Nations Children's Fund (73). 
➢ Developing persistent agitation: when the patient did not respond to the any 
of the clinician’s decisions, which was reflected on the neonate’s high final PIPP 
score. 
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3.2.5 Sample size 
Sample size was calculated for each study evaluation of phase 2 by utilizing 
ClinCalc.com, which is a tool used for evidence-based clinical decision support (50). 
• Evaluation of morphine monotherapy versus fentanyl monotherapy 
There is only one study that compared between morphine and fentanyl in a head to 
head comparison by Saarenmaa et al (58), that showed that the level of pain using b-
Endorphin was significantly reduced in favor of fentanyl. Based on this result and the 
estimation from specialists at the Qatari NICU of 70% success rate with morphine, a 
sample size to measure an anticipated sedation rate increase of at least 30% (i.e. an 
anticipated over 90% success rate with fentanyl), with alpha= 0.05 and power= 80%, 62 
needed to be included in the morphine monotherapy and 62 in the fentanyl 
monotherapy group (total= 124).  
• Evaluation of morphine monotherapy versus morphine plus midazolam 
combination 
There are no studies in literature that evaluated morphine monotherapy versus 
morphine and midazolam combination. Midazolam was studied as a sole therapy in a 
study by Anand et al, where it demonstrated to significantly reduce the PIPP scores (59). 
Based on this and the measured outcome of morphine (68% success rate, vide infra) in 
our evaluation of morphine monotherapy versus fentanyl monotherapy, a sample size 
to measure an anticipated sedation increase by at least 40% (i.e. an anticipated 95% 
success rate with the midazolam combination), at alpha= 0.05, power= 80%, 31 needed 
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to be enrolled in morphine monotherapy and 31 in morphine plus midazolam (total= 
64). 
• Evaluation of fentanyl monotherapy versus fentanyl plus midazolam 
combination 
As with the morphine versus combination evaluation, based on the performance of 
fentanyl monotherapy (43% success rate, vide infra) in our evaluation of it against 
morphine monotherapy, and the performance of midazolam in literature, as discussed 
above (59), a sample size to measure an anticipated sedation increase by at least 40% 
(i.e. an anticipated 60% success rate with the midazolam combination), at alpha= 0.05, 
power= 80%, 134 needed to be included in fentanyl monotherapy and 134 in fentanyl 
plus midazolam (total= 268). 
3.2.6 Data collection 
Study neonates were identified through the Cerner electronic medical records 
database at the NICU in WH in HMC between October 2014 and January 2016. The 
Cerner database was not available before then, where the data extraction from the 
physical older medical records was not feasible due to availability and time challenges. 
Data were collected from October 2014 till January 2016. The collection was stopped in 
January 2016 due to the HMC ethics restriction which prevents collecting data after the 
date of getting the approval. Data related to study medications were recorded as de-
identified data. Medical records were ordered based on their Health Care (HC) numbers. 
Each HC number received a unique and random code. Lists of patients in each study 
59 
 
group were selected and sent separately by the HMC collaborator based on their HC 
numerical order. For example, the patient lists for the first study included 63 patients in 
each group before the final selection of patients based on the inclusion and exclusion 
criteria. The excluded patients were replaced by additional patients sent by the HMC 
collaborator until sample size was achieved. Then the selection of patients for analysis 
was based on the shortest duration of sedation or NICU stay. With a similar trend, the 
patients were separately selected for the second and third evaluations. No single 
patient was included in more than one study group in the evaluation. The subject 
identifier and its corresponding code were kept in a separate document. The codes were 
used in the data collection sheet by the student research in the current thesis, while the 
HC numbers were kept with HMC collaborators. Access to patient data was performed 
through access provided by the HMC collaboration. Patients' identification information 
was maintained in a data collection sheet, stored and secured on HMC collaborators’ 
computers. No identifiers were included in the data analysis. The data collection form 
can be seen in Appendix 4. 
3.2.7 Statistical analysis 
Patient baseline demographics were analyzed using SPSS (IBM Corp. Released 
2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp). Based on 
input of practitioner authors in this research, the only demographic characteristics of 
interest in relation to being similar between study groups are (i) full-term versus pre-
term status of neonates and (ii) extent of vecuronium use. Nevertheless, demographic 
characteristics that were analyzed in this research are beyond those of interest. All 
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baseline variable data were categorical and, therefore, Chi-square and Fisher’s exact 
tests were used to test for similarity between any of the two study groups in the three 
evaluations. The p-value of the Chi - square test was used if no more than 20% of cells 
had expected counts of less than five. However, if more than 20% of the expected 
counts were less than five, p-value of Fisher’s exact test was used. Since all data were 
categorical, normality test was not required. All were calculated using an alpha of 0.05. 
Numerical and percentage measures were used to describe the categorical variables. 
Analyzing the effect of individual demographic characteristics as independent factors on 
the study outcomes is not an objective of this research. 
3.2.8 Perspective 
The economic modeling adopted the perspective of WH at HMC. Only direct 
medical costs for managing the RDS in mechanically ventilated neonates were assessed. 
Medical costs related to other underlying diseases (e.g. cost of medications to treat 
other medical disorders) and indirect hospital costs (e.g. staff salary) were not included. 
Intangible costs were also excluded from this study due to the retrospective nature of 
the observational cohort study.  
Direct medical costs included were associated with:  
• Sedative medications. 
• Therapies to manage the ADRs associated with sedatives. 
• Mechanical ventilator. 
• Diagnostics, laboratory, and monitoring tests during the NICU stay. 
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• Length of NICU stay. 
3.2.9 Model structure 
The pharmacoeconomics analysis was performed based on the decision analytic 
model as designed to describe the patient management flow in the NICU, where 
possible sedation consequences of interest were considered as shown in the model 
trees in Figures 3.2-3.4. In any tree, for each of the sedatives, the model included seven 
possible treatment pathways depending on whether the initial sedation was successful, 
and on the causes and results of failures. Mechanically ventilated agitated neonates 
with RDS were initially assigned to one of the two sedatives; morphine monotherapy or 
fentanyl monotherapy. Patients who received morphine monotherapy continued 
sedation until therapy was considered successful, with or without ADRs, or considered a 
failure. Patients who failed to respond to the initial sedative, had increased the dose, 
switch to any other alternatives, sedation associated with withdrawal symptoms, death, 
or persistent agitation.   
Based on tree structures, in addition to populated input model data on resources 
consumed and their monetary values, any model generated a weighted average cost for 
treating patients. As per the general decision analysis principles, this was calculated 
through multiplying the costs of treatment outcomes by their respective probabilities. 
The costs of managing a single episode of acute agitation were compared among the 
different therapies in evaluations. 
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Figure 3.2 Decision tree model of morphine monotherapy vs. fentanyl monotherapy 
 
 
Figure 3.3 Decision tree model of morphine monotherapy vs. morphine plus midazolam 
 
63 
 
 
Figure 3.4 Decision tree model of fentanyl monotherapy vs. fentanyl plus midazolam 
3.2.10 Model clinical inputs 
Data inputs for the model in relation to the clinical outcomes and their 
probabilities were extracted from the review of WH medical records within the duration 
from October 2014 to January 2016.  
3.2.11 Model cost inputs and calculations 
All calculated costs were in the Qatari Riyal, adjusted for the financial year 2016-
2017 using inflation rates as obtained from the Central Intelligence Agency (53). No 
discounting was applied given the short timeframe of the analysis. The cost of initial 
sedation was the cost associated with the initial sedative use until success or failure. The 
overall cost of each therapy outcome pathway included both, the primary costs of initial 
sedatives and their secondary costs as associated with patient management, including 
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that of failure. Medication costs involved in this study were based on drug wholesale 
prices, as paid by HMC. All resource costs included in the analysis were derived from the 
Accounting and Finance Department at HMC. The cost inputs used in the model are 
summarized in Table 3.2.  
An assumption was made where cost data of resources were unavailable at HMC. Here, 
the costs of interest were obtained from the accounting system, extracted from Ministry 
of Public Health resources (74), at Al-Ahli Hospital (AH), a major private profit-based 
hospital in Qatar with 100 beds (75). These were then adjusted to their HMC estimated 
values. For any resource, this was based on the average relative difference between 
HMC and AH available prices in within the resources category that the resource belong 
to. The AH prices of interest are summarized in Table 3.3. Some input costs were not 
available (N/A) in both hospitals and were excluded from the study (Table 3.4).  
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Table 3.2 Resource costs based on the NICU at HMC 
Item / Name of test Unit Unit cost (QAR) 
Morphine 15 mg/ml IV vial 1.97 
Fentanyl  50 mcg/ml IV vial 6 
Midazolam  1 mg/ml IV vial 3.29 
Naloxone 0.4 mg/ml IV vial 2.75 
Furosemide  10 mg/ml IV vial 0.6 
Dobutamine 1 mg/ml IV vial 6.81 
Phenobarbital 30 mg/ml IV vial 6.32 
Complete blood count 1 test during NICU 30 
Calcium 1 test during NICU 10 
Bilirubin 1 test during NICU 10 
Protein  1 test during NICU 10 
Albumin  1 test during NICU 10 
Alkaline phosphatase  1 test during NICU 10 
 
Alanine aminotransferase 1 test during NICU 10 
 
Aspartate aminotransferase 1 test during NICU 10 
 
Glucose-6-phosphate 
dehydrogenase screen 
 
1 test during NICU 20 
 
Glucose  1 test during NICU 10 
 
C-reactive protein 1 test during NICU 30 
 
17 Hydroxyprogesterone, dried 
blood spot (DBS) 
 
1 test during NICU 40 
Amino acid and acy serum 
creatinine (Scr) DBS 
 
1 test during NICU 360 
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Biotinidase DBS   1 test during NICU 30 
Galactose-1-phosphate 
uridyltransferase  
 
1 test during NICU 30 
Thyroid stem hormone  
 
1 test during NICU 40 
Homocystine Scr 1 test during NICU 70 
MRSA screening  1 test during NICU 130 
Urine culture 1 test during NICU 50 
PH 1 test during NICU 30 
PO2 1 test during NICU 10 
Partial pressure of carbon 
dioxide (PCO2) 
 
1 test during NICU 10 
Bicarbonate (HCO3) 1 test during NICU 10 
Base excess  1 test during NICU 10 
Cytomegalovirus antibodies 
(CMV Ab) IgG  
 
1 test during NICU 110 
CMV Ab IgM  
  
1 test during NICU 110 
Herpes simplex type I IgG
  
1 test during NICU 30 
Herpes simplex type I IgM
  
1 test during NICU 30 
Herpes simplex type II IgG 1 test during NICU 30 
Herpes simplex type II IgM
  
1 test during NICU 30 
Rubella Ab IgG  
  
1 test during NICU 110 
Rubella Ab IgM  
  
1 test during NICU 90 
Toxoplasma Ab IgG 
  
1 test during NICU 120 
Toxoplasma Ab IgM 1 test during NICU 120 
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Table 3.3 Estimated resource costs based on the NICU at AH 
Item / Name of test Unit Unit cost (QAR) 
Urea 1 test during NICU 7.27 
Creatinine 1 test during NICU 7.27 
Sodium 1 test during NICU 10.91 
Potassium 1 test during NICU 10.91 
Chloride 1 test during NICU 10.91 
Bicarbonate  1 test during NICU 8.48 
Magnesium  1 test during NICU 9.7 
Blood culture  1 test during NICU 125.18 
Cerebrospinal fluid (CSF) culture  1 test during NICU 105.92 
CSF analysis  1 test during NICU 120.37 
Urinalysis tests 1 test during NICU 72.22 
X-radiation (x-ray) 1 test during NICU 26.36 
Computerized tomography scan 
(CT scan) 
 
1 test during NICU 158.14 
Ultrasound scan (US) 1 test during NICU 84.34 
Magnetic resonance imaging (MRI) 1 test during NICU 263.57 
Barium enema  1 test during NICU 71.69 
Electrocardiogram-EKG  1 test during NICU 26.36 
Water soluble contrast enema 1 test during NICU 15.81 
Peripherally inserted central 
catheter (PICC line) insertion  
 
1 test during NICU 21.08 
Echocardiogram  1 test during NICU 115.97 
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Lumbar puncture  1 test during NICU 57.98 
Oxygen therapy 1 test during NICU 211.54 
NICU stay Stay per day 527.14 
Mechanical ventilator  1 machine  430.15 
 
Table 3.4 Unavailable resource costs in HMC and AH 
Item  Unit Unit cost (QAR) 
Respiratory secretion culture 1 test during NICU N/A 
Volume CSF 1 test during NICU N/A 
WBC CSF 1 test during NICU N/A 
RBC CSF 1 test during NICU N/A 
Lymphocyte CSF  1 test during NICU N/A 
Monocyte CSF  1 test during NICU N/A 
Fluoroscopy thorax 1 test during NICU N/A 
Pediatric surgery 1 test during NICU N/A 
NM blood pool scan   1 test during NICU N/A 
Loopogram gastrointestinal 
trace 
 
1 test during NICU N/A 
Central catheter repositioning  1 test during NICU N/A 
Circumcision procedure  1 test during NICU N/A 
Urethrocystogram once 1 test during NICU N/A 
Hepatobiliary function scan 
and stim 
 
1 test during NICU N/A 
Fluoroscopy esophagus  1 test during NICU N/A 
Cardiac catheterization-
diagnostic 
1 test during NICU N/A 
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Pulmonary function studies  1 test during NICU N/A 
Bronchoscopy  1 test during NICU N/A 
 
3.2.12 Sensitivity analysis 
The main goal of sensitivity analysis was, as previously discussed, to indicate the 
robustness of the evaluation conclusion against any potential variations in the model 
inputs 
One-way sensitivity analyses. Variations in the duration of MV and NICU stay, loading 
and maintenance doses of initial medications, and estimated costs were investigated for 
their effect on the study outcomes. Uncertainty of ±3% was used for the duration of MV 
and NICU stay, and an uncertainly of ±5% was used for medication doses. A ±10% range 
was used to investigate the uncertainty associated with the estimated input prices in the 
model. All uncertainty analyses were run via Monte Carlo (see description in the 
following paragraph). Variables and their uncertainty ranges are shown in Table 3.5.  
Probabilistic sensitivity analyses: Uncertainty analysis, by means of Monte Carlo 
simulation, was performed via the @Risk-7.5® analysis tool to investigate the likelihood 
(probability) of a therapy’s economic advantage. Monte Carlo is a method whereby 
simulated input values, chosen randomly across a range of probability distributions of a 
model input, are added into the model. A triangular type of distribution and uncertainty 
of ±3%, based on 10,000 model simulations, was used. The model was run for each 
simulated input, resulting in a range of outputs characterizing the output uncertainty for 
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the input. Based on this, a distribution of “cost savings” or “cost-effectiveness” was 
generated, indicating the probability of one therapy having an economic advantage over 
another. 
 
Table 3.5. Variation ranges of variables of interest in sensitivity analysis 
Variable Base case 
 
Variation range 
Low High 
Cost of urea 7.27 QAR 6.54 8 
Cost of creatinine 7.27 QAR 6.54 8 
Cost of sodium 10.91 QAR 9.82 12 
Cost of potassium 10.91 QAR 9.82 12 
Cost of chloride 10.91 QAR 9.82 11.9 
Cost of bicarbonate  8.48 QAR 8.06 8.9 
Cost of magnesium  9.7 QAR 8.73 10.67 
Cost of blood culture  125.18 QAR 112.67 137.09 
Cost of CSF culture  105.92 QAR 95.34 116.5 
Cost of CSF analysis  120.37 QAR 95.32 116.52 
Cost of urinalysis tests 72.22 QAR 65 79.44 
Cost of x-ray 26.36 QAR 23.72 29 
Cost of CT-scan 158.14 QAR 142.33 173.95 
Cost of US-scan 84.34 QAR 75.91 92.77 
Cost of MRI 263.57 QAR 237.31 289.83 
Cost of barium enema  71.69 QAR 64.52 78.86 
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Cost of electrocardiogram-EKG  26.36 QAR 23.72 29 
Cost of water soluble contrast enema 15.81 QAR 14.23 
 
17.39 
 
Cost of peripherally inserted central 
catheter (PICC line) insertion  
 
21.08 QAR 18.98 
 
23.2 
 
Cost of echocardiogram  115.97 QAR 104.25 
 
127.57 
 
Cost of lumbar puncture  57.98 QAR 52.19 
 
63.79 
 
Cost of oxygen therapy 211.54 QAR 190.39 
 
232.69 
 
Cost of NICU stay 527.14 QAR 474.43 
 
579.85 
 
Cost of MV 430.15 QAR 387.14 473.17 
 
Evaluation 1: Fentanyl monotherapy 
MV duration during sedation success 6 days 5.82 6.18 
MV duration during sedation failure-high 
dose 
4 days 3.88 4.12 
MV duration during sedation failure-
alternative 
 
9.27 days 8.99 9.55 
MV duration during sedation failure-death 6 days 5.82 6.18 
MV duration during sedation failure-
persistent agitation  
 
1 day 0.97 1.03 
NICU duration during sedation success 45 days 43.65 46.35 
NICU duration during sedation failure-high 
dose 
 
27 days 26.19 27.81 
NICU duration during sedation failure-
alternative 
 
33 days 32.01 33.99 
NICU duration during sedation failure-
death 
 
11 days 10.67 11.33 
NICU duration during sedation failure-
persistent agitation  
 
9 days 8.73 9.27 
Loading dose of fentanyl during sedation 
success 
 
2.11 mcg/kg 2 2.22 
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Loading dose of fentanyl during sedation 
failure-high dose 
 
5.32 mcg/kg 5.05 5.59 
Loading dose of fentanyl during sedation 
failure-alternative 
 
3 mcg/kg 2.85 3.15 
Loading dose of morphine during sedation 
failure-alternative 
 
100 mcg/kg 95 105 
Loading dose of fentanyl during sedation 
failure-death 
 
1 mcg/kg 0.95 1.05 
Loading dose of fentanyl during sedation 
failure-persistent agitation  
 
N/A N/A N/A 
Maintenance dose of fentanyl during 
sedation success 
 
4.57 mcg/kg 4.34 4.8 
Maintenance dose of fentanyl during 
sedation failure-high dose 
 
4.3 mcg/kg 4.09 4.52 
Maintenance dose of fentanyl during 
sedation failure-alternative 
 
3.33 mcg/kg 3.17 3.5 
Maintenance dose of morphine during 
sedation failure-alternative 
 
13.33 mcg/kg 12.66 14 
Maintenance dose of fentanyl during 
sedation failure-death 
 
N/A N/A N/A 
Maintenance dose of fentanyl during 
sedation failure-persistent agitation 
  
N/A N/A N/A 
Evaluation 1: Morphine monotherapy 
MV duration during sedation success 6 days 5.82 6.18 
MV duration during sedation failure-high 
dose 
 
27 days 26.19 27.81 
MV duration during sedation failure-
alternative 
 
66 days 64.02 67.98 
MV duration during sedation failure-
withdrawal symptoms 
  
1 day 0.97 1.03 
MV duration during sedation failure-death 16 days 15.52 16.48 
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MV duration during sedation failure-
persistent agitation  
 
1 day 0.97 1.03 
NICU duration during sedation success 47 days 45.9 48.41 
NICU duration during sedation failure-high 
dose 
 
54 days 52.38 55.62 
NICU duration during sedation failure-
alternative 
 
83 days 80.51 85.49 
NICU duration during sedation failure-
withdrawal symptoms  
 
15 days 14.55 15.45 
NICU duration during sedation failure-
death 
20 days 19.4 20.6 
NICU duration during sedation failure-
persistent agitation  
16 days 15.52 16.48 
Loading dose of morphine during sedation 
success 
 
125 mcg/kg 118.75 131.25 
Loading dose of morphine during sedation 
failure-high dose 
 
292.5 mcg/kg 277.88 307.13 
Loading dose of morphine during sedation 
failure-alternative 
 
120 mcg/kg 114 126 
Loading dose of fentanyl during sedation 
failure-alternative 
 
3.73 mcg/kg 3.54 3.92 
Loading dose of morphine during sedation 
failure-withdrawal symptoms  
 
N/A N/A N/A 
Loading dose of morphine during sedation 
failure-death 
 
127.5 mcg/kg  121.13 133.89 
Loading dose of morphine during sedation 
failure-persistent agitation  
 
N/A N/A N/A 
Maintenance dose of morphine during 
sedation success 
 
12.27 mcg/kg 11.66 12.88 
Maintenance dose of morphine during 
sedation failure-high dose 
 
15 mcg/kg 14.25 15.75 
Maintenance dose of morphine during 
sedation failure-alternative 
10 mcg/kg 9.5 10.5 
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Maintenance dose of fentanyl during 
sedation failure-alternative 
 
10 mcg/kg 9.5 10.5 
Maintenance dose of morphine during 
sedation failure-withdrawal symptoms  
 
15 mcg/kg 14.25 15.75 
Maintenance dose of morphine during 
sedation failure-death 
 
11.67 mcg/kg 11.09 12.25 
Maintenance dose of morphine during 
sedation failure-persistent agitation  
 
5 mcg/kg 4.25 5.75 
Evaluation 2: Morphine monotherapy 
MV duration during sedation success 7 days 6.79 7.21 
MV duration during sedation failure-
withdrawal symptoms  
 
25 days 24.25 25.75 
MV duration during sedation failure-death 15 days 14.55 15.45 
NICU duration during sedation success 51 days 49.47 52.53 
NICU duration during sedation failure-
withdrawal symptoms  
 
27 days 26.19 27.81 
NICU duration during sedation failure-
death 
 
16 days 15.52 16.48 
Loading dose of morphine during sedation 
success 
 
175 mcg/kg 166.25 183.75 
Loading dose of morphine during sedation 
failure-withdrawal symptoms  
 
N/A N/A N/A 
Loading dose of morphine during sedation 
failure-death 
 
108.25 mcg/kg 102.84 113.66 
Maintenance dose of morphine during 
sedation success 
 
16.1 mcg/kg  15.3 16.91 
Maintenance dose of morphine during 
sedation failure-withdrawal symptoms  
 
11.8 mcg/kg 11.21 12.39 
Maintenance dose of morphine during 
sedation failure-death 
 
15 mcg/kg 14.25 15.75 
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Evaluation 2: Morphine plus midazolam 
MV duration during sedation success 29 days 28.13 29.87 
MV duration during sedation failure-high 
dose 
 
27 days 26.19 27.81 
MV duration during sedation failure-
alternative 
 
28 days 27.16 28.84 
MV duration during sedation failure-
withdrawal symptoms 
  
11 days 10.67 11.33 
MV duration during sedation failure-death 18 days 17.46 18.54 
MV duration during sedation failure-
persistent agitation  
 
6 days 5.82 6.18 
NICU duration during sedation success 77 days 72.75 77.25 
NICU duration during sedation failure-high 
dose 
 
63 days 61.11 64.89 
NICU duration during sedation failure-
alternative 
 
47 days 45.59 48.41 
NICU duration during sedation failure-
withdrawal symptoms  
 
12 days 11.64 12.36 
NICU duration during sedation failure-
death 
 
54 days 53.38 55.62 
NICU duration during sedation failure-
persistent agitation  
 
6 days 5.82 6.18 
Loading dose of morphine during sedation 
success 
 
102 mcg/kg 96.9 107.1 
Loading dose of midazolam during 
sedation success 
 
N/A N/A N/A 
Loading dose of morphine during sedation 
failure-high dose 
 
207.6 mcg/kg  197.22 217.98 
Loading dose of midazolam during 
sedation failure-high dose 
 
100 mcg/kg 95 105 
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Loading dose of morphine during sedation 
failure-alternative 
 
160 mcg/kg 152 168 
Loading dose of midazolam during 
sedation failure-alternative 
 
100 mcg/kg 95 105 
Loading dose of fentanyl during sedation 
failure-alternative 
 
5.2 mcg/kg  5.04 5.36 
Loading dose of morphine during sedation 
failure-withdrawal symptoms  
 
N/A N/A N/A 
Loading dose of midazolam during 
sedation failure-withdrawal symptoms 
 
N/A N/A N/A 
Loading dose of morphine during sedation 
failure-death 
 
97 mcg/kg 92.15 101.85 
Loading dose of midazolam during 
sedation failure-death 
 
100 mcg/kg 95 105 
Loading dose of morphine during sedation 
failure-persistent agitation  
 
50 mcg/kg 47.5 52.5 
Loading dose of midazolam during 
sedation failure-persistent agitation 
 
200 mcg/kg 190 210 
Maintenance dose of morphine during 
sedation success 
 
10 mcg/kg 9.5 10.5 
Maintenance dose of midazolam during 
sedation success 
 
20.88 mcg/kg 16.44 18.17 
Maintenance dose of morphine during 
sedation failure-high dose 
 
16.1 mcg/kg  15.3 16.91 
Maintenance dose of midazolam during 
sedation failure-high dose 
 
47.5 mcg/kg  45.13 49.88 
Maintenance dose of morphine during 
sedation failure-alternative 
 
160 mcg/kg 152 168 
Maintenance dose of midazolam during 
sedation failure-alternative 
 
100 mcg/kg 95 105 
Maintenance dose of fentanyl during 
sedation failure-alternative 
5.2 mcg/kg  4.94 5.46 
77 
 
 
Maintenance dose of morphine during 
sedation failure-withdrawal symptoms  
 
18.5 mcg/kg  17.58 19.43 
Maintenance dose of midazolam during 
sedation failure-withdrawal symptoms 
30 mcg/kg 28.5 31.5 
Maintenance dose of morphine during 
sedation failure-death 
 
14.5 mcg/kg  13.78 15.23 
Maintenance dose of midazolam during 
sedation failure-death 
 
N/A N/A N/A 
Maintenance dose of morphine during 
sedation failure-persistent agitation  
 
20 mcg/kg 19 21 
Maintenance dose of midazolam during 
sedation failure-persistent agitation 
 
N/A N/A N/A 
Evaluation 3: Fentanyl monotherapy 
MV duration during sedation success 3 days 2.91 3.09 
MV duration during sedation failure-high 
dose 
 
3 days 2.91 3.09 
MV duration during sedation failure-
alternative 
 
7 days 6.79 7.21 
MV duration during sedation failure-
withdrawal symptoms  
 
6 days 5.82 6.18 
MV duration during sedation failure-death 12 days 11.64 12.36 
MV duration during sedation failure-
persistent agitation  
 
8 days 7.76 8.24 
NICU duration during sedation success 41 days 39.77 42.23 
NICU duration during sedation failure-high 
dose 
 
19 days 18.43 19.57 
NICU duration during sedation failure-
alternative 
 
25 days 24.25 25.75 
NICU duration during sedation failure-
withdrawal symptoms  
 
12 days 11.64 12.36 
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NICU duration during sedation failure-
death 
 
12 days 11.64 12.36 
NICU duration during sedation failure-
persistent agitation  
 
27 days 26.19 27.81 
Loading dose of fentanyl during sedation 
success 
 
2.6 mcg/kg 2.47 2.73 
Loading dose of fentanyl during sedation 
failure-high dose 
 
5.4 mcg/kg  5.13 5.67 
Loading dose of fentanyl during sedation 
failure-alternative 
 
5.86 mcg/kg 5.57 6.16 
Loading dose of morphine during sedation 
failure-alternative 
 
280 mcg/kg 266 294 
Loading dose of fentanyl during sedation 
failure-withdrawal symptoms  
 
N/A N/A N/A 
Loading dose of fentanyl during sedation 
failure-death 
 
N/A N/A N/A 
Loading dose of fentanyl during sedation 
failure-persistent agitation  
 
2 mcg/kg 1.9 2.1 
Maintenance dose of fentanyl during 
sedation success 
 
4.5 mcg/kg  4.28 4.73 
Maintenance dose of fentanyl during 
sedation failure-high dose 
 
6.4 mcg/kg  6.08 6.72 
Maintenance dose of fentanyl during 
sedation failure-alternative 
 
3 mcg/kg 2.85 3.15 
Maintenance dose of morphine during 
sedation failure-alternative 
 
28.3 mcg/kg  26.89 29.72 
Maintenance dose of fentanyl during 
sedation failure-withdrawal symptoms  
 
3.5 mcg/kg  3.33 3.68 
Maintenance dose of fentanyl during 
sedation failure-death 
 
5 mcg/kg 4.75 5.25 
Maintenance dose of fentanyl during 
sedation failure-persistent agitation  
3.88 mcg/kg 3.69 4.07 
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Evaluation 3: Fentanyl plus midazolam 
MV duration during sedation success 13 days 12.61 13.39 
MV duration during sedation failure-high 
dose 
 
30 days 29.1 31.9 
MV duration during sedation failure-
alternative 
 
54 days 52.38 55.62 
NICU duration during sedation success 43 days 41.71 44.29 
NICU duration during sedation failure-high 
dose 
 
61 days 59.17 62.83 
NICU duration during sedation failure-
alternative 
 
79 days 76.63 81.37 
Loading dose of fentanyl during sedation 
success 
 
3 mcg/kg 2.85 3.15 
Loading dose of midazolam during 
sedation success 
 
95 mcg/kg 90.25 99.75 
Loading dose of fentanyl during sedation 
failure-high dose 
 
2.25 mcg/kg 2.14 2.36 
Loading dose of midazolam during 
sedation failure-high dose 
 
116.6 mcg/kg  110.2 121.8 
Loading dose of fentanyl during sedation 
failure-alternative 
 
5.1 mcg/kg  4.85 5.36 
Loading dose of morphine during sedation 
failure-alternative 
 
210 mcg/kg 199.5 220.5 
Loading dose of midazolam during 
sedation failure- alternative 
 
200 mcg/kg 190 210 
Maintenance dose of fentanyl during 
sedation success 
 
2.6 mcg/kg  2.47 2.73 
Maintenance dose of midazolam during 
sedation success 
 
20 mcg/kg 19 21 
Maintenance dose of fentanyl during 
sedation failure-high dose 
9.1 mcg/kg  8.65 9.56 
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Maintenance dose of midazolam during 
sedation failure-high dose 
 
15 mcg/kg 14.25 15.75 
Maintenance dose of fentanyl during 
sedation failure-alternative 
 
10 mcg/kg 9.5 10.5 
Maintenance dose of morphine during 
sedation failure-alternative 
 
12.2 mcg/kg  11.59 12.81 
Maintenance dose of midazolam during 
sedation failure- alternative 
 
19 mcg/kg 18.05 19.95 
*N/A: Not applicable  
 
Alternative scenario: In this study, we investigated the scenario of performing the cost- 
effectiveness evaluation of morphine, fentanyl, morphine plus midazolam, and fentanyl 
plus midazolam from the perspective of the private health section in Qatar, i.e. solely 
based on AH prices. This is to generalize the relative sedation outcomes to the neonates 
who are not covered by governmental subsidies, such as those of visitors and/or those 
looking for the five star services in the private sector. 
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Chapter 4: Results 
4.1 Phase 1: Systematic review of literature methods  
4.1.1 Study selection and study description 
The search of literature generated 33 eligible articles for analysis (Figure 4.1). A 
summary description of the included studies is in Table 4.1. The studies were conducted 
between 1989-2014. Twelve studies were conducted in the US (63, 76-86), whereas nine 
reported data from five countries within Europe (58, 61, 62, 87-92), two from Asia (93, 
94), three in Canada (60, 95, 96), two in Brazil (80, 97), and no name of country was 
specified in the remaining studies (n= 5) (59, 98-101). 
4.1.2 Study population 
Of the 33 included studies, 22 were conducted in a population of adults, eight in 
neonates, and three in pediatrics. In about half of the studies (n= 14), patients had 
mixed conditions where respiratory disorders were identified as one of several other 
underlying conditions. In eight studies, the respiratory disorder was identified as the 
underlying condition of interest. Eleven studies did not report the underlying disorder of 
the patients. All studies are summarized in Appendix 5. Four of the studies that 
primarily identified an underlying respiratory disorder were in adults (80, 95, 96, 100) 
and four were in neonates (61-64). 
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Figure 4.1 Flow diagram of literature search results
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Table 4.1. Summary of the characteristics of the included studies 
 
N Subject Author, Year, 
Country 
Study 
Design 
Interventions 
vs. 
Comparators 
Duration 
of 
Therapy 
Economics 
Methods 
Primary 
Outcome 
Definition of 
Primary 
Outcome 
Secondary 
Outcome 
Definition of 
Secondary 
Outcome 
Main Findings 
1 Adult Carrasco et 
al, 1993, USA 
(76) 
RCT Propofol + 
morphine vs. 
midazolam 
NA CBA, NA Treatment 
success 
based on 
the desired 
level of 
sedation 
using RSS 
and GCS 
Adequate 
sedation (if 
sedation level 
was grade 2, 
3, 4, or 5 on 
RSS or degree 
of reactivity 
was 
maintained 
between 8-13 
points on 
GCSC 
Sedatives 
cost and 
Hypotensi
on 
episodes 
NA Propofol and 
morphine 
provided 
significantly 
adequate 
sedation, more 
hypotension 
cases with 
higher short 
term cost and 
lower medium 
and long term 
cost 
2 Adult Al MJ et al, 
2010, 
Netherlands 
(87) 
RCT Remifentanyl 
+ propofol vs. 
fentanyl or 
morphine + 
midazolam, 
propofol or 
lorazepam 
10 days 
maximum 
CCA, 
Markov 
Sedatives 
cost 
NA NA NA Remifentanyl + 
propofol 
was less costly 
3 Adult Zhou et al, 
2014, China 
(93) 
RCT Midazolam + 
fentanyl vs. 
propofol vs.  
sequential use 
of midazolam 
+ propofol 
More than 
72 hours 
CA, NA Recovery 
and 
extubation 
time 
NA Sedatives 
and ICU 
costs 
hypotensi
on 
episodes 
Hypotension 
defined as 
reduce in 
systolic 
blood 
pressure 
Sequential use 
of propofol + 
midazolam was 
better in 
relation to 
earlier 
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more than 
20% 
extubation, less 
sedation and 
total ICU costs, 
and less 
hypotension 
cases compared 
the other 
groups 
4 Adult Barrientos et 
al, 1997, NA 
(98) 
RCT Midazolam + 
morphine vs. 
propofol + 
morphine 
More than 
24 hour 
CA, 
Predictive 
Weaning 
time and 
cost 
NA Tachyphyl
axis, 
treatment 
failures 
associated 
with 
sedatives 
Treatment 
failures 
(patients 
needing >12 
mL/hour of 
study 
medication) 
Propofol + 
morphine 
reduced the 
weaning time, 
cost, and 
therapeutic 
failure 
5 Adult Swart et al, 
1999, USA 
(77) 
RCT lorazepam + 
fentanyl vs. 
midazolam + 
fentanyl 
NA CA, NA Treatment 
success 
based on 
the desired 
level of 
sedation 
using 
Addenobro
oke Scale 
Adequate 
sedation level 
was 
considered as 
lightly asleep 
but easily 
roused by 
voice 
Total cost 
of 
sedation 
NA Lorazepam 
provided easier 
management of 
the sedation 
level and 
offered a 
significant cost-
savings 
6 Adult Mehta et al, 
2008, Canada 
(95) 
RCT Midazolam + 
morphine 
(PS+DIS) vs. 
midazolam + 
morphine (PS 
only) 
NA NA, NA Treatment 
success 
based on 
the desired 
level of 
sedation 
using SAS 
Adequate 
sedation level 
was scored as 
level 3 and 4 
Duration 
of MV, ICU 
and 
hospital 
stay, and 
mortality 
rate 
Duration of 
MV from the 
time of 
intubation to 
extubation 
for 2 days 
PS achieveed 
better desired 
SAS score 
 
No difference 
was observed in 
the duration of 
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MV, ICU and 
hospital stay, 
and mortality 
7 Adult Rozendaal et 
al, 2009, 
Netherlands 
(88) 
RCT Remifentanyl 
+ propofol vs. 
fentanyl or 
morphine + 
midazolam, 
propofol or 
lorazepam 
10 days 
maximum 
NA, NA Duration of 
MV 
NA Weaning 
time 
and ICU-
LOS 
NA Duration of MV, 
weaning time 
and ICU stay 
was statistically 
lower in the 
remifentanyl + 
propofol 
8 Adult Breen et al, 
2005, NA 
(99) 
RCT Remifentanyl 
vs. midazolam 
+ morphine or 
fentanyl 
 
10 days NA, NA Extubation 
time 
NA Weaning 
time, ICU 
stay, and 
treatment 
success 
based on 
the 
desired 
level of 
sedation 
based on 
SAS 
Adequate 
sedation was 
considered 
as level 3 or 
4 
 
ICU stay until 
discharge 
Extubation and 
weaning time 
and ICU stay 
were lower in 
remifentanyl 
with same 
sedation score 
9  Adult Karir et al, 
2012, USA 
(78) 
Observa
tional 
Morphine vs. 
fentanyl 
14 days NA, NA Cumulative 
14 days 
dose 
NA NA NA The median 
dose of fentanyl 
was higher 
during the 14 
days 
10  Adult Watling et al, 
1996, Canada 
(96) 
Observa
tional 
Lorazepam 
with/out 
morphine 
NA NA, NA Apnea and 
respiratory 
effort 
NA NA NA Lorazepam and 
morphine 
combination 
caused apnea 
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and reduced 
the respiratory 
effort during 2 
to 50 days of 
sedation 
11 Adult Strom et al, 
2010, 
Denmark 
(89) 
RCT Morphine vs. 
morphine + 
propofol 
28 days NA, NA MV free 
days 
ICU and 
hospital 
stay, 
mortality  
MV free days 
in 28 days 
period  
The need 
for CT or 
MRI brain 
scans, 
accidental 
removal of 
endotrach
eal tube, 
and VAP 
VAP: new 
lung 
parenchymal 
opacity on a 
chest 
radiograph 
of a patient 
who had 
been 
intubated for 
> 48 hours, 
and 
simultaneous 
presentation 
of 2 or more 
of: 
temperature 
of <36°C or 
>38°C; white 
blood cell 
count of 
<4×10⁹/L or 
>10×10⁹/L; 
or purulent 
secretions 
from the 
endotracheal 
MV free days 
was statistically 
lower in the 
morphine + 
propofol group  
 
LOS in ICU and 
hospital, 
tracheostomy, 
VAP and 
mortality were 
less but not 
significant in 
morphine 
monotherapy 
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tube 
12 Adult Jarman et al, 
2013, USA 
(79) 
Observa
tional 
Morphine + 
propofol vs. 
midazolam 
NA NA, NA MV free 
days, ICU 
LOS, 
mortality 
rate 
NA NA NA MV free days 
was significantly 
lower in 
midazolam 
 
ICU LOS was 
significantly 
lower in 
propofol + 
morphine 
 
No difference 
between both 
in relation 
mortality 
13 Adult Tedders et al, 
2014, USA 
(86) 
Observa
tional 
Fentanyl vs. 
propofol 
NA NA, NA Duration of 
MV 
NA ICU stay, 
the 
percentag
e of the 
desired 
level of 
pain and 
sedation 
and 
frequency 
of 
hypotensi
on 
Hypotension 
defined as 
reduce in the 
systolic 
blood 
pressure 
to less than 
90 mmHg at 
two 
repeated 
periods 
or reduce in 
systolic 
blood 
pressure to 
more than 
Duration of MV 
was significantly 
lower in the 
fentanyl group 
 
No difference 
was associated 
between both 
groups in ICU 
stay, 
hypotension, 
and desired 
RASS score 
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40 mmHg 
14 Adult Riker et al, 
2009, USA, 
brazil, 
Australia, 
Argentina, 
New Zealand 
(80) 
RCT Dexmedetomi
dine + 
fentanyl vs. 
midazolam + 
fentanyl 
30 days 
maximum 
NA, NA Time to 
reach the 
desired 
RASS score 
Target 
sedation 
range (RASS 
score −2 to 1) 
The 
duration 
and free 
days of 
delirium 
Delirium free 
days were 
calculated as 
days alive 
and free of 
delirium 
during study 
drug 
exposure 
Time to reach 
the desired 
RASS score was 
not significantly 
lower in the 
midazolam and 
fentanyl group 
 
Delirium free 
days were 
significantly 
lower in 
midazolam 
group 
15 Adult Junior et al, 
2014, Brazil 
(97) 
RCT Intermittent 
sedation 
(fentanyl) vs. 
daily 
interruption 
(fentanyl) 
28 days NA, NA MV-free 
days 
In a 28 day 
period 
ICU and 
hospital 
mortality, 
ICU and 
hospital 
LOS, 
incidence 
of 
delirium, 
time to 
reach the 
desired 
SAS score 
Target SAS 
(level 3 or 4) 
 
Delirium 
within 7 days 
MV free days 
and time to 
reach desired 
SAS score were 
higher in the 
intermittent 
group 
 
ICU and hospital 
mortality and 
delirium 
happened less 
in the 
intermittent 
group 
16 Adult Shehabi et al, RCT Lightly vs. NA NA, NA Treatment Target Delirium Delirium was Median target 
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2013, 
Malaysia (94)  
deeply 
sedation of 
(midazolam, 
propofol, 
morphine, 
fentanyl, 
dexmedetomi
dine) 
success 
based on 
the level of 
sedation 
using RASS  
sedation 
range (RASS 
score −2 to 1) 
and free 
days of 
delirium  
defined if 
patients had 
positive 
results using 
the 
confusion 
assessment 
methods for 
intensive 
care 
 
Subjects 
were 
considered 
delirium free 
if they had a 
RASS above 
3  
RASS scores and 
delirium-free 
days were 
higher in the 
lightly sedated 
group after 48 
hours 
 
17 Adult Aitkenhead 
et al, 1989, 
NA (100) 
RCT Propofol + 
morphine vs. 
midazolam + 
morphine  
Less than 
24 hours 
NA, NA Treatment 
success 
based on 
the desired 
level of 
sedation 
using RSS  
Desired level 
was defined 
as 
cooperative, 
oriented, and 
tranquil, 
responding to 
command 
only, or 
showing a 
brisk 
response to 
light glabellar 
tap or a loud 
Weaning 
time, 
mortality 
and 
hypotensi
on 
episodes  
NA Higher desired 
RSS score and 
lower weaning 
time were in 
the propofol 
and morphine 
group 
 
Mortality and 
hypotension 
happened more 
frequently in 
the propofol 
and morphine 
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auditory 
stimulus  
group 
 
18 Adult Cox et al, 
2008, 
Denmark 
(90) 
RCT Propofol vs. 
lorazepam vs. 
morphine 
NA CEA, 
Decision 
analysis 
MV- free 
days 
Within 28 
days from 
intubation 
Cost NA Propofol 
dominated 
lorazepam due 
to its lower 
overall costs 
and greater MV 
free days 
19 Neonate Anand et al, 
1999, NA 
(59) 
RCT Morphine vs. 
midazolam vs. 
placebo 
14 days 
maximum 
NA, NA Severity of 
illness using 
PIPP scale 
and level of 
sedation 
using 
COMFORT 
scale 
PIPP defined 
as no or mild 
pain if the 
score was 
between 0-6, 
moderate 
pain if the 
score was 
between 7-
12, and 
severe pain if 
the score was 
above 12 
 
COMFORT 
score defined 
as target 
range of 
sedation 
between 17 
and 26 
Poor 
neurologic
al 
outcomes 
(neonatal 
death, IVH 
grade 3 or 
4, PVL) 
 
MV free 
days, ICU 
stay, 
tolerance 
of enteral 
feeds 
Neonatal 
death 
occurring at 
0 to 28 days 
of age 
without 
discharge 
from NICU 
Only morphine 
had elevated 
COMFORT score 
which 
decreased 
significantly the 
level of 
sedation 
 
Morphine and 
midazolam 
groups reduced 
significantly the 
pain score 
 
Three deaths; 
two in placebo, 
one in 
midazolam, and 
none in 
morphine 
 
Poor 
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neurological 
outcomes 
occurred more 
frequently in 
placebo group 
and least in the 
morphine group 
 
No difference 
between both 
groups in MV 
free days and 
ICU stay 
20 Neonate Saarenmaa 
et al, 1999, 
Finland (58)   
RCT Fentanyl vs. 
morphine 
2 days NA, NA Severity of 
illness using 
behavioral 
pain scale 
NA Decreased 
gastrointe
stinal 
motility,  
 
necrotizin
g 
enterocoli
tis, urinary 
retention 
Decreased 
gastrointesti
nal motility 
through daily 
meconium 
passage 
assessment 
 
Urinary 
retention 
defined as 
the inability 
to urinate 
spontaneous
ly with 
bladder 
enlargement 
or reversible 
hydro 
No difference 
was observed in 
the pain score 
response 
between both 
groups except 
in the b-
Endorphin in 
favor of 
fentanyl 
 
Decreased 
gastrointestinal 
motility 
occurred 
significantly less 
frequently in 
fentanyl group 
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nephrosis  
 
Necrotizing 
enterocolitis 
and urinary 
retention were 
more diagnosed 
in the fentanyl 
group 
21 Neonate Wood et al, 
1998, UK (61) 
RCT Diamorphine 
vs. morphine 
25 hours NA, NA Treatment 
success 
based on 
desired 
level of 
sedation 
using a 
study 
specific 
scale 
NA Duration 
of MV and 
mortality, 
IVH 
NA No difference 
was seen after 
24 hour of 
optimum 
sedation score, 
duration of MV, 
and mortality 
 
Incidence of IVH 
was higher in 
diamorphine 
22 Neonate Quinn et al, 
1992, Ireland 
(62) 
RCT Morphine vs. 
pancuronium 
vs. Morphine+ 
pancuronium 
Until O2 
concentrat
ion fell 
below 45% 
NA, NA Duration of 
MV and 
mortality, 
IVH 
NA NA NA No difference 
among the 
groups in terms 
of MV reduction 
and mortality 
 
IVH happened 
least in 
pancuronium 
23 Pediatric Tobias et al, 
1999, NA 
(101) 
Observa
tional 
Fentanyl+ 
midazolam vs. 
midazolam 
3-7 days NA, NA Withdrawal 
symptoms 
prevention 
NA NA NA No subjects 
developed 
withdrawal 
symptoms in 
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both groups 
24 Pediatric Tobias et al, 
2004, USA 
(81) 
RCT Midazolam + 
morphine vs. 
dexmedetomi
dine + 
morphine 
NA NA, NA Treatment 
success 
based on 
desired 
level of 
sedation 
using RSS 
Adequate 
sedation level 
was grade 2, 
3, 4, or 5 on 
the RSS 
Blood 
pressure 
and heart 
rate 
NA No difference 
was seen 
between groups 
in relation to all 
the measured 
outcomes 
25 Adult Kress et al, 
2000, USA 
(82) 
RCT Midazolam + 
morphine vs. 
propofol + 
morphine 
NA NA, NA Duration of 
MV, ICU 
and 
hospital 
stay 
NA The need 
for CT, 
MRI scan 
NA Duration of MV 
and ICU stay 
and need for 
diagnostic tests 
were 
significantly 
lower in the 
midazolam+ 
morphine group 
 
The hospital 
stay did not 
differ between 
the groups 
26 Adult Carson et al, 
2006, USA 
(83) 
RCT Lorazepam + 
morphine vs. 
propofol + 
morphine 
NA NA, NA Duration of 
MV 
From the time 
of intubation 
to the first 
time of 
extubation for 
≥ 3 days 
MV free 
days, ICU 
and 
hospital 
stay, and 
mortality 
NA Lorazepam + 
morphine 
reduced 
significantly the 
MV duration 
 
No difference 
between the 
groups in the 
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MV free days, 
ICU and hospital 
stay, and 
mortality 
27 Adult Barrientos et 
al, 2001, 
Spain (91) 
Observa
tional 
Propofol 2% + 
morphine vs. 
propofol 1% + 
morphine vs. 
midazolam 
+morphine 
14 days 
maximum 
CBA, 
Predictive 
Treatment 
failure and 
the ability 
to reach 
the desired 
sedation 
using RSS 
NA ICU cost ICU cost for 
duration of 
MV, sedative 
cost 
depending 
on dose 
used, and 
ICU cost 
during 
weaning 
No difference 
was seen in the 
ability to reach 
the desired 
sedation score 
and the 
treatment 
failure between 
propofol 1% 
and 2% 
 
Lowest ICU cost 
in propofol 2% 
and highest in 
the midazolam 
group 
28 Neonate Simons et al, 
2003, 
Netherland 
(92) 
RCT Morphine vs. 
placebo 
7 days NA, NA Level of 
pain using 
VAS, NIPS, 
PIPP 
VAS defined 
as scores 
range 
between 0-
10, low scores 
indicates low 
pain, while 
high scores 
indicates 
severe pain 
 
NIPS defined 
Poor 
neurologic
al 
outcomes 
Poor 
neurologic 
outcome 
defined as 
severe IVH, 
PVL, or death 
within 28 
days and the 
incidence of 
all grades of 
IVH 
No significant 
differences 
between groups 
in pain scores 
 
Poor 
neurological 
outcome 
happened in 
the lower ages 
but not 
associated with 
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as scores 
range 
between 0-
above 4, 0 
indicate no or 
mild pain and 
above 4 
means severe 
pain 
PIPP as 
defined by 
Anand et al 
study 
sedative 
29 Neonate Grunau et al, 
2009, Canada 
(60) 
RCT Morphine vs. 
placebo 
NA NA, NA Neurodevel
opmental 
outcomes  
MDI 
measures 
cognitive and 
language 
function and 
includes eye-
hand items 
such as 
stacking 
blocks, 
concrete 
problem 
solving tasks, 
receptive and 
expressive 
vocabulary 
items;  
PDI measures 
the gross 
NA NA Morphine was 
associated with 
poor 
neurodevelopm
ental outcome 
at 8 months 
only after 
sedation 
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motor 
development  
30 Neonate Orsini et al, 
1996, USA 
(63) 
RCT Fentanyl vs. 
placebo 
5 days NA, NA Behaviors’ 
of infants 
using 
behavioral 
state score 
Low score 
reflects 
sedated 
neonate while 
high score 
indicates not 
well sedated 
Duration 
of 
ventilation 
use, 
incidence 
of IVH 
NA Fentanyl 
showed 
significantly 
lower 
behavioral state 
score compared 
with placebo 
 
No difference 
was seen in 
relation to 
other outcomes 
31 Neonate Guinsburg et 
al, 1998, 
Brazil (64)  
RCT Fentanyl vs. 
placebo  
NA NA, NA Behaviors’ 
of infants 
using NFCS 
and MPC 
Scores 
NA Blood 
pressure 
and heart 
rate 
NA Lower 
behavioral state 
score in 
fentanyl 
 
Fentanyl 
reduced heart 
rate and blood 
pressure 
32 Adult Richman et 
al, 2006, USA 
(84) 
RCT Midazolam vs. 
midazolam + 
fentanyl 
NA NA, NA The 
number of 
hour /day 
that 
patients’ 
RSS 
deviated 
from the 
NA Number of 
patient-
ventilator 
asynchron
ous 
events/ 
day 
Number of 
times/day 
the chest 
wall 
respiratory 
rate exceeds 
the 
measured 
Midazolam and 
fentanyl 
reduced 
significantly the 
off target RSS 
score and 
number of 
patient-
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target value  ventilator 
rate by 
3/min 
ventilator 
asynchronous 
  
33 Pediatric   Anand et al, 
2013, USA 
(85) 
Observa
tional  
Morphine vs. 
fentanyl  
NA NA, NA Increased in 
opioid dose  
NA NA NA Doubling the 
dose of opioids 
was more likely 
to happen after 
opioid infusion 
for 7 days or 
longer 
 
More dose 
doubling 
happened when 
morphine was 
used as the 
initial opioid or 
if the child had 
prior PICU 
admission 
*RCT = randomized controlled trial; CBA = cost-benefit analysis; NA = not available; RSS = Ramsey Sedation Scale 
†GCS = Glasgow Coma Scale; CCA = cost consequence analysis; CA = cost analysis; ICU = intensive care unit 
‡PS = protocol sedation; DIS = daily interruption sedation; MV = mechanical ventilation; SAS = Sedation-Agitation Scale 
§LOS = length of stay; CT = computer tomography; MRI = magnetic resonance imaging; VAP = ventilator-associated pneumonia 
|| RASS = Richmond Agitation and Sedation Scale; CEA = cost-effectiveness analysis; PIPP = Premature Infant Pain Profile 
¶ IVH = intraventricular hemorrhage; PVL = periventricular leukomalacia; NICU = neonatal intensive care unit; VAS = Visual Analogue Scale  
** NIPS = Neonatal Infant Pain Scale; MDI = Mental Development Index; PDI = Psychomotor Development Index 
††NFCS = Neonatal Facial Coding System; MPC = Modified Postoperative Comfort; PICU = pediatric intensive care unit 
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4.1.3 Study comparators 
Only six studies compared between morphine and fentanyl in a head to head 
comparison (58, 78, 85, 87, 88, 99). In 23 studies, morphine was evaluated as 
monotherapy (n= 9) and/or combined with other agents, including propofol, midazolam, 
or lorazepam (n= 16) (58-62, 76, 78, 79, 81-83, 85, 87-92, 94-96, 98-100). Comparators 
were fentanyl, midazolam, propofol, lorazepam, diamorphine, pancuronium, or placebo. 
In contrast, fentanyl was evaluated in fifteen of the 33 studies, given alone (n= 7) or in 
combination with midazolam, propofol, lorazepam, or dexmedetomidine (n= 8) (58, 63, 
64, 77, 78, 80, 84, 86-88, 93, 94, 97, 99, 101). Comparators were morphine, 
remifentanyl, propofol, midazolam, lorazepam, or placebo. Study interventions and 
comparators are as shown in Table 4.1 and Appendices 6 and 7. 
4.1.4 Adult patients 
The age range of adult subjects was between fourteen and eighty years. The 
doses of morphine and fentanyl varied between (0.08-5 mg/kg/hr) and (0.5-2 
mcg/kg/hr), respectively. The majority of the 22 adult studies were RCTs (n= 17) and the 
remaining were observational studies (n= 5) (Table 4.1). 
Comparison of morphine and fentanyl was identified in four studies, two of which 
compared between remifentanyl plus propofol and fentanyl or morphine plus either 
midazolam, propofol or lorazepam while the third study compared between 
remifentanil and morphine or fentanyl in addition to midazolam (87, 88, 99). Two 
studies evaluated only the use of both sedatives without a direct comparison (78, 94).  
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The primary endpoint measured in the majority of the studies was the optimum level of 
sedation (n= 8). Studies by Richamn et al, Carrasco et al, Barrientos et al and Aitkenhead 
et al utilized Ramsay Sedation Scale (RSS) score to evaluate optimum sedation (76, 84, 
91, 100), which is defined as “cooperative, oriented, and tranquil, responding to 
command only, or showing a brisk response to light glabellar tap or a loud auditory 
stimulus”. The Addenobrook scale, however, was used in the Swart et al study (77). This 
is defined as “lightly asleep, but easily roused by voice”. Other studies, by Riker et al and 
Shehabi et al (80, 94), used the Richmond Agitation-Sedation Scale (RASS), which is 
defined as achieving target RASS score range of (-2 to +1), “briefly awakens with eye 
opening, not fully alert, anxious with movements”. Sedation Agitation Scale (SAS) which 
is defined as “calm, cooperative, and sedated” was used by Mehta et al (95). 
Only the study by Riker at al included study populations that were based on sample size 
calculations (80). 
All the scales were utilized differently without any specification in relation to the 
outcome of the study or the type of sedative as illustrated in Table 4.1. 
The duration of the MV was evaluated in seven different studies as another primary 
outcome by Rozendaal et al, Strom et al, Jarman et al, Tedders et al, Junior et al, Cox et 
al, Kress et al, and Carson et al (79, 82, 83, 88-90, 97). This was reported as mean or 
median days/hrs, in addition to ranges in all studies and was defined as MV free days in 
a 28 day period in Strom et al, Junior et al, and Cox et al studies and as from the time of 
intubation to the first time of extubation for equal to or more than three days in Carson 
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et al study. The other studies did not provide definitions for the duration of MV. Only in 
the studies by Rozendaal et al, Strom et al, Jarman et al, Tedders et al, Junior et al, Kress 
et al, and Carson et al, the statistical difference in outcome between comparators was 
reported. 
The optimum level of sedation was assessed as a secondary outcome in Breen et al and 
Junior et al studies (97, 99) where SAS was used and defined similar to the Mehta et al 
study. Mehta et al study used the duration of MV as their secondary outcome and 
defined it as from the time of intubation to extubation (95). The most identified 
secondary outcome measures were the length of stay in ICU (83, 86, 88, 95, 97, 99), 
adverse events, weaning time (88, 99, 100), delirium events and free days of delirium 
(80, 94, 97), and mortality (83, 95, 97, 100).   
The ICU length of stay was reported as mean/median days in addition to a range in all 
studies. Only Breen et al study defined this outcome as patients’ stay in the ICU until 
discharge. Others only followed up stay during sedation. The statistical difference in 
relation to the  duration of ICU stay was reported in the studies by Carson et al, Junior et 
al, Rozendaal et al, Tedders et al, Mehta et al, and Breen et al. Mortality events were 
defined as ICU mortality, but without any clarification if this is sedation related, in 
Mehta et al and Junior et al studies (95, 97), while Carson et al measured the mortality 
during hospital stay (83) and were reported as total number of cases. In Aitkenhead et al 
study, mortality was not defined. The statistical difference in the mortality was reported 
in the Mehta et al, Junior et al, and Carson et al studies.   
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With respect to adverse events, these were hypotension episodes (76, 86, 93, 100), and 
ventilator-associated pneumonia (VAP) (89). These were reported as total number of 
cases occurred during the sedation. Resources used to manage these events were not 
reported in any of the studies. 
In relation to delirium events, these were reported in the studies by Riker et al, Junior et 
al, and Shehabi et al (80, 94, 97) and were defined as the number of days without 
delirium during sedation by Riker et al study, delirium within seven days by Junior et al, 
and, by Shehabi et al, as a RASS score of more than -3 or if the patients had positive 
results using the confusion assessment methods for intensive care. Measurement of 
delirium was assessed via the confusion assessment methods in Shehabi et al study 
only. 
How statistically different secondary outcomes are among alternatives was only 
reported in the studies by Zhou et al, Tedders et al, Strom et al, Shehabi et al, and Riker 
et al. 
4.1.5 Neonatal patients 
Only one study of the eight neonatal studies involved direct comparison of 
fentanyl with morphine (58). The doses of morphine and fentanyl varied as 0.01-0.1 
mg/kg/hr and 0.5-1 mcg/kg/hr, respectively. Seven studies were RCTs, and only one was 
an observational study. 
Similar to studies in adults, the desired level of sedation was the most common primary 
endpoint measured in the majority of the studies (n= 6). This was measured in the study 
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by Anand et al, via the PIPP score, which is defined as neonate who has no or mild pain 
if the score is between 0 and 6, moderate pain if the score is between 7 and 12, and 
severe pain if the score is above 12, which indicates the need for sedation (59). Both 
COMFORT score and the PIPP score were used in one study to compare the same 
medications by Anand et al. Optimal sedation is defined as a COMFORT score between 
17 and 26. Simons et al measured the level of sedation using three tools; VAS (defined 
as scores range between 0 and 10, with lower scores indicating low pain, while high 
scores indicating severe pain), NIPS (defined as scores range between 0 and above 4, 
with 0 indicating no or mild pain, and above 4 meaning severe pain), and PIPP as defined 
by Anand et al study. In the study by Guinsburg et al, two scales were used to assess the 
behavior of the neonates, being NFCS and PCS which were not clearly defined (64). In 
the studies by Saarenmaa et al and Orsini et al, the outcome of sedation was measured 
by looking at the behavioral state of the neonates, low score reflects sedated neonate 
while high score indicates not well sedated neonates, as defined by Orsini et al study 
only (58, 63). 
Only in the Saarenmaa et al study, the studied population was based on sample size and 
power calculations. Outcomes in the study by Anand et al were of a pilot trial. 
Duration of MV and mortality were other primary endpoints measured in the Quinn et 
al study. This was reported as median days, and total number of cases, respectively. The 
definitions of these outcomes however were not provided.  
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As another primary outcome, the neurodevelopmental function was measured in the 
study by Grunau et al. This was performed through measuring the cognitive and 
language function using the MDI and the gross motor development using the PDI. 
Only in the study by Saarenmaa et al, the statistical difference between comparators’ 
outcomes was identified. 
The main secondary endpoints reported in the included studies were the duration of MV 
(59, 61), length of NICU stay (59), Gastrointestinal motility (58), urinary retention (58), 
poor neurological outcomes (59), and mortality (61).  
The duration MV and NICU stay was defined and reported as in the adult studies, so 
does the mortality. For the gastrointestinal motility and urinary retention, these were 
reported through measuring the daily meconium passage and inability to urinate 
spontaneously with bladder enlargement or reversible hydronephrosis.  
The neurological outcomes were defined as occurrence of cases of death, IVH grade 3 or 
4, or PVL.  
The statistical difference in secondary outcomes among alternatives was only reported 
in the studies by Saarenmaa et al and Wood et al.  
4.1.6 Pediatric patients 
Of the three eligible studies, two did not specify the respiratory disorder of 
patients. Direct comparison of morphine versus fentanyl was identified in one study by 
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Anand et al (85). The age range of children was 2 to 9 years old. The doses of morphine 
and fentanyl varied between 0.08-0.1 mg/kg/hr and 11-19 mcg/kg/hr, respectively.   
Two of the studies, by Anand et al and Tobias et al, were observational studies (85, 101), 
and one was RCT, also by Tobias et al (81). Tobias et al compared between fentanyl and 
midazolam as per their association with withdrawal symptoms after prolonged sedation 
(101). This was not defined, and is reported as mean. In a different study, Tobias et al 
measured the level of sedation using three different scales, i.e. RSS, Pediatric Intensive 
Care Unit (PICU) scale, and tracheal suctioning scale, in subjects receiving morphine with 
either midazolam or dexmedetomidine. The definitions of optimum sedation were not 
identified. Fentanyl and morphine were compared by Anand et al in a multicenter study 
that only measured the increase in opioids use to attain the level of sedation as seen at 
the beginning of management.  
In none of the three studies, study outcomes were based on power and sample size 
calculations. Also in none of the studies, efforts to report the power of outcomes were 
made. 
Secondary outcomes were only measured in one of the Tobias et al studies (81), in 
which the HR was comparatively reported. This was measured during receiving therapy. 
Despite the non-powered study population, statistical significance of the outcome was 
reported by Tobias et al and Anand et al studies (81, 85).  
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4.1.7 Economics evaluations 
Economic outcomes were evaluated in seven of the included studies; all in the 
adult population. Four studies used cost analysis (77, 91, 93, 98), one used CEA (90), one 
used CBA (76), and one used CCA (87). All the studies employed a hospital perspective, 
including medications, ICU stay, and hospital stay costs. Only one study, by Carrasco et 
al, reported the additional/marginal costs in which the subject needed a special care 
after sedation, such as nursing, respiratory or physiotherapy care (76). Only four studies 
used modeling approaches in this review, one was described as having a Markov 
structure (87), one used basic decision model (90), and two were described as predictive 
models (91, 98). 
The Markov model by Al MJ et al, in their cost consequence study, defined a variety of 
health states: MV (maintenance); MV (eligible to start weaning); MV (weaning started); 
MV (eligible to extubate); post-extubation; post-extubation (eligible for discharge ICU); 
discharged from ICU (final state); and death (final state). The time horizon of follow up 
was 28 days and the cycle length was one hr. Probabilistic sensitivity analysis was 
performed in the study, and an outcome probability was reported (87).  
In the predictive cost analysis models (77, 98), which only were cost analysis based, 
similar elements were considered throughout all studies for cost of medication 
calculations. Here, the total cost was depended on death, therapeutic failures, sedation 
time, medication cost, and length of stay in ICU during sedation and weaning cost. 
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Resources that were included in the cost analysis are medication costs and medication 
costs during MV. Both predictive models were based on simple linear regression. 
The remaining two studies that conducted cost analysis, by Zhou et al and Barrientos et 
al (91, 93), did not use a modeling approach. The comparative cost in both studies was 
the total ICU stay, including therapy and ICU management cost.  
A CBA was conducted by Carrasco et al who evaluated both the sedation and post 
sedation costs of the same therapies in three different sedation subgroups (76). These 
are short term 24 hr sedation, medium term 24 hrs up to one week sedation, and long 
term over one week sedation. While the duration of follow up differed among these, the 
outcomes and resources that were accounted for in cost calculations were similar, 
including medication costs, special therapy care costs such as physiotherapy and 
tracheal aspiration, and nursing care costs. Final outcomes were reported as the cost to 
benefit ratio.  
Cox et al compared among three therapies based on a cost-effectiveness basic decision 
model analysis. The model was for a follow up duration of 28 days, and included the 
cost of resources, such as costs of medication, MV, hospital stay, physicians, and 
laboratory tests. The ICER evaluation was the cost per additional MV-free days. The 
decision analytic model included nine possible treatment pathways depending on 
whether (the patient tolerated the medication with survival or death in the ICU or 
hospital ward and whether the patient was on or off MV) or (the patient developed 
ADRs due to inadequate sedation, hypertriglyceridemia, hemodynamic changes or 
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metabolic acidosis). As in the study by Al MJ et al, a probabilistic sensitivity analysis was 
conducted in this study.  
In none of the studies a deterministic, one-way or multivariate, analysis was conducted 
to investigate uncertain inputs.  
 
4.1.8 Quality assessment of the studies 
Results of the quality assessment of included studies can be summarized as in 
Tables 4.2, 4.3, and 4.
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Table 4.2. Quality assessment of the randomized controlled trials based on CONSORT criteria 
 
 
                Questions                                                                                                                                                                                                 Studies – Part 1     
  Anand  
et al  
Saarenmaa 
et al 
Wood 
et al   
Quinn 
et al  
Simons         
et al   
Orsini 
   et al 
Guinsburg 
et al 
Mehta 
et al   
Richman 
et al 
1a Identification as a 
randomized trial in the title 
NA A A NA A NA NA A NA 
1b Structured summary of trial 
design, methods, results, 
and conclusions (for specific 
guidance see CONSORT for 
abstracts) 
A A A A A A A A A 
2a Scientific background and 
explanation of rationale  
A A A A A A A A A 
2b Specific objectives or 
hypotheses  
A A A A A A A A A 
3a Description of trial design 
(such as parallel, factorial) 
including allocation ratio  
A A A A A A A A A 
3b Important changes to 
methods after trial 
commencement (such as 
eligibility criteria), with 
reasons  
NA NA NA NA NA NA NA NA NA 
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4a Eligibility criteria for 
participants  
A A A A A A A A A 
4b Settings and locations where 
the data were collected  
A A NA NA A A A A A 
5 The interventions for each 
group with sufficient details 
to allow replication, 
including how and when 
they were actually 
administered 
A A A A A A A A A 
6a Completely defined pre-
specified primary and 
secondary outcome 
measures, including how 
and when they were 
assessed  
A A A A A A A A A 
6b Any changes to trial 
outcomes after the trial 
commenced, with reasons  
NA NA NA NA NA NA NA NA NA 
7a How sample size was 
determined  
NA A NA A A NA NA NA NA 
7b When applicable, 
explanation of any interim 
analyses and stopping 
guidelines  
NA NA NA NA NA NA NA NA NA 
8a Method used to generate 
the random allocation 
sequence  
A A A A NA A A A NA 
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8b Type of randomization; 
details of any restriction 
(such as blocking and block 
size)  
A A NA A NA A A A NA 
9 Mechanism used to 
implement the random 
allocation sequence (such as 
sequentially numbered 
containers), describing any 
steps taken to conceal the 
sequence until interventions 
were assigned 
A A NA NA NA A A A NA 
10 Who generated the random 
allocation sequence, who 
enrolled participants, and 
who assigned participants to 
Interventions 
A A A A NA NA NA A NA 
11a If done, who was blinded 
after assignment to 
interventions (for example, 
participants, care providers, 
those assessing outcomes) 
and how 
A A A A A A A A NA 
11b If relevant, description of 
the similarity of 
interventions 
A A A NA A A A A A 
12a Statistical methods used to 
compare groups for primary 
and secondary outcomes 
A A A A A A A A A 
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12b Methods for additional 
analyses, such as subgroup 
analyses and adjusted 
analyses 
A NA NA NA NA NA NA NA NA 
13a For each group, the 
numbers of participants 
who were randomly 
assigned, received intended 
treatment, and were 
analyzed for the primary 
outcome 
A A A A A A A A A 
13b For each group, losses and 
exclusions after 
randomization, together 
with reasons 
NA NA NA NA NA NA NA NA NA 
14a Dates defining the periods 
of recruitment and follow-
up 
NA A NA A A NA A A A 
14b Why the trial ended or was 
stopped 
NA NA NA NA NA NA NA NA NA 
15 A table showing baseline 
demographic and clinical 
characteristics for each 
group 
A A A NA A A A A A 
16 For each group, number of 
participants (denominator) 
included in each analysis 
and whether the analysis 
was by original assigned 
A A A A A A A A A 
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groups 
17a For each primary and 
secondary outcome, results 
for each group, and the 
estimated effect size and its 
precision (such as 95% 
confidence interval) 
A A A A A A A A A 
17b For binary outcomes, 
presentation of both 
absolute and relative effect 
sizes is recommended 
A NA A A NA NA NA A NA 
18 Results of any other 
analyses performed, 
including subgroup analyses 
and adjusted analyses, 
distinguishing pre-specified 
from exploratory 
A NA NA NA NA NA NA NA NA 
19 All-important harms or 
unintended effects in each 
group (for specific guidance 
see CONSORT for harms) 
A A A A A A NA A A 
20 Trial limitations, addressing 
sources of potential bias, 
imprecision, and, if relevant, 
multiplicity of analyses 
A A A N/A A NA NA A A 
21 Generalizability (external 
validity, applicability) of the 
trial findings 
NA NA NA NA NA NA NA A NA 
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22 Interpretation consistent 
with results, balancing 
benefits and harms, and 
considering other relevant 
evidence 
A A A A A A A A A 
23 Registration number and 
name of trial registry 
NA NA NA NA NA NA NA NA NA 
24 Where the full trial protocol 
can be accessed, if available 
NA NA NA NA NA NA NA NA NA 
25 Sources of funding and 
other support (such as 
supply of drugs), role of 
funders 
NA NA NA NA A NA NA NA NA 
 
                Questions                                                                                                                                                                                                 Studies – Part 2   
          Rozenda 
et al 
Breen  
et al  
Strom 
et al    
Riker 
et al   
Junior 
et al  
Aitkenhead 
et al   
Kress  
et al    
Tobias 
et al 
Carson 
et al 
1a Identification as a 
randomized trial in the title 
A A A A A NA NA NA A 
1b Structured summary of trial 
design, methods, results, 
and conclusions (for specific 
guidance see CONSORT for 
abstracts) 
A A A A A A A A A 
2a Scientific background and 
explanation of rationale  
A A A A A A A A A 
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2b Specific objectives or 
hypotheses  
A A A A A A A A A 
3a Description of trial design 
(such as parallel, factorial) 
including allocation ratio  
A A A A A A A A A 
3b Important changes to 
methods after trial 
commencement (such as 
eligibility criteria), with 
reasons  
NA NA NA NA NA NA NA NA NA 
4a Eligibility criteria for 
participants  
A A A A A A A A A 
4b Settings and locations where 
the data were collected  
A A A A A A A A A 
5 The interventions for each 
group with sufficient details 
to allow replication, 
including how and when 
they were actually 
administered 
A A A A A A A A A 
6a Completely defined pre-
specified primary and 
secondary outcome 
measures, including how 
and when they were 
assessed  
A A A A A A A A A 
6b Any changes to trial 
outcomes after the trial 
NA NA NA NA NA NA NA NA NA 
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commenced, with reasons  
7a How sample size was 
determined  
A N/A A A A NA NA NA A 
7b When applicable, 
explanation of any interim 
analyses and stopping 
guidelines  
NA NA NA A A NA A A A 
8a Method used to generate 
the random allocation 
sequence  
A A A A A A A A A 
8b Type of randomization; 
details of any restriction 
(such as blocking and block 
size)  
A A A A A A A NA A 
9 Mechanism used to 
implement the random 
allocation sequence (such as 
sequentially numbered 
containers), describing any 
steps taken to conceal the 
sequence until interventions 
were assigned 
A A A A A A A A A 
10 Who generated the random 
allocation sequence, who 
enrolled participants, and 
who assigned participants to 
Interventions 
NA A A A A A A A A 
11a If done, who was blinded A A A A A A A NA A 
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after assignment to 
interventions (for example, 
participants, care providers, 
those assessing outcomes) 
and how 
11b If relevant, description of 
the similarity of 
interventions 
A A A A A A A A A 
12a Statistical methods used to 
compare groups for primary 
and secondary outcomes 
A A A A A NA A A A 
12b Methods for additional 
analyses, such as subgroup 
analyses and adjusted 
analyses 
NA NA NA NA NA A A NA NA 
13a For each group, the 
numbers of participants 
who were randomly 
assigned, received intended 
treatment, and were 
analyzed for the primary 
outcome 
A A A A A A A A A 
13b For each group, losses and 
exclusions after 
randomization, together 
with reasons 
NA NA NA NA NA NA NA NA NA 
14a Dates defining the periods 
of recruitment and follow-
NA NA NA A A NA NA NA A 
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up 
14b Why the trial ended or was 
stopped 
NA NA NA NA A NA NA NA NA 
15 A table showing baseline 
demographic and clinical 
characteristics for each 
group 
A A A A A A A A A 
16 For each group, number of 
participants (denominator) 
included in each analysis 
and whether the analysis 
was by original assigned 
groups 
A A A A A A A A A 
17a For each primary and 
secondary outcome, results 
for each group, and the 
estimated effect size and its 
precision (such as 95% 
confidence interval) 
A A A A A A A A A 
17b For binary outcomes, 
presentation of both 
absolute and relative effect 
sizes is recommended 
NA NA NA NA A NA NA NA A 
18 Results of any other 
analyses performed, 
including subgroup analyses 
and adjusted analyses, 
distinguishing pre-specified 
NA NA NA NA NA A A NA NA 
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from exploratory 
19 All-important harms or 
unintended effects in each 
group (for specific guidance 
see CONSORT for harms) 
A A A A A A A A A 
20 Trial limitations, addressing 
sources of potential bias, 
imprecision, and, if relevant, 
multiplicity of analyses 
A NA A A A NA A A A 
21 Generalizability (external 
validity, applicability) of the 
trial findings 
NA NA A NA A NA NA NA A 
22 Interpretation consistent 
with results, balancing 
benefits and harms, and 
considering other relevant 
evidence 
A A A A A A A A A 
23 Registration number and 
name of trial registry 
NA NA A A A NA NA NA NA 
24 Where the full trial protocol 
can be accessed, if available 
NA NA NA NA NA NA NA NA NA 
25 Sources of funding and 
other support (such as 
supply of drugs), role of 
funders 
NA NA A A NA NA NA NA NA 
A: Adequate (information was explicitly presented in the text) 
PA: Partially adequate (information was NOT explicitly presented but it was suggested) 
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NA: Not adequate (No information about the matter was available in the text) 
 
Table 4.3. Cohort evaluations according to STROBE instrument 
                                      Questions                                                 Studies 
                                                                                                      Tedder  
                                                                                                        et al 
Walting      Karir        Jarman       Shehabi     Tobias       Anand        Grunanu 
et al            et al          et al              et al          et al           et al             et al 
1 (a) Indicate the study’s design with a commonly 
used term in the title or the abstract 
NA NA NA NA NA NA NA NA 
 (b) Provide in the abstract an informative and 
balanced summary of what was done and what 
was found 
A A A A A A A A 
2 Explain the scientific background and rationale for 
the investigation being reported 
A A A A A A A A 
3 State specific objectives, including any 
prespecified hypotheses 
A A A A A A A A 
4 Present key elements of study design early in the 
paper 
A NA A A A A A A 
5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, exposure, 
follow-up, and data collection 
A A A A A NA A A 
6 (a) Give the eligibility criteria, and the sources and 
methods of selection of participants. Describe 
methods of follow-up 
A A A A A A A A 
 (b) For matched studies, give matching criteria A A A A A A A A 
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and number of exposed and unexposed 
7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
A A A A A A A A 
8 For each variable of interest, give sources of data 
and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than one 
group 
A NA A A NA A A A 
9 Describe any efforts to address potential sources 
of bias 
NA NA NA A NA NA NA NA 
10 Explain how the study size was arrived at NA NA NA NA A NA NA NA 
11 Explain how quantitative variables were handled 
in the analyses. If applicable, 
describe which groupings were chosen and why 
A NA A NA A NA A A 
12 (a) Describe all statistical methods, including 
those used to control for confounding 
A NA A A A NA A A 
 (b) Describe any methods used to examine 
subgroups and interactions 
NA NA NA NA NA NA NA NA 
 (c) Explain how missing data were addressed NA NA NA NA NA NA NA NA 
 (d) If applicable, explain how loss to follow-up 
was addressed 
NA NA NA NA A NA NA NA 
 (e) Describe any sensitivity analyses NA NA NA NA NA NA NA NA 
13 (a) Report numbers of individuals at each stage of 
study—eg numbers potentially 
NA NA NA A A NA A NA 
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eligible, examined for eligibility, confirmed 
eligible, included in the study, 
completing follow-up, and analysed 
 (b) Give reasons for non-participation at each 
stage 
NA NA NA A NA NA A NA 
 (c) Consider use of a flow diagram NA NA NA A NA NA A NA 
14 (a) Give characteristics of study participants (eg 
demographic, clinical, social) and information on 
exposures and potential confounders 
A A A A A A A NA 
 (b) Indicate number of participants with missing 
data for each variable of interest 
NA NA NA NA NA NA NA NA 
 (c) Summarise follow-up time (eg, average and 
total amount) 
NA NA NA NA NA NA NA NA 
15 Report numbers of outcome events or summary 
measures over time 
A A A A A NA A A 
16 (a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their 
precision (eg, 95% confidence interval). Make 
clear which confounders were adjusted for and 
why they were included 
A A A A A NA A A 
 (b) Report category boundaries when continuous 
variables were categorized 
NA NA NA NA NA NA NA NA 
 (c) If relevant, consider translating estimates of 
relative risk into absolute risk for a meaningful 
time period 
NA NA NA NA NA NA NA NA 
17 Report other analyses done—eg analyses of NA NA NA NA NA NA NA NA 
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subgroups and interactions, and sensitivity 
analyses 
18 Summarise key results with reference to study 
objectives 
A A A A A A A A 
19 Discuss limitations of the study, taking into 
account sources of potential bias or 
imprecision. Discuss both direction and 
magnitude of any potential bias 
A NA A A A NA A A 
20 Give a cautious overall interpretation of results 
considering objectives, limitations, 
multiplicity of analyses, results from similar 
studies, and other relevant evidence 
A A A A A A A A 
21 Discuss the generalizability (external validity) of 
the study results 
NA NA NA NA 916 NA NA NA 
22 Give the source of funding and the role of the 
funders for the present study and, if 
applicable, for the original study on which the 
present article is based  
NA NA NA NA N/A NA NA NA 
 A: Adequate (information was explicitly presented in the text) 
PA: Partially adequate (information was NOT explicitly presented but it was suggested) 
NA: Not adequate (No information about the matter was available in the text) 
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Table 4.4. Quality assessment of the pharmacoeconomics evaluations based on CHEERS criteria 
Section/Items                                                                                                                                              Studies 
                                                                          Carrasco                Al MJ             Barrientos              Swart                Barrientos                 Zhou                Cox 
                                                                              et al                     et al                  et al                      et al                      et al                        et al                et al 
Title/Abstract/Introduction 
Title  
Abstract  
Background/objectives 
Methods 
Population/subgroups 
Setting/location 
Study perspective 
Comparators 
Time horizon 
Choice of health outcomes 
Measurement of effectiveness 
       
A A A A A        A A 
A A A A A        A A 
A A A A A        A A 
       
PA PA A PA A        A PA 
PA A NA A A         A A 
A A A A A         A A 
A A A A A         A A 
NA A NA NA NA         NA A 
A NA A A A        A A 
A NA A A A        A A 
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Estimating resources and costs                     NA A NA A NA        NA A 
Currency, price date, conversion                         NA A PA PA PA       PA A 
Choice of model  
Assumptions  
Analytical model 
Results 
Study parameters  
Incremental costs and outcomes 
Characterizing uncertainty  
Characterizing heterogeneity  
Discussions/others  
Study findings, limitations, 
generalizability, current knowledge  
Source of funding 
Conflict of interests 
NA A NA NA NA       NA A 
NA A NA NA A       NA A 
NA A NA NA NA       NA A 
       
A A A A A        A A 
NA PA NA NA NA       NA A 
NA A NA NA NA       NA A 
NA A NA NA NA       NA A 
       
A A PA PA PA      A A 
NA NA NA NA NA       NA       NA 
NA NA NA NA NA       NA       NA 
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A: Adequate (information was explicitly presented in the text) 
PA: Partially adequate (information was NOT explicitly presented but it was suggested) 
NA: Not adequate (No information about the matter was available in the text) 
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4.2 Phase 2: Evaluation 1: morphine monotherapy versus fentanyl monotherapy 
4.2.1 Demographic characteristics of the study participants 
 Out of total 126 neonates included in the study, 63 received morphine and 63 
received fentanyl. All baseline demographic characteristics were not significantly 
different (P <0.05) between both groups (Table 4.5).  
 
Table 4.5. Main baseline patient demographics 
Characteristic Morphine (n= 63) Fentanyl (n= 63)  p-Value 
              No (%)                               No (%)  
Gender  
Male  
Female  
 
 
 34 (53.97) 
 29 (46.03) 
 
 
          38 (60.32) 
          25 (39.68) 
 
 
 0.59 
Gestational Age (weeks)  
Pre-term (<37 weeks)                                              
Full-term (≥37 weeks) 
 
 
Birth Weight (g)  
  ≥2500 g  
 <2500 g and ≥ 1500 g 
 <1500 g and ≥ 1000 g 
 <1000 g 
 
 
Nationality  
Qatari 
Arab 
Non-Arab 
 
 
 
 
        55 (87.30) 
         8 (12.70) 
 
 
 
19 (30.16) 
8 (12.70) 
17 (26.98) 
19 (30.16) 
 
 
 
         19 (30.16) 
25 (39.68) 
19 (30.16) 
 
 
 
 
50 (79.37) 
13 (20.63) 
 
 
 
21 (33.33) 
17 (26.98) 
12 (19.05) 
13 (20.64) 
 
 
 
         26 (41.27) 
         25 (39.68) 
         12 (19.05) 
 
 
 
 0.34 
 
 
 
 
0.15 
 
 
 
 
 
 
0.32 
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Type of Delivery 
Vaginal  
Caesarean  
 
 
28 (44.44) 
35 (55.56) 
 
 
 
20 (31.75) 
43 (68.25) 
 
 
0.2 
Received Vecuronium 
Yes  
No  
 
   11 (17.46) 
     52 (82.54) 
 
          11 (17.46) 
          52 (82.54) 
 1 
     
 
4.2.2 Neonates with sedation success with or without ADRs 
The number of neonates who were successfully sedated was significantly higher 
in the morphine group compared with the fentanyl group [43 (68%) versus 27 (43%)], 
risk ratio (RR) = 1.72, 95% confidence interval (CI) = (1.16 – 2.56), (P= 0.0075)]. The 
average loading and maintenance doses of fentanyl were 2.11 mcg/kg (range, 0.4 to 3) 
and 4.57 mcg/kg/hr (range, 2 to 10), respectively. Whereas, they were 125 mcg/kg 
(range, 100 to 150) and 10.27 mcg/kg/hr (range, 10 to 20) with morphine. The average 
duration of fentanyl given as the first sedative was shorter compared with morphine; 24 
hrs (range, 1 to 96) versus 120 hrs (range, 1 to 864). Six patients successfully responded 
to the fentanyl treatment; this was observed through a reduction in their PIPP scores 
after initiating the sedative and 21 patients maintained their PIPP scores below 7. In 
patients who were given morphine, nine successfully responded to the sedation and 34 
maintained their sedation scores. The average duration of MV was similar in the two 
groups; 144 hrs (range, 5 to 1374) with fentanyl and 144 hrs (range, 5 to 1405) with 
morphine. The average duration of NICU stay was also almost similar between the two 
groups; 45 days (range, 6 to 96) with fentanyl and 47 days (range, 1 to 132) with 
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morphine. The ranges of vital signs for morphine were 36.4 to 38.70 Celsius (°C), 9 to 
202 bpm (HR), 13 to 233 bpm (respiratory rate, RR), and 17.30 to 83 mmHg (mean blood 
pressure, MAP). For fentanyl, these were 36.2 to 37.5 °C, 90 to 222 bpm (HR), 10 to 100 
bpm (RR), and 17.3 to 84 mmHg. All patients in the two groups experienced ADRs, 
whether self-resolved or needing further management (Table 4.6).  
4.2.3 Neonates with sedation failure due to receiving an increased dose 
Out of patients who failed sedation, more patients received high doses of 
fentanyl compared with morphine (27 out of 36 versus 4 out of 20). In the fentanyl 
group twelve patients had increases in doses above the normal range and fifteen 
patients received higher doses within the therapeutic range. In the morphine 
monotherapy group, only four patients were given higher doses above the normal 
range. The average loading and maintenance doses of fentanyl were 5.32 mcg/kg 
(range, 2 to 10) and 4.30 mcg/kg/hr (range, 1 to 10), respectively. In patients receiving 
morphine, the average loading and maintenance doses were 292.5 mcg/kg (range, 270 
to 300) and 15 mcg/kg/hr (range, 10 to 20), respectively. The duration of sedation was 
48 hrs (range, 1 to 480) with fentanyl and 48 hrs (range, 1 to 69) with morphine. The 
average duration of the MV and NICU stay were shorter in patients sedated with 
fentanyl compared with morphine; 96 hrs (range, 1 to 674) versus 648 hrs (range, 39 to 
2340), and 27 days (range, 7 to 130) versus 54 days (range, 4 to 162), respectively. In 
relation to the vital signs of patients in both groups, the temperature was between 36.1 
and 38 °C, HR was between 91 to 198 bpm, RR was between 14 and 100 bpm, and MAP 
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was between 23.3 and 121 mmHg in the fentanyl group, while in the morphine group, 
the temperature was between 36.5 and 37.4 °C, HR was between 110 and 234 bpm, RR 
was between 13 and 96 bpm, and MAP was between 25 and 66.3 mmHg. 
4.2.4 Neonates with sedation failure due to receiving alternative sedative 
 Under sedation failure, neonates who received alternative therapy in the 
fentanyl group was double the number of patients in the morphine group (6 out of 36 
versus 3 out of 20). The average initial loading and continuous infusion doses of fentanyl 
were 3 mcg/kg (range, 1 to 5) and 3.33 mcg/kg/hr (1 to 5), respectively, with an average 
duration of 48 hrs (range, 1 to 73), and 120 mcg/kg (range, 60 to 180) and 10 mcg/kg/hr 
(range, 10 to 20), respectively, with an average duration of 864 hrs (range, 24 to 1562), 
with morphine. In relation to the alternative sedation of morphine in patients who 
received initial fentanyl, the average loading and maintenance doses of morphine were 
100 mcg/kg and 12.5 mcg/kg/hr (range, 10 to 20) with an average duration of 96 hrs 
(range 12 to 216). For the patients receiving initially morphine, the average loading and 
maintenance doses of fentanyl as an alternative were 3.73 mcg/kg (range, 2.08 to 5.12) 
and 10 mcg/kg/hr with 24 hrs duration of sedation (range, 1 to 73). Similar to the failure 
due to increased dose pathway, the MV duration and NICU stay were shorter in the 
fentanyl group compared with morphine with 216 hrs (range, 19 to 774) and 33 days 
(range, 13 to 70 days) versus 1584 hrs (range, 144 to 2731) and 83 days (range, 49 to 
123 days), respectively. The ranges of vital signs in patients receiving morphine were 
36.5 to 38.7 °C for temperature, 62 to 191 bpm for HR, 21 to 153 bpm for RR, and 28 to 
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56.6 mmHg for MAP, respectively. For those who received fentanyl, the temperature, 
HR, RR, and MAP were between 36.3 and 38.1 °C, 72 and 209 bpm, 13 and 98 bpm, and 
17 and 121 mmHg, respectively. 
4.2.5 Neonates with sedation failure due to withdrawal symptoms  
 While one patient experienced withdrawal symptom in the morphine group, 
none was found in the fentanyl group. That patient only received continuous infusion of 
morphine (15 mcg/kg) for one day and conventional MV for one day. Additionally, the 
stay at the NICU was 15 days. In relation to the vital signs, the patient had temperatures 
between 36.2 and 37.4 °C, HR between 16 and 186 bpm, RR between 51 and 97 bpm, 
and MAP between 34 and 57.3 mmHg. 
4.2.6 Neonates with sedation failure due to death  
 Although the sedation success was higher in neonates sedated with morphine, 
eleven patients died in the morphine group compared with one patient only in the 
fentanyl group. The average loading and maintenance doses were 127.5 mcg/kg (range, 
65 to 180) and 11.67 mcg/kg/hr (range, 10 to 20) with morphine versus one mcg/kg 
loading dose and 0 mcg/kg/hr maintenance dose with fentanyl group. Longer duration 
of sedation, MV, and NICU stay were noticed in the morphine group compared with the 
fentanyl group; 312 hrs (range, 48 to 1562), 384 hrs (range, 52 to 1806 hr), and 20 days 
(range, 6 to 75 days), versus 24 hrs, 216 hrs and 11 days, respectively. In the morphine 
group, the ranges of vital signs of the patients were between 36 and 38 °C, 106 and 213 
bpm for HR, 27 and 96 bpm for RR, and 14.6 and 66.3 mmHg for MAP. While in the 
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fentanyl group, the patient’s vital signs were between 36.5 and 37.4 °C, 48 and 196 bpm 
for HR, 31 and 65 bpm for RR, and 29.3 and 59.3 mmHg for MAP. 
4.2.7 Neonates with sedation failure due to persistent agitation 
 Only one patient in the morphine group had persistent agitation compared with 
two patients in the fentanyl group. The average loading dose of fentanyl was 2.5 mcg/kg 
(range, 2 to 3) with 1 hr duration and none received continuous infusion. With respect 
to the morphine group, the patient received only maintenance dose (5 mcg/kg) with a 
duration of six days. Both groups had about similar average duration of MV (1 day in 
each group), however, the average duration of NICU stay was higher in the morphine 
group; 16 days versus 9 days (range, 3 to 14 days). The ranges of vital signs were: 32 to 
37.3 °C for temperature, 49 to 164 bpm for HR, 13 to 88 bpm for RR, 33 to 76.6 mmHg 
for MAP in patients sedated by morphine, and were 36.6 to 37.3 °C for temperature, 
139 to 189 bpm for HR, 41 to 94 for RR, and 27 to 44.6 mmHg for MAP in patients 
receiving fentanyl, respectively. 
Baseline clinical and probability outcomes are summarized in (Table 4.7).  
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Table 4.6 Summary of the ADRs associated with sedation success 
The ADRs associated with 
sedation success  
Morphine Fentanyl  
 
Total number 
of patients 
Cost per 
patient 
(QAR) 
Total number 
of patients 
Cost per 
patient 
(QAR) 
 
Desaturation  23 38,440.17 21 36,207.61 
Desaturation and urinary 
retention 
1 38,450.17 2 36,217.61 
Desaturation, urinary retention, 
MV adjustment and edema 
1 38,485.17 0 N/A 
Desaturation and MV adjustment 7 38,440.17 0 N/A 
Desaturation, MV adjustment, 
and urinary retention 
1 38,450.17 1 36,217.61 
Desaturation, MV adjustment, 
and edema 
 
3 38,263.63 0 N/A 
Desaturation and edema 6 38,263.63 0 N/A 
Desaturation and respiratory 
depression 
 
1 38,441.61 0 N/A 
Desaturation, MV adjustment, 
and joint stiffness 
0 N/A 1 36,215.95 
MV adjustment   0 N/A 2 35,996.07 
*N/A: Not applicable  
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Table 4.7. Clinical outcomes and probabilities of morphine monotherapy vs. fentanyl 
monotherapy 
Study clinical outcome Probability with morphine 
monotherapy (n= 63) 
Probability with fentanyl 
monotherapy (n= 63) 
Sedation success  0.68 (n= 43) 0.43 (n= 27) 
With ADRs 0.68 (n= 43) 0.43 (n= 27) 
Without ADRs 0 (n= 0)   0 (n= 0) 
Sedation failure  0.32 (n= 20) 0.57 (n= 36) 
Increased dose 0.2 (n= 4) 0.75 (n= 27) 
Therapy switch to alternatives 0.15 (n= 3) 0.17 (n= 6) 
Withdrawal symptoms  0.05 (n= 1) 0 (n= 0) 
Death 0.55 (n= 11) 0.03 (n= 1) 
Persistent agitation  0.05 (n= 1) 0.05 (n= 2) 
 
4.2.8 Cost of sedation 
 Morphine monotherapy achieved successful sedation in 68% of patients, 
compared to 43% with fentanyl monotherapy, with an ICER of QAR 490.36 per extra 
case of sedation success compared to fentanyl. Sedation success with ADRs (Table 4.6) 
was the major clinical outcome that had an impact on the total therapeutic cost of 
morphine and fentanyl, as shown in Table 4.8, where the weighted probabilities and 
costs for therapy outcomes are also given in Table 4.8. Cost components of the overall 
therapy are shown in Table 4.9. 
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4.2.9 Sensitivity analysis 
 One-way sensitivity analyses. The model was insensitive to the changes in the 
majority of the variables in the morphine and fentanyl monotherapy groups. The result 
was sensitive to the changes in the cost of MV. When the cost of MV decreased to from 
QAR 430.15 to QAR 404.35, fentanyl became more expensive that morphine (Figure 
4.2). The result was also sensitive to the changes in the NICU stay in the fentanyl’s 
successful sedation pathway and in the fentanyl’s increased dose pathway. When these 
decreased from 45 and 27 days to 44.65 and 26 days, respectively, cost saving shifted in 
the favor of morphine (Figures 4.3-4.4). The results were also sensitive to changes in the 
NICU stay in patients sedated successfully with morphine. Fentanyl became more 
expensive than morphine when the NICU stay of successful patients decreased from 47 
to 46.6 days (Figure 4.5).  
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Table 4.8. The weighted probabilities and costs of morphine monotherapy and fentanyl 
monotherapy 
Therapy outcome Morphine Fentanyl 
P
ro
b
ab
ility 
Cost per 
patient (QAR) 
P
ro
p
o
rtio
n
al 
co
st (Q
A
R
) 
P
ro
b
ab
ility 
Cost per 
patient 
(QAR) 
P
ro
p
o
rtio
n
al 
co
st (Q
A
R
) 
Sedation success with ADRs 0.68 56,477.59 38,404.76 0.43 84,170.60 36,193.36 
Sedation success without 
ADRs 
 
0 N/A N/A 0 N/A N/A 
Sedation failure       
Sedation failure due to 
increased dose 
 
0.06 49,990.06 3,173.97 0.43 25,304.46 10,844.77 
Sedation failure due to need 
for alternatives (fentanyl or 
morphine) 
 
0.05 85,375.86 4,065.52 0.1 31,137.43 2,965.47 
Sedation failure due to 
withdrawal symptoms 
 
0.02 13,126.36 208.35 0 N/A N/A 
Sedation failure due to death 0.17 25,941.17 4,529.41 0.02 14,690.98 233.19 
Sedation failure due to 
persistent agitation  
 
0.02 16,059.43 254.91 0.03 8,681.53 275.60 
Total cost per patient                                                 50,636.93                                            50,512.39 
*N/A: Not applicable  
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Table 4.9. Cost components of the overall therapy 
  Cost (QAR)                                         Cost (QAR) 
Cost component  Morphine  Fentanyl  
Sedation success with ADRs 
Initial sedation 19.7 12 
MV 2,580.89 2,580.89 
NICU stay 24,775.72 23,721.44 
Hematological tests 240 180 
Chemistry tests 1,759.09 2,736.36 
Metabolic tests 1,140 1,140 
Microbiology tests 1,644.44 1,233.33 
Blood gases tests 2,940 2,310 
Virology tests 1,560 780 
Urinalysis tests N/A N/A 
Diagnostic tests 1,568.78 1,302.04 
Oxygen therapy 211.54 211.54 
Catheter  10 10 
Medications to treat ADRs 36.45  8.34 
Sedation failure due to increased dose 
Initial sedation 41.37 18 
MV 11,614.02 1,720.59 
NICU stay 28,465.72 14,232.86 
Hematological tests 210 N/A 
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Chemistry tests 2,345.45 2,540.91 
Metabolic tests 1,140 1,140 
Microbiology tests 822.22 1,233.33 
Blood gases tests 2,310 1,750 
Virology tests 1,560 780 
Urinalysis tests N/A 216.67 
Diagnostic tests 1,481.27 1,672.1 
Medications to treat ADRs N/A N/A 
Sedation failure due to receiving alternative 
Initial sedation 17.73 12 
Alternative sedation  4.76 102.03 
MV 28,389.82 3,871.34 
NICU stay 43,752.87 17,395.72 
Hematological tests 510 180 
Chemistry tests 3,713.64 3,127.27 
Metabolic tests 1,710 1,140 
Microbiology tests 2,466.67 1,233.33 
Blood gases tests 2,800 3,220 
Virology tests N/A N/A 
Urinalysis tests N/A 72.22 
Diagnostic tests 2,003.14 869.79 
Medications to treat ADRs N/A N/A 
Sedation failure due to withdrawal symptoms 
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Initial sedation 1.97 N/A 
MV 430.15 N/A 
NICU stay 7,907.15 N/A 
Hematological tests 120 N/A 
Chemistry tests 586.36 N/A 
Metabolic tests 570 N/A 
Microbiology tests 1,644.44 N/A 
Blood gases tests 770 N/A 
Virology tests 780 N/A 
Urinalysis tests 0 N/A 
Diagnostic tests 316.29 N/A 
Medications to treat ADRs N/A N/A 
Sedation failure due to death 
Initial sedation 19.7 6 
MV 6,882.38 2,580.89 
NICU stay 10,542.86 5,798.57 
Hematological tests 210 60 
Chemistry tests 1,563.64 1,954.55 
Metabolic tests 1,140 570 
Microbiology tests 1,233.33 411.11 
Blood gases tests 2,030 2,730 
Virology tests 780 N/A 
Urinalysis tests N/A N/A 
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Diagnostic tests 1,539.26 579.86 
Medications to treat ADRs N/A N/A 
Sedation failure due to persistent agitation 
Initial sedation 1.97 6 
MV 430.15 430.15 
NICU stay 8,434.29 4,744.29 
Hematological tests 120 60 
Chemistry tests 1,172.73 781.82 
Metabolic tests 570 1,140 
Microbiology tests 822.22 822.22 
Blood gases tests 4,060 560 
Virology tests N/A N/A 
Urinalysis tests N/A N/A 
Diagnostic tests 448.07 137.06 
Medications to treat ADRs N/A N/A 
*N/A: Not applicable 
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Figure 4.2. ICER probability curve of morphine with the variable “cost of MV” 
 
 
Figure 4.3. ICER probability curve of morphine with the variable “NICU stay in patients 
successfully sedated by fentanyl” 
 
  
Figure 4.4. ICER probability curve of morphine with the variable “NICU stay in patients receiving 
increased doses of fentanyl” 
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Figure 4.5. ICER probability curve of morphine with the variable “NICU stay in patients 
successfully sedated by morphine” 
  
Probabilistic sensitivity analyses. Figure 4.6 shows the tornado diagram that illustrates 
the ranking of the clinical variables as per impact on the model outcome. Here, the 
sedation failure due to receiving higher doses in the fentanyl group had the highest 
uncertainty that influenced the outcome and the sedation success in the fentanyl group 
had the lowest uncertainty that affected the outcome.  
The cost of all variables remained unchanged in favor of fentanyl. Morphine had a 98% 
probability of having an economic advantage over fentanyl. An ICER probability curve is 
shown in Figure 4.7.  
Alternative scenario: The total management cost of morphine and fentanyl were QAR 
420,375.99 and QAR 418,398.61, respectively. Morphine monotherapy had an ICER of 
QAR 7,785.96 per extra case of sedation success compared to fentanyl monotherapy.  
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Figure 4.6. Tornado diagram of the variables as per their influence on the outcome of the Monte 
Carlo simulation 
 
 
 
 
Figure 4.7. ICER with morphine probability curve 
 
 
4.3 Phase 2: Evaluation 2: morphine monotherapy versus morphine plus midazolam  
4.3.1 Demographic characteristics of the study participants 
 Out of total 64 patients included in the analysis, 32 were in the morphine group 
and 32 were in the morphine plus midazolam combination group. All baseline 
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characteristics were not significantly different between the two groups except in the use 
of vecuronium (Table 4.10). 
Table 4.10. Main baseline patient demographics 
Characteristic Morphine 
Monotherapy        
 (n = 32) 
Morphine 
Plus 
midazolam    
   (n= 32) 
 
 p-Value 
 No (%) No (%)   
Gender  
Male 
Female 
 
25 (78.12) 
7 (21.88) 
 
   23 (71.88) 
  9 (28.12) 
        0.77 
Gestational Age (weeks)  
Pre-term (<37 weeks) 
Full-term (≥37 weeks) 
 
 
Birth Weight (g)  
≥2500 g 
< 2500 g and ≥1500 g 
<1500 g and ≥1000 g 
<1000 g 
 
 
Nationality  
Qatari 
Arab 
Non-Arab 
 
 
Type of Delivery 
Vaginal  
Caesarean  
 
      24 (75) 
     8 (25)  
 
 
 
       10 (31.25) 
      3 (9.38) 
       7 (21.87) 
       12 (37.50) 
 
 
 
          13 (40.63) 
            15 (46.87) 
             4 (12.5) 
 
 
 
     14 (43.75) 
     18 (56.25) 
 
23 (71.88) 
9 (28.12) 
 
 
 
8 (25) 
3 (9.38) 
3 (9.38) 
18 (56.25) 
 
 
 
12 (37.5) 
              14 (43.75) 
               6 (18.75) 
 
 
 
16 (50) 
16 (50) 
 
 
 
 
 
 
 
   1  
 
 
 
 
0.41 
 
 
 
 
 
 
0.8 
 
 
 
 
 
 0.8 
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Received Vecuronium  
Yes  
No  
 
    6 (18.75) 
    26 (81.25) 
          
             18 (56.25) 
             14 (43.75)  
0.004 
 
    
 
4.3.2 Neonates with sedation success with or without ADRs 
Successful sedation was significantly achieved in 66% (n= 21) and 34% (n= 11) in 
the morphine monotherapy group and combination of morphine and midazolam group, 
respectively, with an RR of 1.91, 95% CI= (1.11 to 3.28), (P= 0.019). Hundred percent of 
patients (n= 21) who were successfully sedated with morphine monotherapy were 
during the maintenance stage of therapy, whereas 91% of patients (n= 10) maintaining 
their sedation scores in the combination regimen and 9% (n= 1) successfully responding 
to the therapy. In the monotherapy group, the average loading and maintenance doses 
of morphine were 175 mcg/kg (range, 150 to 200) and 16.1 mcg/kg/hr (range, 10 to 30), 
respectively. In the combination regimen, doses were 102 mcg/kg (range, 70 to 270) and 
10 mcg/kg/hr (range, 10 to 25) for morphine and 20.88 mcg/kg/hr (range, 8 to 30) for 
midazolam. Longer duration of sedation was observed with the combination therapy; 
144 hrs (range, 1 to 744) versus 504 hrs (range, 24 to 1824). Moreover, both of the 
average of the duration of MV and stay at the intensive unit were longer in the 
combination regimen; 696 hrs (range, 35 to 1926) and 75 days (range, 3 to 192) versus 
168 hrs (range, 1 to 797) and 51 days (range, 6 to 210). The HR and MAP vital signs 
ranges were 60 to 207 bpm and 21 to 100 mmHg in the monotherapy group, 
respectively, and 70 to 219 bpm and 20 to 100 mmHg in the combination group, 
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respectively. The temperature and RR ranges were 33 to 38 °C and 6 to 202 bpm, and 
33.8 to 39.4 °C and 13 to 105 bpm for the two groups, respectively. All sedated 
neonates in both groups had ADRs, self-resolving or needing further management 
(Table 4.11). 
4.3.3 Neonates with sedation failure due to receiving an increased dose  
None of the neonates who were sedated by morphine monotherapy required 
high administration of doses compared with midazolam and morphine together (0 
versus 8 neonates). Out of the eight, one had an increase in the morphine dose, two had 
an increase in the midazolam dose above the normal range, and five received higher 
doses within the therapeutic range. The average loading and continuous infusion doses 
were:  207.6 mcg/kg (range, 150 to 273) and 16.1 mcg/kg/hr (range, 10 to 25) for 
morphine and 100 mcg/kg followed by 47.5 mcg/kg/hr (range, 5 to 85) for midazolam. 
The average sedation duration of morphine and midazolam regimen was  432 hrs 
(range, 1 to 1848). With respect to the average duration of the MV and NICU stay, 
patients needed 648 hrs (range, 34 to 2568) and 63 days (range, 11 to 180), respectively. 
The vital signs ranges were a temperature of 33.4 to 39.9 °C, an HR of 70 to 246 bpm, a 
RR of 4 to 140 bpm, and a MAP of 23 to 119 mmHg. 
4.3.4 Neonates with sedation failure due to receiving alternatives 
 Similar to the failure due to increased dose pathway, only neonates who were 
sedated by the combination regimen were switched to alternative (n= 5). The average 
initial loading and continuous infusion doses of morphine were 160 mcg/kg (range, 100 
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to 270) and 15.6 mcg/kg/hr (10 to 25), respectively, while the average doses of 
midazolam were 100 mcg/kg and 61.67 mcg/kg/hr (range, 20 to 85), with an average 
duration of 648 hrs (range, 1 to 1848), respectively. Fentanyl was used as an alternative 
sedative to morphine with an average loading and maintenance dose of 5.2 mcg/kg 
(range, 2 to 8.4) and 12.5 mcg/kg/hr (range, 10 to 20), for average 144 hrs (range, 1 to 
912), respectively. The average MV duration and NICU stay were 504 hrs (range, 81 to 
2568) and 128 days (range, 11 to 180), respectively. The vital signs were 33.8 to 38.5 °C, 
70 to 197 bpm, 4 to 14 bmp, and 24 to 82.6 mmHg for temperature, HR, RR, and MAP 
respectively.  
4.3.5 Neonates with sedation failure due to withdrawal symptoms  
 Two neonates had withdrawal symptoms in the morphine monotherapy group 
compared with only one case in the combination regimen. In both groups, none 
received loading doses of morphine, however the continuous infusion doses were 11.6 
mcg/kg (range, 10 to 15) and 18.5 mcg/kg/hr (range, 10 to 29), respectively, in addition 
to 30 mcg/kg/hr of midazolam in the combination group. The average duration of 
monotherapy sedation was almost half of the combination therapy’s duration (12 days 
versus 22 days). However, the monotherapy group has longer average duration of MV 
(25 days versus 11 days) and NICU stay (27 days versus 12 days). Values of main vital 
signs were as follows: temperature (36.3 to 37.5 °C versus 26 to 37.6°C), HR (28 to 196 
bpm versus 0 to 218 bpm), RR (22 to 75 bpm versus 38 to 90 bpm), and MAP (14.6 to 
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59.3 mmHg versus 20 to 82.6 mmHg) in the monotherapy and combination groups, 
respectively. 
4.3.6 Neonates with sedation failure due to death  
 The mortality rate was higher in neonates managed by morphine alone 
compared with the combination (9 out of 11 versus 6 out of 21). The average loading 
and maintenance doses of the monotherapy were 108.3 mcg/kg (range, 100 to 128) and 
15 mcg/kg/hr (range, 10 to 40) with 192 hrs duration (range, 1 to 916), respectively. 
With the combination, these are 97 mcg/kg followed by 14.5 mcg/kg/hr (range, 10 to 
20) of morphine plus 7 mcg/kg (range, 4 to 10) loading dose of midazolam, with longer 
duration of sedation, 1176 hrs (range, 1 to 2918). Add to this, the need for MV and ICU 
stay was less in the monotherapy group compared with the combination regimen; 360 
hrs (range, 5.00 to 1892) and 16 days (range, 1 to 89) versus 432 hrs (range, 77 to 1144) 
and 54 days (range, 31 to 138), respectively. The temperature and HR were of ranges of 
34 to 38.5 °C, 70 to 246 bpm, 36 to 40.4 °C, and 63 to 214 bpm, for the monotherapy 
and combination regimens, respectively. The RR and MAP were 4 to 147 bpm and 10 to 
82.3 mmHg and 6 to 91 bpm and 18.6 to 67.3 mmHg, respectively.   
4.3.7 Neonates with sedation failure due to persistent agitation  
 With similar trend to the increased doses and alternative sedative failure 
pathways, none experienced persistent agitation in the morphine monotherapy group. 
Only one case was seen in the combination group. The patient received 50 mcg/kg 
loading dose of morphine, 20 mcg/kg/hr maintenance dose of morphine and 200 
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mcg/kg loading dose of midazolam. The durations of sedation and MV, and the NICU 
stay were 5, 6, and 6 days, respectively. Patient’s temperature, HR, RR, and MAPs were 
32 to 37.4 °C, 0 to 192 bpm, 46 to 74 bpm, and 34 to 43.3 mmHg, respectively. 
Baseline clinical and probabilities inputs are summarized in Table 4.12. 
 
Table 4.11. Summary of the ADRs associated with sedation success 
The ADRs associated with sedation 
success  
Morphine monotherapy Morphine plus midazolam 
 
Total number 
of patients 
Cost per 
patient 
(QAR) 
Total number 
of patients 
Cost per 
patient 
(QAR) 
 
Desaturation  13 42,711.49 4 7,426.81 
Desaturation and urinary retention 3 42,721.49 1 7,437.17 
Desaturation and MV adjustment        2 42,711.49 2 7,462.81 
Desaturation, MV adjustment, and 
urinary retention 
1 42,721.49 0 N/A 
Desaturation and edema 1 42,847.7                2 7,426.81 
Desaturation and joint stiffness 1 42,712.89              0 N/A 
Desaturation, MV adjustment, and 
edema 
 
0 N/A 2 7,428.75 
*N/A: Not applicable 
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Table 4.12. Clinical and probability of outcomes of the morphine monotherapy vs. morphine 
plus midazolam combination 
Study clinical outcome Probability with morphine 
monotherapy (n= 32) 
Probability with morphine 
plus midazolam (n= 32) 
Sedation success  0.66 (n= 21) 0.34 (n= 11) 
With ADRs 0.66 (n= 21) 0.34 (n= 11) 
Without ADRs 0 (n= 0) 0 (n= 0) 
Sedation failure  0.34 (n= 11) 0.66 (n= 21) 
Increased dose 0 (n= 0) 0.38 (n= 8) 
Therapy switch to alternatives 0 (n= 0) 0.24 (n= 5) 
Withdrawal symptoms  0.18 (n= 2) 0.05 (n= 1) 
Death 0.82 (n= 9) 0.28 (n= 6) 
Persistent agitation  0 (n= 0) 0.05 (n= 1) 
 
4.3.8 Cost of sedation 
 The base case analysis demonstrated that the morphine monotherapy was 
associated with a successful sedation level of 66%, compared to 34% with the 
combination, with an ICER of QAR 21,206.85 per additional case of sedation success. For 
those who received the morphine monotherapy, sedation success with ADRs (Table 
4.11) was the main clinical outcome that influenced the total cost, and with the 
combination, it was the sedation failure due to increased doses that prevailed (Table 
4.13). The weighted probabilities and costs for therapy outcomes are also given in Table 
4.13. Cost components of the overall drug therapies are shown in Table 4.14. 
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Table 4.13. The weighted probabilities and costs of morphine monotherapy and morphine plus 
midazolam regimen 
Therapy outcome Morphine monotherapy Morphine plus midazolam 
 
P
ro
b
ab
ility 
Cost per 
patient 
(QAR) 
P
ro
p
o
rtio
n
al 
co
st (Q
A
R
) 
P
ro
b
ab
ility 
Cost per 
patient 
(QAR) 
P
ro
p
o
rtio
n
al 
co
st (Q
A
R
) 
Sedation success 
with ADRs 
 
0.66 64,718.42 42,714.16 0.34 21847.35 7,428.10 
Sedation success 
without ADRs      
                                    
0 N/A N/A 0 N/A N/A 
Sedation failure       
Sedation failure due 
to increased dose 
 
0 N/A N/A 0.25 66,254.51 18,634.08 
Sedation failure due 
to need for 
alternatives 
 
0 N/A N/A 0.16 52,012.83 
 
8,127.01 
Sedation failure due 
to withdrawal 
symptoms 
 
0.06 39,930.42 2,495.65 0.03 18,562.82 580.09 
Sedation failure due 
to death 
 
0.28 25,184.45 7,083.13 0.19 56,252.23                       10,547.29 
Sedation failure due 
to persistent 
agitation  
 
0 N/A N/A 0.03 11,175.32 349.23 
Total cost per 
patient  
 
                                                 52,292.94                                                45,665.80 
*N/A: Not applicable  
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Table 4.14. Cost components of the overall therapy 
 Cost (QAR) Cost (QAR) 
Cost component  Morphine monotherapy Morphine plus midazolam 
Sedation success with ADRs 
Initial sedation 27.58 19.05 
MV 3,011.04 12,474.31 
NICU stay 26,884.3 39,535.73 
Hematological tests 210 390 
Chemistry tests 3,127.27 4,300.00 
Metabolic tests 1,140 1,140 
Microbiology tests 1,644.44 1644.44 
Blood gases tests 3,080 3,990 
Virology tests 2,340 780 
Urinalysis tests 144.44 N/A 
Diagnostic tests 890.87 2,229.82 
Oxygen therapy 211.54 211.54 
Catheter  10 10 
Medications to treat ADRs 16.19 1.94 
Sedation failure due to increased dose 
Initial sedation N/A 131.64 
MV N/A 11,614.02 
NICU stay N/A 33,210.01 
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Hematological tests N/A 510 
Chemistry tests N/A 5,668.18 
Metabolic tests N/A 1,140 
Microbiology tests N/A 1,233.33 
Blood gases tests N/A 8,190 
Virology tests N/A 1,560 
Urinalysis tests N/A N/A 
Diagnostic tests N/A 2,997.34 
Medications to treat ADRs N/A N/A 
Sedation failure due to receiving alternative 
Initial sedation N/A 32.19 
Alternative sedation  N/A 25.34 
MV N/A 12,044.16 
NICU stay N/A 24,775.72 
Hematological tests N/A 390 
Chemistry tests N/A 4,104.55 
Metabolic tests N/A 1,140 
Microbiology tests N/A 1,233.33 
Blood gases tests N/A 5,600 
Virology tests N/A 780 
Urinalysis tests N/A N/A 
Diagnostic tests N/A 1,900.88 
Medications to treat ADRs N/A N/A 
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Sedation failure due to withdrawal symptoms 
Initial sedation 1.97 3.94 
MV 10,753.72 4,731.64 
NICU stay 14,232.86 6,325.72 
Hematological tests 300 210 
Chemistry tests 5,472.73 1,368.18 
Metabolic tests 570 570 
Microbiology tests 2,055.56 1,233.33 
Blood gases tests 5,600 2,660 
Virology tests N/A 780 
Urinalysis tests N/A N/A 
Diagnostic tests 943.59 680.01 
Medications to treat ADRs N/A N/A 
Sedation failure due to death 
Initial sedation 17.73 19.05 
MV 6,452.23 7,742.68 
NICU stay 8,434.29 28,465.72 
Hematological tests 120 570 
Chemistry tests 1,954.55 4,886.36 
Metabolic tests 1,140 1,140 
Microbiology tests 822.22 1,233.33 
Blood gases tests 4,620 8,400 
Virology tests 780 1,560 
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Urinalysis tests N/A N/A 
Diagnostic tests 843.43 2,235.09 
Medications to treat ADRs N/A N/A 
Sedation failure due to persistent agitation 
Initial sedation N/A 15.11 
MV N/A 2,580.89 
NICU stay N/A 3,162.86 
Hematological tests N/A 120 
Chemistry tests N/A 781.82 
Metabolic tests N/A 570 
Microbiology tests N/A 822.22 
Blood gases tests N/A 2,590 
Virology tests N/A N/A 
Urinalysis tests N/A N/A 
Diagnostic tests N/A 532.41 
Medications to treat ADRs N/A N/A 
*N/A: Not applicable 
4.3.9 Sensitivity analysis  
One-way sensitivity analyses. The model was insensitive to the changes in all the 
variables in the both groups.  
Probabilistic sensitivity analyses: Tornado diagram is given in (Figure 4.8) which shows 
that the uncertainty in the sedation failure outcome in the morphine plus midazolam 
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group had the highest potential impact on the study outcome, while the sedation failure 
due to withdrawal symptoms in the combination group was the outcome that had the 
lowest influence the study outcome. Monto Carlo simulation illustrated that morphine 
remained more costly over the combination of morphine plus midazolam in 100% of 
cases, with 0% probability of having an economic advantage over the combination 
therapy. An “ICER” probability curve is shown in (Figure 4.9) as well. 
Alternative scenario: A total of QAR 424,864.17 and QAR 890,817.09 resulted from the 
management of morphine monotherapy and the morphine and midazolam 
combination, respectively. Unlike in the HMC perspective scenario, morphine 
monotherapy dominated the combination of morphine plus midazolam combination 
with an economic saving of QAR 465,952.91 per patient.  
 
 
Figure 4.8. Tornado diagram of the variables as per their influence on the outcome of the Monte 
Carlo simulation 
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Figure 4.9. ICER probability curve with morphine monotherapy 
 
 
4.4 Phase 2: Evaluation 3: fentanyl monotherapy versus fentanyl plus midazolam 
4.4.1 Demographic characteristics of the study participants 
Out of 54 neonates included in the study, 39 received fentanyl monotherapy and 
15 received fentanyl based analgesia using midazolam. Due to the small number of 
neonates with RDS admitted to the NICU, the sample size was not met. Both groups did 
not show any significant difference in terms of the baseline demographic characteristics 
(Table 4.15). 
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Table 4.15. Main baseline patient demographics 
Characteristic Fentanyl Monotherapy         
(n= 39) 
Fentanyl Plus 
midazolam     
  (n= 15) 
 
 p-Value 
 No (%) No (%)   
Gender  
Male 
Female 
 
 
19 (48.72) 
20 (51.28) 
 
 
9 (60) 
6 (40) 
 
        0.55 
Gestational Age (weeks) 
Pre-term (<37 weeks) 
Full-term (≥37 weeks) 
 
 
Birth Weight (g)  
≥2500 g  
<2500 g and ≥1500 g 
 <1500 g and ≥1000 g 
<1000 g 
 
 
Nationality 
Qatari 
Arab 
Non-Arab  
 
 
Type of delivery 
Vaginal  
Caesarean 
 
26 (66.67) 
13 (33.33) 
 
 
 
16 (41.03) 
9 (23.08) 
6 (15.38) 
8 (20.51) 
 
 
 
17 (43.59) 
13 (33.33) 
9 (23.08) 
 
 
21 (53.85) 
18 (46.15) 
 
10 (66.67) 
5 (33.33) 
 
 
 
5 (33.33) 
2 (13.34) 
3 (20) 
5 (33.33) 
 
 
 
7 (46.66) 
4 (26.67) 
4 (26.67) 
 
 
5 (33.33) 
10 (66.67) 
  1 
 
 
 
 
0.72 
 
 
 
 
 
 
0.86 
 
 
 
 
0.23 
 
 
Received Vecuronium  
Yes  
No  
 
 
 
10 (25.64) 
29 (74.36) 
 
 
 
 7 (46.67) 
8 (53.33)  
  
 
0.19 
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4.4.2 Neonates with sedation success with or without ADRs 
About 51% of neonates managed by fentanyl as a sole agent were successfully 
sedated (n= 7, responded with a reduced PIPP score and an= 13, maintained their 
scores) compared to 33% by fentanyl and midazolam regimen (n= 1 responded with 
reduced PIPP score and n= 4, maintained their scores) with RR of 1.22, 95% CI= (0.88-
1.70), (P= 0.24). For those who received fentanyl monotherapy, the average loading and 
maintenance doses were 2.6 mcg/kg (range, 0.5 to 10) and 4.5 mcg/kg/hr (range, 0.6 to 
10), respectively. On the other hand, the regimen of fentanyl and midazolam consisted 
of 3 mcg/kg (range, 2 to 5) followed by 2.6 mcg/kg/hr (range, 2 to 4) fentanyl and 95 
mcg/kg (range, 30 to 160) followed by 20 mcg/kg/hr midazolam. Neonates sedated by 
fentanyl only needed shorter period of sedation compared to the combination regimen 
(48 hrs, range 1 to 150, versus 264 hrs, range 1 to 720). Also, the duration of MV was 
shorter in the monotherapy group (72 hrs, range 1 to 320, versus 312 hrs, range 51 to 
936). Both groups had almost similar average duration of NICU stay (41 days, range 2 to 
102, versus 43 days, range 16 to 66). The patients who were managed with the 
combination of fentanyl and midazolam, had vital signs ranges between 34.2 and 37.8 
°C, 107 and 180 bpm, 22 and 187 bpm and 33 and 78.3 mmHg, of temperature, HR, RR, 
MAP, respectively. Respectively, these were between 36 and 39 °C, 95 and 196 bpm, 10 
and 100 bpm, and 16.3 and 71 mmHg in patients treated by fentanyl only. The ADRs as 
self-resolved or requiring further management were noticed in both groups (Table 
4.16).  
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4.4.3 Neonates with sedation failure due to receiving an increased dose 
 The majority of sedation failure was due to increased doses in the two groups 
(12 out of 19) in the monotherapy group versus (5 out of 10) in the combination group. 
In the fentanyl monotherapy, out of twelve patients, five patients received higher doses 
above the therapeutic range and the doses for the other seven patients remained within 
the normal range. All the five patients in the fentanyl plus the midazolam combination 
group received normal doses. The monotherapy management consisted of 5.4 mcg/kg 
(range, 3.50 to 12) followed by 6.40 mcg/kg/hr (range, 2 to 12) of fentanyl for 48 hrs 
(range, 1 to 168). Whereas, in the combination group, fentanyl was of initial 2.25 
mcg/kg (range, 2 to 2.5) and a follow up 9.10 mcg/kg/hr (range, 2.50 to 20), combined 
with 117 mcg/kg (range, 50 to 200) followed by 15 mcg/kg/hr (range, 10 to 20) 
midazolam for 48 hrs (range, 2 to 170). Both the average duration of MV and stay at 
NICU were longer in the combination regimen compared with the sole therapy; 720 hrs 
(range, 82 to 2882) and 61 days (range, 12 to 151) versus 72 hrs (range, 4 to 148) and 19 
days (range, 5 to 67 days), respectively. For fentanyl versus fentanyl based analgesia, 
the vital signs were about 36.5 to 38.7 °C, 76 to 202 bpm, 9 to 100 bpm, and 23.6 to 
75.3 mmHg, versus 35.7 to 38.5 °C, 90 to 206 bpm, 6 to 100 bpm, and 25.3 to 92 mmHg, 
respectively, for the temperature, HR, RR and MAP.  
4.4.4 Neonates with sedation failure due to receiving alternative 
 Five patients (50% of patients with sedation failure) in the combination group 
were switched to an alternative therapy after the initial fentanyl therapy, compared 
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with three patients (16%) in the monotherapy group. The average loading dose of 
fentanyl was 5.86 mcg/kg (range, 5 to 6.72), while the average maintenance dose was 3 
mcg/kg/hr for 72 hrs (range, 1 to 124). In relation to the combination group, the 
patients were started on a loading fentanyl dose of 5.1 mcg/kg (range, 2 to 10) and 
continuous infusion of 10 mcg/kg/hr, and then received midazolam with 200 mcg/kg 
(range, 150 to 300) as loading dose followed by 19 mcg/kg/hr (range, 5 to 20) for 264 
hrs (range, 1 to 1224). Patients in the monotherapy group received morphine (280 
mcg/kg followed by 28.30 mcg/kg/hr, range 5 to 60) for 48 hrs (range, 15 to 70) as an 
alternative therapy. However, the duration of the alternative sedation was higher in the 
combination group (336 hrs, range 2 to 1128) using 210 mcg/kg (range, 120 to 300) 
followed by 12.2 mcg/kg (range, 5 to 30) of morphine. Both the MV duration and NICU 
stay were longer in the combination group with 1296 hrs (range, 27 to 4368) and 79 
days (range, 8 to 153) versus 168 hrs (range, 36 to 354) and 25 days (range 7 to 48). The 
vital signs were 36.5 to 37.5 °C, 75 to 191 bpm (HR), 20 to 91 bpm (RR), 35 to 74.6 
mmHg (MAP) with the monotherapy, and 36.5 to 38.6 °C, 68 to 208 bpm, 15 to 171 bpm 
and 20 to 100 mmHg, respectively, with the combination therapy. 
4.4.5 Neonates with sedation failure due to withdrawal symptoms  
Withdrawal symptoms were only developed in one patient in the fentanyl group 
who was given two doses of continuous infusions ranging from 3 to 4 mcg/kg/hr for an 
average 2 days. The duration of NICU stay was 12 days, and the duration of the MV was 
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6 days. The patient’s vital signs were as follows: (36.5 to 37.4 °C), HR (110 to 195 bpm), 
RR (0 to 80 bpm), and MAP (15.6 to 62.3 mmHg). 
4.4.6 Neonates with sedation failure due to death  
 No one in the combination therapy group died, while two cases of mortality 
were seen in the monotherapy group. These two patients received only maintenance 
dose of 5 mcg/kg/hr for an average of 10 days. The average duration of MV and NICU 
stay were equal to 12 days each. The ranges of vital signs while on sedation for the two 
patients were 36.5 to 37.6 °C (temperature), 0 to 195 bpm (HR), 24 to 65 bpm (RR), and 
21.6 to 75.3 mmHg (MAP). 
4.4.7 Neonates with sedation failure due to persistent agitation 
The persistent agitation occurred only in one neonate sedated by fentanyl alone 
using 2 mcg/kg followed by 3.89 mcg/kg/hr for seven days. That patient received MV for 
about 8 days and stayed in the ICU for about 27 days. The patient had a temperature 
range of 36.4 to 37.3 °C, HR of 139 to 181 bpm, RR of 34 to 84 bpm, and MAP of 66 to 
18.6 mmHg.  
Baseline clinical and probabilities inputs are summarized in Table 4.17.  
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Table 4.16 Summary of the ADRs associated with sedation success 
The ADRs associated with 
sedation success  
Fentanyl monotherapy Fentanyl plus midazolam 
 
Total number 
of patients  
Cost per 
patient (QAR) 
Total number 
of patients  
Cost per  
patient (QAR) 
 
Desaturation  13 35,039.15 4 40,691.29 
Desaturation and urinary retention 1 35,049.15 0 N/A 
Desaturation and MV adjustment        2 35,039.15 0 N/A 
Desaturation and edema 1 35,041.49 0 N/A 
Desaturation, MV adjustment, and 
edema 
 
3 35,041.49 1 40,481.72 
*N/A: Not applicable  
 
Table 4.17. Clinical outcomes and probabilities of fentanyl monotherapy vs. fentanyl plus 
midazolam combination used in the model 
Study clinical outcome Probability with fentanyl 
monotherapy (n= 39) 
Probability with fentanyl 
plus midazolam (n= 15) 
Sedation success  0.51 (n= 20) 0.33 (n= 5) 
With ADRs 0.51 (n= 20) 0.33 (n= 5) 
Without ADRs 0 (n= 0) 0 (n= 0) 
Sedation failure  0.49 (n= 19) 0.67 (n= 10) 
Increased dose 0.63 (n= 12) 0.5 (n= 5) 
Therapy switch to alternatives 0.16 (n= 3) 0.5 (n= 5) 
Withdrawal symptoms  0.05 (n= 1) 0 (n= 0) 
Death 0.11 (n= 2) 0 (n= 0) 
Persistent agitation  0.05 (n= 1) 0 (n= 0) 
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4.4.8 Cost of sedation 
 Compared to the combination of fentanyl and midazolam, fentanyl monotherapy 
had an economic advantage of QAR 43,811.83 per patient and a 51% successful sedation 
rate, compared to 33%. In the fentanyl monotherapy group, the sedation success 
associated with ADRs (Table 4.16) had the most impact on the total therapeutic cost, 
while the sedation failure due to receiving alternative mostly influenced the total cost of 
the combination regimen as shown in Table 4.18, where the weighted probabilities and 
costs for therapy outcomes are also given. Cost components of the overall therapy as 
summarized in Table 4.19. 
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Table 4.18. The proportional cost of fentanyl monotherapy and fentanyl plus midazolam 
regimen 
Therapy outcome Fentanyl monotherapy Fentanyl plus midazolam 
P
ro
b
ab
ility 
Cost per 
patient 
(QAR) 
P
ro
p
o
rtio
n
al 
co
st (Q
A
R
) 
P
ro
b
ab
ility 
Cost per 
patient 
(QAR) 
P
ro
p
o
rtio
n
al 
co
st (Q
A
R
) 
Sedation success with ADRs 0.51 68,706.12 35,040.12 0.33 123,179.94 40,649.38 
Sedation success without 
ADRs            
                              
0 N/A N/A 0 N/A N/A 
Sedation failure       
Sedation failure due to dose 
increased 
 
0.31 20,600.71 6,338.68 0.33 71,778.10 23,926.03 
Sedation failure due to 
switch to alternative 
(morphine) 
0.08 21,991.79 1,691.68 0.33 73,534.35 24,511.45 
Sedation failure due to 
possibility of withdrawal 
symptoms 
 
0.03 10,874.15 278.82 0 N/A N/A 
Sedation failure due to 
death 
 
0.05 18,762.99 962.20 0 N/A N/A 
Sedation failure due to 
persistent agitation  
 
0.03 37,577.38 963.52 0 N/A N/A 
Total cost per patient                                        45,275.03                                                 89,086.86 
*N/A: Not applicable  
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Table 4.19. Cost components of the overall therapy 
 Cost (QAR)                                          Cost (QAR) 
Cost component  Fentanyl monotherapy  Fentanyl plus midazolam  
Sedation success with ADRs 
Initial sedation 12 18.58 
MV 1,290.45 5,591.93 
NICU stay 21,612.86 22,667.15 
Hematological tests 150 210 
Chemistry tests 6,254.55 4,104.55 
Metabolic tests 1,140 1,140 
Microbiology tests 1,644.44 822.22 
Blood gases tests 840 3,430 
Virology tests 780 780 
Urinalysis tests 72.22 N/A 
Diagnostic tests 1,031.09 1,715.32 
Oxygen therapy 211.54 211.54 
Catheter  10 N/A 
Medications to treat ADRs 2.34 1.97 
Sedation failure due to increased dose 
Initial sedation 12.00 18.58 
MV 1,290.45 12,904.46 
NICU stay 10,015.72 32,155.73 
Hematological tests 90 750 
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Chemistry tests 4,104.55 12,900 
Metabolic tests 1,140 2,280 
Microbiology tests 1,233.33 2,055.56 
Blood gases tests 1,750 5,530 
Virology tests N/A 780 
Urinalysis tests N/A 144.44 
Diagnostic tests 964.67 2,259.34 
Medications to treat ADRs N/A N/A 
Sedation failure due to receiving alternative 
Initial sedation 12 18.58 
Alternative sedation  1,127.49 53.21 
MV 3,011.04 23,228.03 
NICU stay 13,178.58 41,644.30 
Hematological tests 90 390 
Chemistry tests 2,540.91 3,127.27 
Metabolic tests 1,140 1,140 
Microbiology tests 822.22 1,644.44 
Blood gases tests 560 910 
Virology tests N/A N/A 
Urinalysis tests N/A N/A 
Diagnostic tests 595.67 1,431.72 
Medications to treat ADRs N/A N/A 
Sedation failure due to withdrawal symptoms 
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Initial sedation 6 N/A 
MV 2,580.89 N/A 
NICU stay 6,325.72 N/A 
Hematological tests N/A N/A 
Chemistry tests N/A N/A 
Metabolic tests 570 N/A 
Microbiology tests 822.22 N/A 
Blood gases tests N/A N/A 
Virology tests N/A N/A 
Urinalysis tests N/A N/A 
Diagnostic tests 569.31 N/A 
Medications to treat ADRs N/A N/A 
Sedation failure due to death 
Initial sedation 6 N/A 
MV 5,161.78 N/A 
NICU stay 6,325.72 N/A 
Hematological tests 150 N/A 
Chemistry tests 1172.73 N/A 
Metabolic tests 1,140 N/A 
Microbiology tests 1,233.33 N/A 
Blood gases tests 2,730 N/A 
Virology tests N/A N/A 
Urinalysis tests N/A N/A 
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Diagnostic tests 843.43 N/A 
Medications to treat ADRs N/A N/A 
Sedation failure due to persistent agitation 
Initial sedation 12 N/A 
MV 3,441.19 N/A 
NICU stay 14,232.86 N/A 
Hematological tests N/A N/A 
Chemistry tests 13,095.45 N/A 
Metabolic tests 3,990 N/A 
Microbiology tests N/A N/A 
Blood gases tests 70 N/A 
Virology tests N/A N/A 
Urinalysis tests N/A N/A 
Diagnostic tests 2,735.87 N/A 
Medications to treat ADRs N/A N/A 
*N/A: Not applicable  
 
4.4.9 Sensitivity analysis  
One-way sensitivity analyses. The model was insensitive to the changes in all the 
variables in the both groups. 
Probabilistic sensitivity analyses. The tornado diagram in Figure 4.10 shows that the 
study outcome was mostly influenced by the uncertainty in sedation success in the 
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fentanyl plus midazolam. In the monotherapy regimen, however, the uncertainty in the 
sedation failure due to persistent agitation had the lowest impact on the outcome. The 
probabilistic curve illustrates that fentanyl alone achieves cost saving over the 
combination regimen in 100% of cases, as seen in Figure 4.11. 
Alternative scenario. A net saving of QAR 380,871.79 per patient was associated with 
fentanyl monotherapy compared with the fentanyl and midazolam combination. The 
total cost of management for both groups were QAR 381,876.67 and QAR 762,748.45, 
respectively.  
 
Figure 4.10. Tornado diagram of the variables as per their influence on the outcome of the 
Monte Carlo simulation 
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Figure 4.11. ICER probability curve with fentanyl plus midazolam 
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Chapter 5: Discussion 
5.1 Phase 1: Systematic review of literature methods 
The first phase was a comprehensive systematic review of the literature designs 
and methods used in the evaluations of morphine and fentanyl in critically ill patients 
who are on MV due to respiratory diseases, especially in relation to the economic aspect 
of research. This guides future research, including, to the best possible, the current one, 
in relation to these two medications. This review assessed the quality of 33 publications, 
including RCTs, observational studies, and economic evaluations, with none published 
after 2014. Studies were characterized by a number of weaknesses and variations in the 
methodological strategies used, especially in relation to the economic evaluations. A 
medication performed differently in different studies with similar populations, providing 
a very limited aggregate evidence to guide decision makers in other settings.  
In adult patients, the studies differed in their clinical outcome measures. While some 
only looked at sedation based on scales, others looked at the duration of MV. Here, 
while most studies used the optimal sedation level as the primary study outcome, some 
incorporated duration of therapy when made their conclusions. These variations in 
endpoint measures make it difficult to compare the results of the studies. Different 
types of scales were used, including RSS, RASS, Addenobrook, and SAS. In one 1993 
study, the RSS scale of sedation was used, despite that this was not validated until the 
year 2000 (102, 103). In addition, the majority of studies in the review did not define the 
duration of sedation, which raises a concern in relation to the proper time of 
management. Findings of studies performed with short term follow up, for example, 
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cannot be applied to patients in need for over 24 hrs sedation since these may not 
reflect the routine clinical practice in ICU settings. As another example, remifentanyl 
was found to have similar sedation efficacy compared with morphine or fentanyl, except 
for the purpose of a shorter ICU stay. Generalizability was also limited because of the 
very high heterogeneity in the approaches used to evaluate similar medications as first-
line sedatives for similar indications. Sedatives were different in the doses administered 
and in the comparators they were evaluated against. While most of these were within 
therapeutic range of dose, some were not. For example, Strom et al reported doses 
given as a range, including higher than 4 mg/kg/hr dose of propofol for more than 48 
hrs. This dose however was found to be problematic as it increases the risk of propofol 
infusion syndrome without switching to alternatives (89). All of such methods variability, 
and the lack of justification of methods, raise the concern in relation to the validity and 
reliability of results and their interpretation.  
In the neonate population, similar to the adults, different studies also made different 
conclusions in relation to the same drugs because of targeting different types of primary 
and secondary outcomes, though the level of sedation was a more common outcome 
here than in adults. Additional primary outcomes were duration of sedation, death and 
the neurodevelopmental functions. A variety of scales were used to assess sedation in 
studies, including PIPP, NIPS, COMFORT, NFCS, PCS and VAS, with the former two being 
more specific for pain than agitation. NFCS and PCS scales were not defined in the study 
in relation to targeted score levels, limiting the ability to know if the standard measures 
were used.  
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In the pediatric patients, each of the different studies used a different primary outcome, 
which included withdrawal symptoms and increased dosing. The level of sedation was 
measured via RSS, PICU and tracheal suctioning scales.  
In all age groups, the intention to treat analysis in the RCT studies was not conducted in 
the majority of the studies (n= 23), especially where cases of subjects receiving 
alternatives after initial treatments existed, in one study which was RCT design (80). This 
is a confounder that affects the interpretation in clinical practices and should be 
considered. Also, the majority of the studies (n= 16) was not conducted specifically in 
patients with respiratory disorders, which were among patients with a variety of 
underlying diseases, such as congenital anomalies, cardiac disorders, neurological 
diseases, gastrointestinal diseases, infectious diseases, post operation patients, and 
respiratory disorders. Such studies, therefore, may not be representative of patients 
with pure respiratory disorders, seeing that different medical conditions may require 
different types of assessments due to differences in clinical outcomes. In all populations, 
the majority of studies were RCTs, which is best for achieving internal validity. When 
RCTs are infeasible due to ethical or resource availability, observational studies are a 
useful, efficient source of effectiveness data, especially due to the associated savings in 
time, effort and expenses.  An observation of interest is the limited number of economic 
evaluations in studies. The pharmacoeconomics evaluation strengthens the 
multidimensional evidence in promoting the rational use of medications, and is now an 
integral type of research in practices. Less than a quarter of reviewed studies included 
any form of these.  
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The CONSORT checklist does not allow a quantitative overall quality scoring of RCTs. 
Threats to quality/validity, however, occurred in 0-100% of studies in relation to several 
items of validity (out of a total 18) measured. Especially high were problems in relation 
to important changes to methods after trial commencement (such as eligibility criteria), 
any changes to trial outcomes after the trial commenced, losses and exclusions after 
randomization for each group, and where the full trial protocol can be accessed, which 
were reported in none of the studies. To lesser extent, studies did poorly in relation to 
several items; how sample size was determined, with 44% of trials reporting this; 
explanation of any interim analyses and stopping guidelines (when applicable), with 28% 
reporting in studies; methods for additional analyses, such as subgroup analyses and 
adjusted analyses (only reported in 17% of studies); for binary outcomes, presentation 
of both absolute and relative effect sizes (only in 33% of studies); results of other 
analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory (only in 17%); generalizability (external validity, 
applicability) of the trial findings (only discussed in 22% of studies); registration number, 
sources of funding and other support (in 17% of studies). These are mostly methods and 
results related topics, and while example weaknesses in relation to the sample size 
calculations and the outcome effect size estimations can limit the reliability and 
interpretability of results, the results of research will also less likely be generalizable 
beyond study populations due to the limitations in discussing the external validity of 
findings.  
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The quality of observational studies was less than ideal in 0-100% of studies with 
studies’ scoring out of total 8 in several items of validity measured. All publications were 
lacking in relation to power analysis, any methods used to assess subgroups and 
interactions, explanation of how missing data were addressed, sensitivity analyses, the 
number of patients with missing data, follow-up time, category boundaries for 
continuous variables, translation of relative risk to absolute risk, other analyses 
(subgroups/interactions/sensitivity), and funding for studies. To a lesser extent, studies 
performed poorly in relation to the validity items relating to follow-up time, define all 
outcomes, exposures, predictors, potential confounders, and effect modifiers, and 
number of patients at each stage of study for example patients possibly eligible and 
confirmed eligible, with around 38% of studies reporting these; define potential 
confounders, how bias addressed, how quantitative variables addressed and how loss to 
follow up addressed, and directions or magnitude of bias and generalizability (only 13% 
of studies reported these); diagnostic criteria and use of a flow diagram (only found in 
25% of studies). As with clinical trials, these weaknesses are mostly methods and results 
related, which in addition to translating to major problems in relation to reliability, 
validity of interpretation and the generalizability to other settings, also especially 
representing a problem in relation to controlling for selection, confounding and 
channeling bias.  
The relatively limited pharmacoeconomics research is mostly due to the lack of proven 
treatments, where the utility of pharmacoeconomics becomes questionable, unless 
there is an advantage due to reduced adverse events. Of the seven economic 
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evaluations included in this review, four did not identify the exact respiratory disorder in 
the population for which they received MV, and none was conducted in neonates or 
pediatrics. Overall, the CHEERS checklist indicated that all of the included 
pharmacoeconomics evaluations were about poor in quality. The main shortcomings 
identified through the tool, to a large extent in the majority of studies, were related to 
the time horizon, analytical model, incremental costs and outcomes, characterizing 
uncertainty, the choice of model and characterizing heterogeneity, with 71% of the 
studies not reporting these; estimating resources and costs and assumptions (57% of 
trials did not report these); source of funding and conflict of interests (100% of studies 
did not report this). 
Modeling analysis in economic evaluations simplifies the understanding of the effect 
and cost of the intervention. Out of the seven economic evaluations, however, only four 
included modeling. Out of these only one included the Markov modeling. This is 
anticipated as the Markov modeling is ideal for pharmacoeconomics evaluations in 
recurrent diseases, which the agitation due to MV is not. Markov extends the results of 
clinical studies and extrapolate intermediate endpoints into final outcomes, which was 
not necessary in the included studies. While variable in different studies, as discussed 
above, outcomes were mostly clinically relevant and short term in nature, which is not 
surprising due to the acute nature of the ICU setting. Except for a single study that did 
not clarify the type of setting (104), the included studies were evaluated from the 
perspective of hospital, including the direct medical type of costs. This is anticipated and 
is appropriate given that the non-health resources use and the work productivity are 
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minimally affected as a result of sedatives use in the ICU setting. An issue to discuss is 
the lack of clarity of costing methodology and components. Unclear description of cost 
methods and components leads to difficulty in having different settings benefiting from 
(and applying) results. Only the Barrientos et al and Cox et al studies provided detailed 
definitions of the costing methods. None of the studies, for instance, differentiated 
hospital charges from costs. This is as hospital charges are not ideal estimations of cost 
in the hospital setting as the latter uses it to compensate for the cost of other services in 
the setting, producing less robust conclusions. Another example is that only two studies 
reported the currency along with the financial year of cost values as part of analysis and 
modeling (87, 90), making it difficult to judge the need and appropriateness of time 
adjustment of cost. In one study, as another example, cost terminologies were misused, 
whereby the marginal or indirect cost were referred to as a secondary medical cost to 
include under the hospital perspective (76). 
Further in relation to economic evaluations, while the sensitivity analysis, where 
uncertain input values are systematically changed to investigate robustness of study 
conclusions, is a corner stone in any economic evaluation, sensitivity analysis was 
conducted in only the Al MJ et al and Cox et al studies of the seven studies, which 
cannot be acceptable. And though conducted sensitivity analyses indicated studies 
robustness, in none of the studies justifications for the changes made were provided. 
This is added to the limited variability in the types of sensitivity analysis conducted. 
Most studies conducted one-way sensitivity analyses only. This, in the absence of 
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multivariate analyses, and even if interpreted correctly, can underestimate uncertainty 
(105).  
To add, while studies included the analysis of adverse event costs, none of the studies 
modelled the discontinuations associated with adverse events. The impact of 
discontinuation is not clear in studies, which was also not part of sensitivity analyses 
conducted. Quantifying the side effects that are associated with discontinuations as 
equivalent to those that are not is not ideal when guiding decision making. 
While it is attractive and easily acceptable to transfer findings from one setting to 
another, given the observed weaknesses and limited consistency in methodological 
approaches observed in the included studies, decision makers should maintain caution 
when making decisions based on the current available body of clinical and economic 
evidence in relation to the use of morphine and/or fentanyl with MV in ICUs. It seems 
that health outcomes and costs have limited transferability across settings in relation to 
ICU practices. 
Based on observations in the current study, several priority recommendations can be 
made for the purpose of enhancing the quality of future research and evidence.  
• Economic evaluations should more often be incorporated in studies, especially in 
neonates and pediatrics. Future work needs to ensure the availability of relevant 
research experiences and a better cost data, including secondary costs of 
interventions. Further to this, economic evaluations should more rely on the cost-
effectiveness type of research as compared to the cost and cost-consequence 
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analyses, which is because, unlike with the latter two, the cost-effectiveness 
research does not only identify and measure outcomes and costs, but also 
compare among them. This is ideal for decision making as it enables conclusions in 
relation to whether an intervention’s outcome justifies its cost.  
• Details of studies should be better identified and presented, including in relation 
to RCTs, observational and economic evaluations. Main details include sample size 
and power analysis, follow up, generalizability, missing data, effect size, sensitivity 
analyses, cost and costing methods, and funding. There are several quality 
assessment checklists that can be used to guide methods reporting. These include 
CONSORT and JADAD for RCTs, and STROBE and GRACE for observational studies, 
Quality of Health Economic Studies and CHEERS for economic evaluations.  
• Future work should include a head to head comparison of morphine with fentanyl 
in subjects with respiratory disorders, making it difficult to determine which agent 
is more efficacious. Current differences in design, reporting, assumptions, 
definitions, and estimations limit the ability to make head-to-head conclusions 
between these two medications. 
• Adherence to methodological standards should be enhanced. Researchers should 
better follow good practice guidelines in relation to RCTs, observational studies, 
economic evaluations, and the clinically relevant. This relates to increasing the 
utilization of power and sample size calculations in studies and better controlling 
for systematic errors within study designs, in addition to eliminating errors that 
would affect generalizability to other settings. Also, to use reliable outcome 
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measures to evaluate sedation as well as justified tools for the assessing of these 
measures. This will improve uniformity among tools, i.e. scales, used in similar 
comparisons in literature. Also of relevance is to minimize the attrition rate, where 
data analyzed and reported are based on a sample size that is lower than that 
initially calculated to achieve power, which limits the validity of study results. In 
relation to economic evaluations, uncertainty will need to be accounted for in 
future research, which is by incorporating comprehensive sensitivity analyses in 
studies, in addition to incorporating (when meaningful) correlation effects of 
variables. Furthermore, future studies need to evaluate adverse events that results 
in discontinuation in isolation from those that do not, better guiding decision 
making based on secondary consequences and costs. 
• Long-term outcomes should be incorporated more often, especially in the 
neonatal and pediatric populations. For example, out of all studies, only one 
looked at the neurodevelopmental function as an outcome. This however requires 
the better availability of long-term data, including cost, and the use of analytical 
models adopting longer term horizons. Here, future research should map beyond-
ICU effects as well as associations between intermediate and final outcomes.  
• Finally, the narrow scope of most study questions limit the ability of decision 
makers when trying to prioritize sedatives. Studies have mostly focused on how a 
drug performs based on an outcome or two at a time. Methods to better 
synthesize evidences that are multidimensional in nature should be developed and 
tested into the decision making. The multi-criteria decision analysis, for example, 
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enables comparative single numerical measures that are based on a wide variety 
of the drug’s multiple criteria, which may include efficacy, safety, formulation and 
dosing, adverse events, drug interactions, ability to combine, and costs (106).  
To the best of our knowledge, this is the first systematic review to assess the 
methodological quality of studies in relation to fentanyl and morphine with MV in the 
ICU setting, identifying priority aspects for improving the quality of future research. 
Limitations in the review include the possibility that relevant studies were not included 
in this study due to the English restricted search. Studies may exist in other less 
common languages, such as French, Chinese and German. Authors however do not have 
the resources to translate the non-English language literature. Moreover, despite the 
comprehensive search conducted via several search engines in the study, additional 
literature search terms and/or combinations among them are possible and, hence, we 
cannot exclude the possibility that we missed relevant studies. Also, while different 
journals have varying publication criteria, all journals were weighted equally in this 
study, which can be associated with bias.  
5.2 Phase 2: Comparative evaluation of sedatives 
While the HMC, as a public provider, is regulated by the Supreme Council of 
Health in Qatar, the drug formulary selection at the hospitals within HMC is determined 
by pharmacy and therapeutic (P&T) committees within the corporation, and this is 
where the context of this research is most relevant. While the HMC P&T committees 
traditionally judged medications based on safety and efficacy considerations mostly, due 
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to the notion of economic wealth, these have also been increasingly looking at the 
economic considerations of medications in recent year. Indeed, while unrestricted 
formularies are powerful, they are not economically practical or efficient, including in a 
rich country like Qatar. 
The study is the first to compare the pharmacoeconomics of fentanyl monotherapy 
versus morphine monotherapy as sedatives in the management of mechanically 
ventilated neonates during the NICU stay worldwide. It is also the first study in the 
literature to evaluate each sedative alone against its combination therapy (morphine 
monotherapy versus morphine plus midazolam, and fentanyl monotherapy versus 
fentanyl plus midazolam) for the same population. All patients were followed up until 
NICU discharge. The study followed all the different patient pathways in the Qatari 
practice of managing the critically ill neonates who are on MV due to RDS.  
Morphine monotherapy improved sedation and agitation levels over fentanyl 
monotherapy and the morphine plus midazolam combination, with relatively enhanced 
sedation success by a significant 36.76 % and 48.48% in favor to morphine, respectively. 
These corresponded to ICERs of QAR 490.36 and QAR 21,206.85 with morphine per the 
additional case of sedation success over the two comparators, respectively.  
For the purpose of the current research, the evaluation of fentanyl versus its 
combination with midazolam is considered a pilot study as required sample size was not 
achieved in the study. As discussed above in section “3.2.6” of the methods, it is difficult 
to obtain records of WH patients from the period prior to October 2014, and due to the 
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fact that the first-line use of fentanyl was stopped in WH in December 2015, it is not 
possible to obtain patients sedated by fentanyl from any period afterwards. 
Fentanyl monotherapy was found superior to its combination with midazolam, giving 
higher clinical effectiveness by 35.29% and a cost saving of QAR 43,535.89. The patient 
baseline characteristics did not differ between comparators in each of the evaluations 
except in the use of vecuronium in the morphine monotherapy and morphine plus 
midazolam combination (107, 108). In the Qatari NICU at WH, vecuronium is potentially 
administered in addition to sedatives prior to intubation to paralyze the critically ill 
neonates. This raises the concern that vecuronium can bias the sedation effect of 
sedatives. Nevertheless, while in the evaluations of the fentanyl versus its combination 
more patients in the combination regimen received the vecuronium, the outcome was 
in favor of the fentanyl monotherapy. Adjusting for the difference will only add to the 
advantage of the monotherapy. 
For the purpose of the main clinical endpoint in this study, the PIPP score was used to 
reflect the sedation status of the patient in the Qatari NICU. It has been previously 
validated and used by studies to reflect the clinical and agitation status of the patient 
and neonate’s need of sedation (70). There is a clear cut off criteria in relation to the 
PIPP score or the agitation level and the use of sedatives, which the current practice at 
the Qatari NICU follows.  
The only study that directly compared between morphine and fentanyl as sole sedatives 
was conducted by Saarenmaa et al, who reported no significant difference between the 
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sedatives (58). In this study, however, morphine and fentanyl were evaluated in 
neonates with different disorders, including RDS, infection, persistent pulmonary 
hypertension (PPHN), NEC, and IVH. Since the study was not purely conducted in 
neonates with RDS, and stratification by underlying medical conditions was not 
performed, generalizability of the results to all population is limited. Patients with 
PPHN, for example, do not respond to the conventional type of ventilation, and they 
require high frequency ventilation in addition to inhaled nitric oxide with different range 
of doses of sedation (109). In another study, by Anand et al, morphine was compared to 
midazolam and placebo in which both morphine and midazolam reduced the level of 
pain compared to the placebo. Nevertheless, this was a pilot study, where the 
underlying diseases were not specified, with patients who would benefit from the study 
not identified (59).   
Additional limitation in the studies by Saarenmaa et al, Wood et al, and Quinn et al (58, 
61, 62), which were conducted in preterm infants, is that the level of sedation was 
based on measuring the hormonal response levels of adrenaline and noradrenaline. 
However, these are not applicable or accurate indicators of sedation in preterm 
neonates as the level of them changes with maturity, where with the increase in age the 
adrenaline level is increased as the noradrenaline is converted to it. The level is also not 
specific to the pain, they can be affected by other factors such as the RDS itself (62). For 
instance, in the included studies by Saarenmaa et al and Quinn et al no change in the 
levels of these hormones was observed in any of the treated groups, except the 
noradrenaline level in the morphine monotherapy group in the Quinn et al study (58, 
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62), while in the Wood et al study the adrenaline level was reduced in neonates sedated 
with morphine and diamorphine, and noradrenaline was only reduced in the morphine 
group (61).  
In our study, neonates who received morphine monotherapy or fentanyl monotherapy 
experienced greater success compared to the combination regimen with either of them. 
The addition of midazolam to either morphine or fentanyl did not show any advantages 
in terms of achieving better sedation, instead longer duration of sedation, extended 
NICU stay and longer MV were required compared to the monotherapy regimens. The 
results of this study indicate the limitation of the HMC practices regarding the addition 
of a combination therapy to enhance sedation, which is based on personal points of 
views, clinical judgment, and individual experiences. Pain management in neonates that 
is not evidence based is not an issue only in Qatar but also in most of the clinical NICU 
practices, where limited consensus on the use of opioids as sedatives is common, 
including the combination with other sedatives (110).  
An important clinical endpoint was the evaluation of the sedation and non-sedation 
related mortality associated with the study sedatives. The mortality rate was higher in 
patients managed with morphine monotherapy compared to fentanyl monotherapy or 
the morphine plus midazolam combination. Large differences in the duration of 
sedation were noticed among the groups (12 days with morphine over fentanyl, and 41 
days with morphine over its combination). In the third study, none died in the 
midazolam plus fentanyl group while two cases were reported in the fentanyl 
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monotherapy group. One may suggest that mortality increases with longer durations of 
therapy or decreases with the use of midazolam. The confirmation of this however, is 
not feasible is this study. This is especially when one looks at the RCT by Anand et al, for 
example, where mortality rate was found to be comparable based on similar durations 
of sedation between study groups. To note however, while death was reported by 
Anand et al in two cases with placebo, one with midazolam, and none with morphine, 
no doses of sedatives were specified in the study (59). In another RCT by Quinn et al, 
mortality among study groups, i.e. morphine alone, pancuronium alone, morphine plus 
pancuronium, was also measured based on equal duration of sedation, where no 
significant differences were observed. Important, is that the mortality was not clearly 
defined in this study (62).  
The withdrawal symptoms outcome measure in the current study was not measured in 
any of the previous neonatal studies. The interest in this was based on the fact that 
withdrawal symptoms from an opioid are considered one of the most important factors 
that cause abnormalities in release of noradrenaline in the brain that is responsible for 
controlling the alertness, respiration, and muscle tone, which lead to opioid’s 
dependence (111). In our study, this was seen in patients receiving morphine 
monotherapy, while none experienced it in the fentanyl monotherapy group. Although 
one day of sedation by morphine may not be considered prolonged enough to cause 
withdrawal symptoms, other associated etiologies cannot be ruled out. Also in this 
study, withdrawal symptoms were higher with the monotherapies compared to their 
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combinations. This is expected since midazolam has proven to be effective in treatment 
of seizure and agitation (112).  
Persistent agitation was found to be more associated with fentanyl monotherapy than 
with the morphine monotherapy. While the addition of midazolam to fentanyl seemed 
to prevent the agitation in all patients, the midazolam plus morphine was associated 
with persistent agitation in one patient. The reason behinds this could be that 
midazolam, which is indicated to treat agitation, was only given to the patient as loading 
dose (with no follow up maintenance doses), despite that the patient was on 
maintenance doses of morphine for 5 days.  
The total cost of morphine monotherapy was higher compared to that with the fentanyl 
monotherapy. Looking at the factors that contributed to the overall cost management 
of morphine monotherapy, sedation success that is associated with ADRs was the most 
influential, followed by sedation failure due to death. With fentanyl, these were the 
success that is associated with ADR, followed by sedation failure due to receiving 
increased doses. Out of all of these, the success associated with ADRs was associated 
with the highest cost per patient. Taking this into consideration, and that morphine was 
associated with more of the success associated with ADRs than fentanyl, translated into 
a higher cost with morphine. The justification of the higher ADRs with morphine is 
mostly the longer duration of sedation, MV, and NICU stay in the morphine 
monotherapy group. This surely contributes to the increased total cost of therapy, 
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especially as the MV and NICU stay durations were found to be more expensive (QAR 
430.15 and QAR 527.14 per day, respectively) compared to the other variables.  
Although the morphine plus midazolam regimen was associated with longer durations 
of MV, NICU stay and sedation compared to the morphine alone, the total cost of the 
former was lower. However, the cost per patient in the success with ADRs pathway was 
over five times higher with morphine versus the morphine plus midazolam combination, 
in addition to that the probability of success with ADRs is higher with morphine than 
with its combination regimen. It seems that this led to a higher morphine cost that 
surpassed the high cost of the longer duration of MV, NICU and sedation with the 
combination.  
With improved agitation and better cost saving (QAR 45,275.03 versus QAR 89,086.86) 
fentanyl monotherapy demonstrated dominance over its combination with midazolam, 
keeping in consideration that this imporved agitation connot be confirmed due to 
limited sample size. Success with ADRs and the failure due to switching to alternatives 
were the most two contributing outcomes in the total cost of both fentanyl and fentanyl 
plus midazolam. But while the proportional cost of the success with ADRs was about 
QAR 4,400 more with fentanyl per patient, the proportional cost of the failure due to a 
switch to an alternative was about QAR 22,819 higher with the combination. This, taking 
in consideration the effect of a longer duration in the combination therapy, which 
allows for more utilization of MV that leads to the longer stay at the NICU, justifies the 
overall cost saving associated with the fentanyl monotherapy.  
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Based on the above, it seems that the addition of midazolam was associated with 
reduced incidence of ADRs associated with morphine or fentanyl. This finding is 
supported by RCT studies by Kim et al and Mahajan et al that suggested that treatment 
with midazolam did not yield desaturation (113, 114). As demonstrated in our study, 
desaturation contributes the most to the ADRs in the monotherapy groups. 
The sensitivity analyses demonstrated robustness of the all the economic outcomes of 
evaluations to all variables, except in the morphine versus fentanyl monotherapies, 
where sensitivity was demonstrated to the cost of MV, NICU stay during sedation 
success, and NICU stay during receiving increased doses in the fentanyl monotherapy. 
The variability in these variables therefor, will need to be taken in consideration by 
decision makers when anticipating outcomes, including for the purpose of 
generalizability to other settings. 
Also, it seems that doses of administered therapies were occasionally below or above 
the therapeutic range. As in many other practices, in the Qatari NICU, the sedatives are 
first ordered through the physicians. Then, the dose, frequency and preparation are 
verified by the inpatient pharmacy, followed by administration and signing the patient’s 
medication record on Cerner by nurses. Sensitivity analysis, however, did not 
demonstrate major influences on economic results by the dosing variability. 
Interestingly, not one patient in all the study groups reported sedation success without 
ADRs, at least experiencing one self-managed ADR which did not require further 
management. Sedation success associated with ADRs that required further management 
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was the clinical outcome that influenced the total therapeutic cost the most for each of 
the different therapies in all of the evaluations, except the morphine plus midazolam 
combination. This is not unexpected as all the patients who were successfully sedated 
by the study sedatives developed at least one ADR that needed further management. 
The outcome that contributed the most towards the cost of the morphine and 
midazolam combination was the failure due to receiving the increased dose, which 
particularly was prevalent with the combination.  
The cost of the alternative therapy was higher in the morphine monotherapy group 
when compared to the fentanyl therapy. This was as few number of patients switched 
to fentanyl in the morphine group as compared to those who switched to the more 
expensive morphine in the fentanyl group. As compared to the morphine combination, 
none in the morphine monotherapy group switched to an alternative therapy, making 
the cost of alternative therapy higher in the combination therapy. As compared to the 
fentanyl monotherapy, up to half the patients who received its combination with 
midazolam failed therapy due to receiving alternative therapies, leading to a higher cost 
with the combination. While it is important for decision makers to not only consider the 
initial medication costs, but also the cost of alternatives, in the current evaluations, it 
seems that the costs of the initial therapies were high enough to minimize the influence 
of alternative therapies on the comparative overall cost of therapies.  
The RCTs are considered an ideal source of evidence for pharmacoeconomics 
evaluations due to well established methodology and internally valid data, including due 
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to random assignments of patients, blinding assessment, and controlling confounding 
factors that minimize bias (115). Nonetheless, RCTs have several drawbacks which limit 
their use in pharmacoeconomics evaluations. RCTs have limited external validity and, 
hence, limited generalizability of results to other settings due to the controlled design of 
studies in relation to the patients’ criteria and medication regimens (116). Also, they can 
be limited by a pre-defined specific duration that might not include important, though 
maybe infrequent, consequences of therapies in real life, which are associated with 
cost. Such consequences and outcomes can include mortality, needs for higher doses, 
switching to alternatives, and possibility of withdrawal symptoms. Such limitations have 
generally led researchers to also depend on the observational cohort retrospective 
studies, which are also considered relatively inexpensive and require less time, effort 
and resource consumption. Also important, is that cohort studies are better suited to 
measure effectiveness as per real practices when compared to RCTs. All this is 
particularly important to consider for the purpose of the current research, where the 
objective is to enhance decision making that is especially based on local evidence and 
practices with the study sedatives, in addition to following patients up until NICU 
discharge, which represent more realistic NICU costs in relation to medications and/or 
procedures. 
Another strength in the current study relates to the fact that the decision analytic 
modeling used is the most comprehensive in the literature so far, reflecting all the 
possible endpoints of sedatives which accurately represented the overall cost of 
sedation. None of previous studies performed in the adult population, where all 
192 
 
sedation-based economic evaluations were conducted, assessed the impact of sedatives 
in mechanically ventilated patients. Cox et al, for example, who conducted a CEA in the 
adult population, performed a modeling that only looked at survival/mortality in the ICU 
and specific ADRs, which consequently affected the total cost of sedatives in the ICU 
(90). Sedative regimens are not only associated with adjusted agitation status, but also  
adverse reactions, adjusted dosing, alternatives, withdrawal symptoms, and death, 
added to the duration of therapies. The latter is particularly important in affecting the 
overall resource utilization, relating to sedation duration, MV, and NICU stay. Such 
outcomes of sedation were all considered in the current model.  
Clinicians, including consultants, physicians, and clinical pharmacists target sedatives 
that decrease the overall resources. The results of this study are important for 
stakeholders and policy makers given an anticipated increase in the ICU expenditures 
over the coming years (117). This is particularly of value due to the limited number of 
high quality CEA studies in literature in relation to guiding the management of sedation 
in the ICU patients (118). Through the alternative scenario analysis, the study results do 
not only represent the perspective of the governmental HMC setting but also the Qatari 
private setting, which is of additional strength to the study. Furthermore, it is common 
that the strength of retrospective studies is jeopardized by missing data in records. This 
was not an issue faced in this study, especially in relation to the PIPP scores, doses, 
duration and ADRs, further adding to the study strength.  
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The main limitation is this research was extracting the costs of several variables for the 
HMC sources. Due to the nature of this governmental corporation, the costs for few 
resources were not available and, thus, had to be extracted from alternative external 
sources, i.e. AH, the major private hospital in Qatar. The costs, however, were to the 
best possible adjusted as discussed in the methods section of this thesis. Another major 
limitation was the limited number of patients who were sedated by fentanyl within the 
study duration compared to morphine as its first-line use stopped in 2015. Hence, 
power was not attained for the purpose of the evaluation of it against its combination.  
Follow up studies are needed to evaluate the effect of morphine with or without 
midazolam on the neurological outcomes in mechanically ventilated patients with RDS 
after NICU discharge, to assess the fine, gross, social, and cognitive motor as clarified in 
previous studies (58, 60). Due to time limits in the current research, the study did not 
measure these long-term outcomes, especially as these will need to include patients 
with RDS in the neonatal clinic at Al-Rumila Hospital in Qatar, to which neonates who 
have HIE or those less than 32 weeks are transferred, in which the fine and gross motor 
should be evaluated over two years, followed by assessment of the social and cognitive 
motor after another two years. Also, future clinical studies are highly recommended to 
measure associations of interest in relation to the sedation use and its consequences. 
These include the sedation-related mortality and the duration of sedation, the 
gestational age and the birth weight with the sedation use in neonatal patients. For 
example, Saarenmaa et al and Thummel et al found that the plasma clearance of 
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fentanyl and morphine increases with the progress of gestational age (107, 108).  
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Chapter 6: Conclusion  
The current research is the first CEA in the literature to evaluate the economic and 
clinical outcomes of morphine and fentanyl as standalone or in combination with 
midazolam in mechanical ventilation due to RDS in neonates. The research also includes 
the first systematic review to assess the methodological quality of studies, including the 
pharmacoeconomics, evaluating the use of morphine and fentanyl in all populations 
undergoing MV. The control of agitation in RDS neonates was statistically significantly 
higher with morphine monotherapy than with either fentanyl monotherapy or the 
morphine plus midazolam combination. The clinical advantage of morphine, however, 
comes at a comparatively higher cost, in only 2% cases. Associated with higher 
effectiveness and lower therapy cost, fentanyl monotherapy demonstrated dominance 
over its combination with midazolam. The higher effectiveness of fentanyl over its 
combination however cannot be robustly interpreted as this was not based on power 
and sample size calculations.   
The current research confirms the appropriateness of recent switching from sedative 
fentanyl to morphine monotherapies in NICU settings of HMC, taking in consideration 
local decision making and budget limits. The study, however, contradicts the current 
Qatari practice of utilizing the midazolam combination, especially with morphine, where 
the addition of midazolam is commonly believed to enhance effectiveness.  
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Appendix 1. PubMed search strategy 
# Search History Results 
#1 "Morphine"[Mesh] OR "Fentanyl"[Mesh] 48504 
#2 "Hypnotics and Sedatives"[Mesh] 25913 
#3 #1 OR #2  73247 
#4 Respiration, Artificial"[Mesh] 66155 
#5 #3 AND #4 1511 
#6 #5 AND "humans"[MeSH Terms] 1437 
#7 #6 AND English[lang] 1202 
#8 #7 AND (Clinical Conference[ptyp] OR Clinical Study[ptyp] OR Clinical 
Trial[ptyp] OR Comparative Study[ptyp] OR Congresses OR Consensus 
Development Conference[ptyp] OR Consensus Development 
Conference, NIH OR Controlled Clinical Trial OR Corrected and 
Republished Article[sb] OR Evaluation Studies[ptyp] OR Government 
Publications[ptyp] OR Guidelines[ptyp] OR Journal Article[ptyp] OR 
Meta-Analysis[ptyp] OR Multicenter Study[ptyp] OR Observational 
Study[ptyp] OR Practical Guideline[ptyp] OR Ranodmized Controlled 
Trials[ptyp] OR Review[ptyp] OR Systematic Reviews[sb]) 
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Appendix 2. PRISMA 2009 checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, 
or both.  
 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal 
and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review 
registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of 
what is already known.  
 
Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-
up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, 
giving rationale.  
 
Information 
sources  
7 Describe all information sources (e.g., databases with 
dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., 
piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from 
investigators.  
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Data items  11 List and define all variables for which data were sought 
(e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this 
was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
 
Synthesis of 
results  
14 Describe the methods of handling data and combining 
results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
 
  
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
Additional 
analyses  
16 Quality assessment of studies   
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for 
eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
 
Study 
characteristics  
18 For each study, present characteristics for which data 
were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if 
available, any outcome level assessment (see item 12).  
 
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), 
present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
 
Synthesis of 
results  
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., 
sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
 
DISCUSSION   
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Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their 
relevance to key groups (e.g., health care providers, 
users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk 
of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the 
context of other evidence, and implications for future 
research.  
 
FUNDING   
Funding  27 Describe sources of funding for the systematic review 
and other support (e.g., supply of data); role of funders 
for the systematic review.  
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Appendix 3: Ethics form from MRC 
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Appendix 4: Data collection form 
PLEASE RECORD: 
Record number: ………… 
Date of collection: ………… 
Subject ID Code: ………… 
Active problems:  
Gender:              Male                   Female 
Gestational age (weeks): ………… 
Weight: …………… (g) 
Type of delivery:              Vaginal delivery                       Cesarean section 
Date of birth: …………                                       Date: …………               Time: ………… 
 
          Monotherapy                  Combination 
Sedative 1: …………….                                               
Loading dose: …………… Received high dose (Yes/No): ………………. Times of receiving high 
doses: ……… 
Maintenance dose: ……………. Received high dose (Yes/No): ………………. Times of 
receiving high doses: ……… 
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Route of administration: …………….       
Duration of sedative: …………….       
Date of administration of sedative: …………….       
Time of administration of sedative: …………… am / pm 
Sedative 2: …………….                                               
Loading dose: …………… Received high dose (Yes/No): ………………. Times of receiving high 
doses: ………   
Maintenance dose: …………… Received high dose (Yes/No): ………………. Times of receiving 
high doses: ………   
Route of administration: …………….       
Duration of sedative: …………….       
Date of administration of sedative: …………….       
Time of administration of sedative: …………… am / pm 
Sedative 3: ……………                   
Loading dose: ……………. Received high dose (Yes/No): ………………. Times of receiving high 
doses: ……… 
Maintenance dose: ……………. Received high dose (Yes/No): ………………. Times of 
receiving high doses: ………     
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Route of administration: …………….       
Duration of sedative: …………….       
Date of administration of sedative: …………….       
Time of administration of sedative: …………… am / pm                           
Duration of mechanical ventilator (hours): …………….      
Date of mechanical ventilation initiation: …………….   
Time of mechanical ventilation initiation: …………….              
Date of mechanical ventilation discontinuation: …………….   
Time of mechanical ventilation discontinuation: …………….           
Mechanical ventilation mode: …………….  
Inspiratory time: …………….  
Data of NICU admission: …………….  
Time of NICU admission: …………….  
Data of NICU discharge: …………….  
Time of NICU discharge: …………….  
Length of NICU stay (days): ……………. 
Death: ….……………….                      Date: ….………………...                               On MV       Off MV 
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Initial Premature Infant Pain Profile (PIPP) Pain score when sedative was initiated: 
……………. 
Final Premature Infant Pain Profile (PIPP) Pain score when sedative was discontinued: 
……………. 
Vital signs during sedation: 
1. Temperature:                              Maximum: …………….                    Minimum: 
……………. 
2. Heart rate:                                   Maximum: …………….                    Minimum: 
……………. 
3. Respiratory rate:                        Maximum: …………….                    Minimum: 
……………. 
4. Blood pressure:                          Maximum: …………….                    Minimum: 
……………. 
Adverse drug reactions, times of events, and sedative associated with event:  
Respiratory Secretion ….…………… 
Airway obstruction ….…………… 
Oxygen desaturation (<90%) ….…………… 
Hypotension (depends on GA and age) ….…………… 
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Tachypnea ….…………… 
Bradycardia ….…………… 
Respiratory depression ….…………… 
Edema ….…………… 
Dystonic reactions/movement disorders ….…………… 
Seizures ….…………… 
Vomiting ….…………… 
Aspiration of stomach contents ….…………… 
Phlebitis, line irritation ….…………… 
Allergic reaction, describe: ……………… 
Urinary retention (need for a urinary catheter) ….…………… 
Enterocolitis: ….……… 
Intraventricular hemorrhage: ….………… 
Other: …………….. 
Medications used to resolve drug reactions: ….…………… 
Other medications administered in NICU: ….…………… 
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Arterial Blood Gas (ABG) 
pH ….………………. 
pCO2 ….…………… 
pO2 ….…………… 
HCO3 ….…………… 
Base D/E ….…………… 
Non- pharmacological interventions while in NICU:  
………………………………………………………………………………………….. 
Laboratory tests while in NICU 
Number of hematology tests: ….…………… 
Number of chemistry tests: ….…………… 
Number of blood gases tests: ….…………… 
Number of metabolic tests: ….…………… 
Number of microbiology tests: ….…………… 
Number of general virology tests: ….…………… 
Number of metabolic tests: ….…………… 
Number of body fluid tests: ….…………… 
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Diagnostic tests while in NICU:  
X-ray scan: ….……………                             Number of tests: ….…………… 
CT scan: ….……………                                  Number of tests: ….…………… 
US: ….……………                                           Number of tests: ….…………… 
MRI: ….……………                                        Number of tests: ….…………… 
Other tests: ……………….                           Number of tests: ….…………… 
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Appendix 5: Underlying diseases in the included studies 
N Study Medical Disorders  
1 Carrasco et al NA 
2 Al MJ et al NA 
3 Zhou et al Sepsis, COPD, CHE, pneumonia, pancreatitis, trauma, and postoperation 
4 Barrientos et al Cardiorespiratory insufficiency, trauma, and postoperation 
5 Tobias et al  NA 
6 Mehta et al Respiratory disorders  
7 Rozendaal et al Cardiovascular, respiratory, sepsis, and GI diseases 
8 Breen et al NA 
9 Karir et al Cardiovascular, pulmonary, neurological, surgical, and infectious diseases  
10 Watling et al Respiratory disorders 
11 Strøm et al Sepsis, respiratory disorders, pancreatitis, peritonitis, GI bleeding, 
trauma, liver, and biliary diseases 
12 Jarman et al NA 
13 Tedders et al NA 
14 Riker et al Severe sepsis, shock, and pneumonia 
15 Junior et al Respiratory failure, ARDS, sepsis, cardiogenic shock, pneumonia, and 
acute pulmonary edema 
16 Shehabi et al Patients with operative, respiratory failure, cardiovascular admission 
17 Aitkenhead et 
al  
Respiratory or ventilator failure   
18 Cox et al NA 
19 Anand et al NA 
20 Saarenmaa et 
al  
ARDS, infection, PPHN, NEC, IVH grades 3, 4 
21 Wood et al ARDS, apnea, pneumonia, and asphyxia 
22 Quinn et al HMD 
23 Tobias et al NA 
24 Tobias et al NA 
25 Kress et al ARDS, pulmonary edema, COPD, ventilator failure, asthma, sepsis, 
cardiogenic shock, delirium, hemorrhagic shock, drug overuse 
26 Carson et al Pneumonia, septic shock, cystic fibrosis, COPD, sickle cell chest 
syndrome, upper airway obstruction, interstitial lung diseases, and other 
diagnosis 
27 Barrientos et al Cardiorespiratory failure, trauma, postoperation, and miscellaneous 
28 Simons et al RDS, primary infection, pneumonia, pulmonary edema, and meconium 
aspiration 
29 Grunau et al NA 
30 Orsini et al RDS 
31 Guinsburg et al RDS 
32 Richman et al Sepsis, pneumonia, COPD, asthma, neuromuscular, and cardiovascular 
diseases 
33 Anand et al Cardiovascular, and neurological disorders, shock, and trauma 
216 
 
*NA= Not available; COPD = chronic obstructive pulmonary disease; CHE = covert hepatic 
encephalopathy 
†GI= gastrointestinal; ARDS = acute respiratory distress syndrome; PPHN = persistent pulmonary 
hypertension of neonate 
‡NEC = necrotizing enterocolitis; IVH = intraventricular hemorrhage; HMD = hyaline membrane 
disease; RDS = respiratory distress syndrome 
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Appendix 6: Sedative comparisons in adult populations 
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Appendix 7: Sedative comparisons in pediatric and neonate populations 
 
 
 
